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1 General introduction and scope 
 
 Biocatalysis and green chemistry 
 
 The employment of biocatalysts can provide the chemist the possibility to utilize enzymes in 
organic syntheses and take advantage of their high chemo-, regio-, and stereospecificity. Due to its 
versatility, enzymes find application in many areas which demand for enantiomerically pure 
compounds. Praised for high activities, high turnover rate and their renewable nature, biocatalysts 
have gained intense attention and application both from academia and industry.[1] Unlike chemically-
catalysed reactions that often rely on harsh and intensive processes, enzymes usually favour 
environmentally-friendly reaction conditions performed at mild temperature and pressure in aqueous 
medium at physiological pH.  
 Biocatalysts are usually compatible with each other, making it easy to combine several 
enzyme classes in one reaction system. This property has been exploited to develop strategies to use 
enzymes to act sequentially or even in a concurrent mode. Such multienzymatic one-pot multistep 
processes opened the possibility to carry out reaction sequences which substantially reduce operating 
times by avoiding lengthy isolation steps, purifications and considerably reducing waste and cost. 
 The cascades of two or more catalysts face an additional challenge with chemoenzymatic 
combinations. Unlike biocatalysts, the combination of bio- with organo- or metallo-catalysts typically 
suffers from compatibility issues in regards of the reaction medium as they often encounter 
inactivation or instability when used in the same environments.[2] The ‘’classic’’ chemical processes 
are typically carried out in organic media whereas enzyme catalysis often requires water as a medium 
of choice. It is thus necessary to find a compatibility window to meet the requirements of each 
catalytic system. To circumvent these limitations a number of techniques like immobilization[3] , 
compartmentalization[4], and protein engineering approaches[5] have been investigated and 
implemented. 
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 Biocatalytic cascades: definition and classification 
 
 The term ‘’cascade’’ has been commonly used for one-pot reactions that proceed 
independently and take place concurrently or in separated timelines. Cascade reactions are more 
effective than the classical single-step reactions for the reason that less chemicals are used in the 
workup stage of the process and unstable or possibly toxic intermediates can instantly be consumed 
or transformed. This leads to a more effective production of compounds and higher yields.[6]  
 Literature examples classify multistep biocatalytic one-pot reactions into cascade (domino) 
processes, tandem reactions and orthogonal tandem catalysis.[7] The recent trend however tends to 
terminologically generalize these types of processes with the term of ‘’cascade reaction’’ as a process 
that includes all concurrent or temporarily separated biocatalytic one-pot reactions irrespective of the 
type and number of catalysts implemented.[8]  Therefore, chemoenzymatic cascade refers as a 
reaction system composed of at least one biocatalyst where two or more processes are carried out in 
the same reaction flask.  
 Cascades can be performed in a ‘’sequential mode’’ when the second key catalyst is added 
after the completion of the first step of the reaction. On the other hand, reaction conditions in 
cascades carried out in a ‘concurrent mode’ do not change in the consecutive steps and all ingredients 
are added from the beginning of the process.[8] Cascade reactions performed in a sequential fashion 
enable to circumvent sometimes the problems associated to inhibition of enzymes or metal catalysts 
by a reagent or compound involved in the preceding steps. Thus, adding one reagent or modifying the 
reaction conditions (pH, T) at a later stage of the sequence could be a practical solution. 
 Incompatible catalysts can be combined in one-pot cascade process via a number of strategies 
and separation methods such as using a two-phase system or involving immobilization on 
nanoparticles or beads offer a solution to these problems.[8] Techniques such as  flow chemistry[9] or 
compartmentalization[10] can spatially separate the two key components as well. Furthermore, 
cascades have their own specific characteristics and can be classified into four different designs. 
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i) Linear cascades consist of one-pot transformations where the starting material (or substrate) is 
converted to the product via one or more intermediates which are not isolated during the process.  
 
Scheme 1. Linear cascade design 
 
ii) In the parallel cascade design two simultaneous biocatalytic reactions are carried out and both 
starting materials are converted into two distinct products. These types of cascades are commonly 
used in redox biocatalysis employing oxidoreductases. 
 
Scheme 2. Parallel cascade design 
 
iii) Orthogonal cascades are closely related to parallel cascades with the difference that they consist 
of main reaction coupled with a second auxiliary reaction often used to remove the formation of 
undesired by-products.[8] 
 
Scheme 3. Orthogonal cascade design 
iv) In cyclic cascades the co-product is formed back into one of the starting materials. This leads to the 
accumulation of the desired product which is left behind in the first transformation. This system has 
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been often used in deracemization of amines, α-amino acids or α-hydroxy acids that consist of a redox 
process.[11] 
 
 
Scheme 4. Cyclic cascade design 
 
 Combination of many different enzyme forms such as isolated or whole cells enzymes are 
likely achievable, but a process to be effective requires optimisation and appropriate operating 
conditions. Future development of successful chemoenzymatic combinations will most likely depend 
on solvent and enzyme engineering. Solvent optimisation allows successful biocatalytic reactions to 
be carried out in alternative reaction media meanwhile the range of available enzymes for novel 
synthetic applications continues to expand.  
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 Combination of bio- and chemocatalysis 
 
 Syntheses of natural products and pharmaceuticals are mostly based on ‘’classical’’ chemical 
synthetic routes with reaction intermediates often isolated and purified. Alternative processes for 
these ‘’classical’’ chemical systems can be represented by multi-step one-pot reactions based on the 
combination of bio- and chemocatalysts. Such processes demonstrate many advantages over 
conventional sequential reaction schemes in terms of productivity, selectivity, and cost as well as 
environmental efficiency. 
 To overcome the limitations of challenging reaction conditions and requirements by bio- and 
chemocatalysis, it is necessary to develop processes equally appropriate for both reactions. Early 
examples of combining the chemo- and biocatalysts date from the 1980 after Van Bekkum et al. 
successfully developed a process based on the use of D-glucose isomerase immobilized on silica in a 
combination of a copper-on-silica catalyst.[12] After this pioneering breakthrough, the group of Allen 
and Williams developed a process that runs in water and which combines a palladium-catalysed 
racemisation with a lipase-catalysed hydrolysis.[13] The use of lipases in organic media has further 
attracted attention as it was possible to carry out metal-catalysed racemisation reactions coupled with 
enzymatic resolution of racemic alcohols, amines and amino acids, employing ruthenium, palladium, 
iridium and a range of other metal complexes.[14] Since then numerous metal-catalysed reactions have 
been successfully coupled with biocatalysts predominantly for DKR type reactions.[15] 
 Although DKR reactions can provide high yields and excellent enantiopurities, these reactions 
often have limitations in terms of reaction temperature and specificity of both catalysts. 
 
Scheme 5. Example of a typical metallo-enzymatic DKR 
 
 In the last decade a number of other types of chemocatalytic reactions such as C-C bond-
forming reactions have been successfully combined with biotransformations.[16] Alcohol 
dehydrogenases (ADH) have been successfully applied in multi-enzyme cascades with Baeyer-Villiger 
monooxygenases,[17] or in a combination with metal-catalysed processes, for the asymmetric synthesis 
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of alcohols by the stereoselective reduction of the corresponding ketones.[16],[18] A lot of these new 
designed chemoenzymatic processes give access to valuable building blocks for the preparation of a 
wide range of pharmaceutically relevant compounds. Recently the use of ω-transaminases has 
become an efficient biocatalytic approach for the synthesis of α-chiral primary amines. Many of these 
enzymes have become widely used in chemoenzymatic systems and some of these processes are 
currently used in the pharmaceutical industry.[19]  
 
 The combination of chemocatalytic and biocatalytic transformations in one-pot processes in 
aqueous medium represents an attractive research topic from both the academic as well as industrial 
perspective. Development of such chemoenzymatic one-pot processes in environmentally friendly 
solvents has emerged enormously in recent years, and numerous proof-of-concepts for the 
combination of metal catalysis with biotransformation has been investigated and successfully 
demonstrated.[20] 
 The first example of a one-pot process based on a combination of an asymmetric metal-
catalytic transformation and an enzyme-catalysed step conducted in aqueous medium in a sequential 
fashion was published in 2006.[21] This study afforded the process for the enantioselective synthesis of 
amino acids in water and increased an interest to combine metal catalysis with biocatalysis for 
reactions that were previously thought to be incompatible processes.  
 Later in 2008, the palladium catalysed Suzuki cross-coupling reaction was combined with a 
further bioreduction.[16] Since then this concept was subject of intensive research and improvement 
with the particular aim to increase the efficiency and performance of this chemoenzymatic 
process.[22],[23]  
 The advantages of the combination of chemo- and biocatalysis enables the development of 
novel synthetic pathways and proof of concepts. It represents an attractive research area with a lot of 
industrial and academic potential towards a green and sustainable chemistry. 
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2 One-pot cascade reaction for the synthesis of enantiomerically pure biaryl 
alcohols in Deep Eutectic Solvents 
 
 Introduction 
 
Due to the growing need for sustainable technologies and integration of biocatalysis in chemical 
cascades and one-pot processes the use of the right solvent system is of high importance. Thus, the 
attention is turned towards a new class of biorenewable solvents, namely the Deep Eutectic Solvents 
(DES), which have been demonstrated as a valuable alternative to volatile organic solvents from the 
standpoint of sustainability.[24] Therefore the focus of this chapter is on the formation of 
enantiomerically pure biaryl alcohols via a one-pot sequential cascade process with particular interest 
on the use of these biorenewable and environmentally friendly solvents. 
To this date there exists only one example of a chemoenzymatic cascade in DESs, which was 
developed in parallel to this research and  consists of the combination of a ruthenium-catalysed 
isomerisation of allylic alcohols with an enzymatic reduction.[25] The proof that DESs have been 
successfully implemented as an efficient reaction medium for many enzymes,[26] as well as metal-
catalysed reactions,[27] increased the motivation for the research in this direction.  
Based upon the concept from 2012 (Scheme 6),[23] when the combination of a metal-catalysed 
reaction and enzymatic process had been carried out at room temperature in a mixture of isopropanol 
and water, the possibility for the cascade process in a mixture of DESs and aqueous buffer is 
investigated.  
 
Scheme 6. Concept of the chemoenzymatic one-pot process in aqueous medium for the synthesis of the chiral 
biaryl alcohols[23] 
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 Therefore, the study developed throughout this chapter investigates the advantages of DESs 
and their utilization as the reaction medium in the chemoenzymatic one-pot process for the synthesis 
of enantiomerically pure biaryl alcohols. 
 
 Goal and motivation 
 
In spite of all the benefits of one-pot processes, such as the palladium-catalysed Suzuki cross-
coupling reaction and a bioreduction,[23] there is still a challenge in finding an improved solvent system. 
One option to achieve this is the use of DESs due to a number of benefits and advantages.[28] Thus, 
this research focuses on this novel class of solvents and their contribution to an improved efficiency, 
while overcoming compatibility limitations and hurdles. 
A mixture of aqueous buffer and DES is used as a solvent in the cascade reaction to synthesize 
biaryl prochiral ketones which are in-situ converted to the chiral biaryl alcohols. Choosing a suitable 
enzyme in the second step provides the corresponding (R)- or (S)-enantiomer in good yields and high 
optical purity (Scheme 7). 
 
Scheme 7. Chemoenzymatic cascade towards chiral biaryl alcohols in DES-buffer medium 
 
At present there are examples of Suzuki cross-coupling reactions being carried out in neat 
DESs,[27] although the feasibility of such process using the water-soluble Pd-catalyst in eutectic 
mixtures requires further investigation.  
The combination of two reactions needs both steps to be studied and optimised separately 
first. Therefore, the aim in the first step of the cascade consists of finding ideal reaction conditions 
bearing in mind basic pH requirement, catalyst loading, substrate concentration, and reaction 
temperature.  Considering the high price of palladium, the reduction of the amount of the metal 
catalysts presents benefits from an economical aspect and avoids any potential negative effect that 
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the metal might have on the enzyme activity. Thus, the decrease of the catalyst loading is another goal 
to be achieved and at the same time reach the highest limit for the substrate concentration.  
The presence of high substrate loading asks for a solvent to completely solubilize highly apolar 
components. Thus, different preparations of eutectic mixtures have to be studied in order to find the 
most suitable choice while also decreasing the amount of co-substrate isopropanol as low as possible, 
a minimal amount necessary only for the co-factor regeneration system in the second step.  
The substrate scope of the Suzuki coupling under optimised conditions has to be evaluated 
for the construction of substituted biaryl ketones. Furthermore, the established substrate scope has 
to be taken into consideration in a screening study for the second step of the cascade to ensure high 
activity of enzymes towards the challenging ketones in question. Once the ideal reaction conditions 
for the Suzuki coupling have been established, focus has to be switched on the forthcoming enzymatic 
reduction step. 
For the reduction of ketones commercially available ketoreductases (KREDs) and 
overexpressed ADHs in E. coli are used. Being a one-pot process, it is highly important to establish 
reaction conditions for the enzymes to be compatible with the components of the first step of the 
cascade. 
Once both catalytic steps are validated and optimised, the cascade reaction will be carried 
out. After the in-situ reduction of the formed ketone the final yield and enantiomeric preference of 
the formed biaryl alcohols will be evaluated. 
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 State of the art 
 
 Palladium-catalysed Suzuki cross-coupling reaction 
 
Palladium catalysed cross-coupling reaction of organoboron compounds was introduced in 1995 
and has since then been one of the most vastly used and popular methods to create carbon-carbon 
bonds to obtain alkenes, styrenes, or biaryl compounds (equation 1).[29] Biaryl molecules are 
important structural components of many pharmaceuticals, herbicides and natural products.[30] 
 
 
 
 Mechanism of the Suzuki cross-coupling reaction 
 
The cross-coupling reaction is usually driven by palladium bonded to a ligand which activates the 
catalyst, and a base that reacts with the boronic acid to give the desired carbon-carbon bond 
formation.  
The Suzuki cross-coupling reaction proceeds via three fundamental steps (Scheme 8):[29]   
1. Oxidative Addition 
2. Transmetalation 
3. Reductive Elimination 
 
Scheme 8. Mechanism of the Suzuki cross-coupling reaction[29] 
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In the first step aryl halides react with the palladium(0)-complex which is oxidized to the 
palladium(II)-complex (Oxidative Addition). Subsequently the transfer of the organic residue (-R’) from 
the organoborane compound to the palladium takes place in the presence of a base (transmetalation). 
Finally in the Reductive Elimination step the desired coupling product R-R’ is cleaved and the original 
palladium(0)-complex is recovered.  
 
 Design of alternative phosphine-based ligands 
 
The Suzuki cross-coupling reaction was initially carried out in the presence of organic solvents 
and inorganic bases. From an industrial point of view, it was however important to further develop 
the process with the aim to use efficient and non-toxic catalysts and water as an inexpensive and safe 
solvent. Among these influencing factors the ligand plays an important role in the reaction. Therefore 
numerous efforts have been done in the last decade to develop efficient ligands based on 
triphenylphosphine which was the earliest and most widely used ligand in Suzuki cross-coupling 
reactions.[31] Potential ligands involve the use of electron-rich bulky phosphines[32], bulky 
phosphines[33]  and phosphine oxides[34] (Scheme 9).  These modifications lead to the formation of 
ligands that allow lower catalyst loading and improve the efficiency of the catalytic cycle by enhancing 
the rate of both the oxidative addition and reductive elimination processes. Different ligands 
furthermore allow to extend the scope of Suzuki cross-coupling reactions. The use of certain ligands 
overcomes solvent incompatibilities and avoids the requirement for higher reaction temperatures, 
and at the same time reduces environmental concerns. An improved ligand system also means the 
catalyst can tolerate reaction conditions suitable for one-pot processes which could also be carried 
out in water. The originally hardly soluble phosphines can be modified and converted to water-soluble 
ligands by introducing polar groups such as sulfonates and ammonium groups. This modification made 
it possible to carry out Suzuki cross-coupling reactions in a variety of solvents ranging from glycerol to 
a mixture of water with acetonitrile and isopropanol respectively.[35],[16,36] 
 
Scheme 9. Example of alternative phosphine-based ligands for the Pd-catalysed cross-coupling reactions 
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 Due to its solubility in water, the ligand triphenylphosphine trisulfonate (TPPTS) has been used 
for carbonylation reactions in aqueous media (Scheme 10).[16]  
 
Scheme 10. A water-soluble (tris(3-sulfonatophenyl)phosphine) ligand (TPPTS) 
 Similarly, the catalytic system consisting of TPPTS/Pd(OAc) has been applied for the synthesis 
of Xenalipin, a potential cholesterol-reducing drug.[37] A water-soluble TPPTS/PdCl2 catalytic system 
was employed by Hoechst for the commercial production of 2-cyano-4’-methylbiphenyl, a key 
intermediate in the synthesis of angiotensin II receptor antagonists used for the treatment of 
hypertension.[38] 
 
 Application of Suzuki cross-coupling reactions 
 
 Homogeneous Suzuki cross-coupling reactions have also find application in chemical 
biology,[39] although high catalyst loadings are often required for the reactions to be performed in this 
environment.  
 Recovery and recycling of palladium has been an important issue from an industrial 
perspective due to its high costs. A number of strategies to develop solid-supported catalytic systems 
have been developed to facilitate the recovery of Pd-catalyst. Such heterogeneous systems are 
particularly interesting for the industrial synthesis of pharmaceutical to avoid any metal residues. 
Supported catalytic systems often include the use of polymer supports and immobilized palladium on 
nanoparticles or silica supports.[40]  
 A study reported in 2014 revealed the use of the heterogeneous Pd/C catalyst in water for 
Suzuki cross-coupling reactions of halophenols with boronic acids for the synthesis of phytoalexins.[41]  
 Carrying out a Suzuki cross-coupling reaction in aqueous media opens up the possibility of a 
combination with enzymatic processes. The first example of such combination was reported by Gröger 
and co-workers with a Pd-catalysed cross-coupling reactions followed by an enzymatic asymmetric 
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reduction of the transiently formed ketones.[16] This process was carried out in a mixture of 
isopropanol (50%) and water, and later successfully optimised to run  both steps at room 
temperature.[23] Another noteworthy example is the asymmetric biocatalytic reduction followed by 
the Suzuki cross-coupling used for the synthesis of the intermediate for the cathepsin K inhibitor 
Odanacatib (Scheme 11). This enantioselective two-step synthesis was carried out to in a continuous 
flow process to achieve the desired product in high yields and enantiomeric excess.[42]  
 
Scheme 11. Combination of a ketone bioreduction with a subsequent Suzuki–Miyaura coupling in a one-pot 
process for the synthesis of the Odanacatib precursor[42] 
 
 Recently the combination of the biocatalytic halogenation of L-tryptophan with subsequent 
Suzuki cross-coupling reaction has been reported. This one-pot three-steps reaction leads to the 
formation of aryl-substituted tryptophan derivatives which can be used for peptide or peptidomimetic 
synthesis.[43]  
 In conclusion, the Suzuki cross-coupling reaction represents one of the most straightforward 
methods for carbon-carbon bond formation and synthesis of biaryl and alkene derivatives. The 
reaction in aqueous media however often requires high temperatures, the use of co-solvents, long 
reaction times and is therefore generally limited by a narrow substrate scope. 
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 Deep Eutectic Solvents as reaction media for chemo- and biocatalysis 
 
 Preparation of DESs and their properties 
 
Many enzymatic reactions predominantly take place under mild conditions (room temperature, 
physiological pH and ambient pressure) in water. Water is a cheap, non-flammable, fairly abundant 
and safe for the environment solvent. Although exhibiting many beneficial properties one major 
disadvantage of using water as a solvent lies within its high polarity.  
Enzymes function preferably in water, which can become a disadvantage for catalysts and organic 
compounds with a limited solubility in this solvent. A common strategy to overcome this limitation 
relies on the use of water-miscible co-solvents that not only increase the solubility of the compounds, 
but also act as co-substrates. This is advantageous in the case of ADH-catalysed reactions whereas 
isopropanol has been used as co-solvent and also as both electron donor for the co-factor 
regeneration system and to shift the unfavourable equilibria towards product formation.  
Although the use of co-solvents usually provides benefits in terms of higher substrates loading it 
is necessary to consider their compatibility with enzymes as they might have unpredicted effects on 
the biocatalyst activity and stability. Thus, it is advisable to optimise reaction conditions each time for 
new processes and biocatalysts.  
The methodology of using two-phase systems consisting of water and a water-immiscible organic 
solvent is another advantageous strategy when substrates are poorly soluble in water. In this case 
greater part of hydrophobic substrates and products are contained in the organic phase, while the 
enzyme and any water-soluble cofactors are in the aqueous phase. The product can then be easily 
obtained from the organic phase via distillation and extraction processes.  
One of the limitations of a two-liquid phase system is a slow transfer rate between the two phases 
which can significantly slow down the overall reaction process.  
Although enzymes prefer water, numerous enzymatic processes in organic media have been 
described.[44] Benefits of carrying out a biocatalytic transformation in organic media includes an easier 
product removal and elimination of contamination. Furthermore, having an enzymatic process in 
organic media allows for some reactions which can hardly be performed in water due to hydrolysis 
such as esterification or formation of amides.[45] The drawback of such processes is often lower 
enzymatic activity compared to the transformation carried out in water. This has led to the 
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investigation of non-conventional media with the intent to perform enzymatic reactions in non-
aqueous solutions.  
The attempts for the search of green solvents led to the discovery of ionic liquids (ILs). In the 
following years a number of enzymatic transformations were reported in ILs.[28] Although having many 
advantages such as high thermal stability, non-flammability, high catalytic activities and many other 
fine-tuning properties,[46] there are a number of drawbacks that include high cost, toxicity, low 
biodegradability and the requirement to use organic solvent at the end of the reaction. These findings 
have increased the interest to another attractive class of alternative solvents, the so-called Deep 
Eutectic Solvents (DESs).  
DESs offer similar properties to those of ILs in terms of low volatility, non-flammability, low vapour 
pressure, high thermal stability and solubility of organic compounds. They have become a subject of 
intense research due to a number of other advantages such as low cost and high availability of their 
starting materials, with minimal toxicity and extremely low environmental disposal issues.  
DESs are readily available, inexpensive, biodegradable and come from renewable resources. They 
are often prepared from choline chloride (ChCl) and a variety of inexpensive raw materials such as 
sugar polyols, D-glucose, itaconic acid and carboxylic acid.[45] Thus, they consist of a hydrogen-bond 
acceptor (HBA) such as quaternary ammonium salts (e. g., choline chloride) and uncharged hydrogen-
bond donors (HBD) such as urea, carboxylic acids or polyols. The interaction between HBA and HBD 
relies mostly on hydrogen bonds, van der Waals interactions and electrostatic forces which stabilise 
liquid configurations and results in lower melting points than those of their individual components 
(Scheme 12).[45] The atom efficiency of the final formulation is the highest possible, as all the initial 
components are included in the final formulation as well. 
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Scheme 12. Examples of HBAs and HBDs used to form DES[45] 
 
 The eutectic mixture is a composition of two or more phase-immiscible solid components that 
completely change their solid phase to become liquids at a certain temperature point called the 
eutectic point (Scheme 13). 
 
 
Scheme 13. Phase diagram of a DES mixture[47] 
 
The use of DESs involves advantages in the work-up stage as high solubility of water in DES allows 
further addition of water followed by the precipitation of organic products. This strategy avoids the 
use of organic solvents for the extraction and the initial DESs to be recycled by simple evaporation of 
water from the aqueous layer.[48] The drawbacks of DESs include reports about high densities and 
viscosities of conventional DESs mixtures which could suggest a problem in continuous flow and 
 17 
 
industrial processes. These issues can be solved by a slight increase of temperature or formation of 
ternary mixtures by addition of different components such as water, carboxylic acid or an organic or 
inorganic halide.[49] 
 Application of DESs 
 
Over the past decade DESs have found applications in several chemical sciences and technologies 
such as electrochemistry and metal processing, material chemistry, nanotechnology, photosynthesis 
and energy technology, separations processes, and stabilisation of DNA. With respect to synthetic 
purposes, DESs have provided examples of improved activity and selectivity in: i) organometallic-
mediated stoichiometric transformations,[50] and ii) metal-,[51,52]enzyme-,[53] or organo-catalysed 
reactions.[54,55] DESs attracted attention from a biocatalysis prospective in 2008 in a research of 
Kazlauskas and co-workers who demonstrated good catalytic activity of hydrolases in mixtures based 
on ChCl/Urea (1:2) and ChCl/Gly (1:2). ChCl-based DESs have shown to be a good solvent of choice for 
lipases that catalyse the aldol reaction of aromatic aldehydes with ketones (Scheme 14).[56] 
 
Scheme 14. Hydrolase-catalysed aldol reaction between 4-nitrobenzaldehyde and acetone in a DES 
mixture consisting of choline chloride and glycerol[56] 
 
DESs could also be used as co-solvents for whole-cell biocatalysis as it was observed that E. coli 
cells retained their integrity in the media. Following that demonstration it was reported the use of 
baker’s yeast in mixtures of ChCl/Gly (1:2) and aqueous buffer for the enantioselective reduction of 
ethyl acetoacetate to optically active alcohols at long reaction times (>200 h).[57] In that study an 
inversion of stereoselectivity was observed with the use of different proportions of DESs and water 
which suggests that certain KREDs present in the baker’s yeast were completely inactivated while 
others with the opposite stereopreference retained activity (Scheme 15). 
 
Scheme 15. Baker’s yeast was used as a reductive catalyst in a mixture of DES and water 
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The use of DESs for an efficient conversion of fructose to 5-(hydroxymethyl)furfural (HMF) was 
reported in a biphasic mixture consisting of ChCl/citric acid.[58] Being a biomass-derived chemical, HMF 
has a great potential in the bio-based industry as a substitute for petroleum-based building blocks as 
well for the production of high-valued chemicals. 
Beside their use as a solvents, preparations of choline chloride and metal chlorides have been 
used as catalysts in different multicomponent reactions for the preparations of β-amino ketones[59] 
and α-aminophosphonates.[60] 
Deep eutectic mixtures have also been used in different carbon-carbon and carbon-heteroatom 
bond-forming processes in particular in different conjugate additions, such as the thia-Michael 
addition to α,β-unsaturated carbonyl compounds for the generation of S-alkylisothiouronium salts.[61]  
Preparations of DESs consisting of ChCl/urea found application in a number of redox reactions at 
room temperature. The use of DESs showed substantial increase of yield and decrease of reaction 
time compared to the process with organic solvents.[62] 
There are a few examples of organometallic reactions in DESs in which Grignard and organolithium 
reagents were added to ketones, or the oxidation of toluene to benzaldehyde with hydrogen peroxide 
as oxygen source.[63] 
 
Very recently several cross-coupling reactions were successfully carried out in a variety of DES 
preparations. A mixture consisting of low-melting sugar mannitol, urea and ammonium chloride was 
used in Suzuki cross-coupling reactions with excellent yields after only 6 hours of reaction time 
(Scheme 16).[51]  Positive results were also obtained in the Heck cross-coupling and copper-
free Sonogashira coupling where D-mannose/DMU was the DES mixture of choice by using cationic 
pyridiniophosphine ligands in association with PdCl2. It is important to mention that in most cases the 
use of DESs allowed to repeatedly use the catalyst and recycle the whole media.[52]  
 
Scheme 16. Suzuki coupling in sugar–urea–salt melts[51] 
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The use of DESs has been recently successfully implemented in chemoenzymatic processes such 
as the tandem reaction consisting of a lipase and organocatalysts[55,64] or a ruthenium-catalysed 
isomeration of racemic allylic alcohols coupled with an enantioselective bioreduction (Scheme 17).[25]  
 
Scheme 17. One-pot ruthenium-catalysed isomerisation of allylic alcohols combined with an 
enantioselective bioreduction in DES-buffer medium 
 
The use of solvents plays an important role in the toxicity profile of a chemical process and for 
a typical pharmaceutical or fine chemical batch operation it usually accounts for between 80 and 90 
% of mass utilization.[65] Given their dominant role in such operations it is necessary to optimise the 
synthetic strategy by choosing the solvent that can provide the desired function without the undesired 
properties that can cause environmental, health and safety issues. For that reason, many neoteric 
solvents such DESs provide an effective alternative being identified as ‘’greener’’ and more sustainable 
option. Unlike petroleum-derived solvents numerous biomass-derived solvents, such as glycerol, 
ethanol, limonene, γ-valerolactone, or tetrahydrofuran could be used as promising alternatives to 
conventional organic solvents, due to a number of beneficial attributes. However, the potential for 
modulation of their properties is not very high.[66] 
To conclude, DESs have emerged as environmentally attractive reaction media for biocatalytic 
processes and can convincingly replace common solvents in many organic reactions. The presence of 
DESs in aqueous medium avoids problems of low solubility and low concentration of substrates. Thus, 
their utilisation in the fields of chemo- and biocatalysis opens up new perspective for such processes. 
Numerous other advantages and beneficial physical properties highlight their positive impact and 
allow for more sustainable organic chemistry synthesis.  
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 Enzymatic reduction of ketones 
 
 Bioreduction approaches 
 
Alcohol dehydrogenases (ADHs) represent a straightforward approach for the synthesis of chiral 
alcohols and have been widely used for the reduction of carbonyl groups (Scheme 18). The 
enantioselective reduction of prochiral ketones generates a stereocenter starting from a planar sp2-
hybridized carbon which is transformed into a tetrahedral sp3-atom. 
 
Scheme 18. Enantioselective biocatalytic reduction for the synthesis of chiral alcohols 
 
Beside their practical application in organic chemistry ADHs have gained enormous industrial 
interest owing to the importance of the application of enantiomerically pure alcohols in the 
production of pharmaceuticals, natural products, flavours and agrochemicals.[67] 
Enzymatic reduction reactions can be catalysed by the use of isolated enzymes or whole-cell 
preparations providing a green, sustainable and efficient process alongside chemical processes based 
on the use of synthetic catalysts such as the metal-catalysed asymmetric hydrogenation of ketones.[68] 
The majority of ADHs are dependent on the nicotinamide cofactors β-1,4-nicotinamide 
adenindinucleotide (NADH) or β-1,4-nicotinamide adenindinucleotide phosphate (NADPH) and a few 
on flavines (FMN, FAD) and pyrroloquinoline quinone (PQQ).[69] The reaction mechanism for the 
production of the alcohol involves the reduction of the carbonyl moiety followed by the concurrent 
oxidation of the coenzyme. For the next cycle of the substrate reduction, the coenzyme has to be 
reduced again.  
Due to high costs of these cofactors they are not to be used stoichiometrically, thus a major task in 
process development is to provide an effective method for the regeneration of the consumed 
cofactors so that only catalytic amounts of coenzyme are required.  
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Many methods for the regeneration of the reduced form of the coenzyme have been 
developed.[70] The production of NAD(P)H can be carried out by chemical, electrochemical, 
photochemical and enzymatic methods, the latter one being much more efficient and representing 
the method of choice. Cofactor recycling is however not a major problem when whole cells are used 
as biocatalysts, as the organisms already possess the necessary cofactors. The most widely used 
organism for that purpose is baker’s yeast (Saccharomyces cerevisiae).[71] In those cases inexpensive 
sugars such as sucrose and glucose can be used as auxiliary substrates to give the corresponding (S)-
alcohols in good optical purities. 
For the enzymatic method there are two different approaches, the (i) enzyme coupled and 
the (ii) substrate coupled process.[72]  
The enzyme-coupled approach requires the application of two independent enzymes, one 
that reduces the main substrate, and the second one used for the cofactor recycling in the opposite 
redox direction (Scheme 19).  
 
 
Scheme 19. Enzyme-coupled method for the co-factor recycling 
 
 
 
The substrate-coupled approach requires the presence of a second auxiliary substrate for the 
cofactor regeneration and uses the same enzyme for both processes (Scheme 20). 
 
 
 
Scheme 20. Substrate-coupled method for the co-factor recycling 
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One example of a two-enzyme system is the use of formate dehydrogenase (FDH) for the 
regeneration of NADPH by the oxidation of formate to carbon dioxide. Similarly, the method using 
glucose dehydrogenase (GDH) or glucose-6-phosphate dehydrogenase (G6PDH) has been widely 
employed for the regeneration of NADPH and NADH as well. These enzymes oxidise glucose or 
glucose-6-phosphate to gluconolactone or gluconolactone-6-phosphate respectively, which 
spontaneously hydrolyses in water to form gluconic acid.  
For the substrate-coupled method isopropanol is frequently used as a co-substrate and it is 
oxidised to acetone. Isopropanol is used in excess to shift the equilibrium towards the direction of the 
desired product.  
ADHs can be (S) and (R) specific, depending on the preference for the attachment of the 
hydride either on the si- or the re-side of the ketone. The stereochemical preference depends on the 
steric hindrance of the molecule and follows the model of the so called ‘’Prelog’s rule’’.[1] Most of the 
alcohol dehydrogenases such as yeast ADH or Rhodococcus ruber ADH follow the ‘’Prelog’s rule’’ and 
the hydride attacks the molecule from the re-face yielding (S)-configured alcohols. Anti-Prelog 
dehydrogenases, such as Lactobacillus sp. are (R)-selective and the hydride attacks the ketone 
molecule on the si-side giving alcohols with the opposite stereopreference.  
 
 
 Application of ADHs 
 
The use of ADHs in organic synthesis was at first limited to the substrate scope of aceto-type 
substrates bearing a large and small substituent like the derivatives of acetophenone, 2-alkanones and 
α- and β-ketoesters. Multi-substituted and hydroxyl-substituted acetophenone derivatives along with 
bulky ketones with large substituents that are structurally demanding remained a challenge for the 
enzymatic reduction.[69] In the last decade however a lot of effort has been put into the discovery of 
novel enzymes that are able to accept more sterically demanding ketones.  
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A highly enantioselective reduction of bulky-bulky ketones could be carried out using a 
recombinant ADH from Ralstonia sp.to give the corresponding optically active alcohols in high 
purity.[73] The reduction of bulky aryl alkyl ketones was reported using an isolated ADH from 
Sporobolomyces salmonicolor to obtain the corresponding alcohols in excellent optical purity. The 
enantioselective synthesis of chiral biaryl alcohols was also reported in that period.[74] Whole cells of 
Candida chilensis were also successfully applied for the enantioselective 1,2‐reduction of prochiral 
α,β‐unsaturated ketone to (R) allylic alcohols.[75] 
ADHs received much attention for their broad substrate tolerance and are very useful 
biocatalysts for the production of important building block for many APIs. The discovery of a new 
CgKR2 reductase is attractive for its ability to efficiently reduce chiral precursors necessary for 
synthesis of Angiotensin-Converting Enzyme (ACE) Inhibitors.[76] Likewise, KREDs from Streptomyces 
nodosus can be used for the reduction of protected amino acid derived α-haloketone to give 
intermediates used in the synthesis of an HIV protease inhibitor.[77] 
ADHs were successfully combined with a number of metal-catalysed transformations. The 
combination of a Pd-catalysed Heck reaction with an enzymatic reduction towards a one-pot process 
in aqueous medium was successfully carried out for the synthesis of (R)-(-)-Rhododendrol (Scheme 
21). 
 
Scheme 21. One-pot chemoenzymatic synthesis of (R)-(-)-Rhododendrol 
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Another important transformation is the combination of a Wacker oxidation starting from a 
prochiral alkene which is successfully coupled with an enzymatic reduction in a one-pot process in 
aqueous media for the synthesis of 1-phenylethanol (Scheme 22).[78] 
 
Scheme 22. Chemoenzymatic one-pot process for the enantioselective synthesis of 1-phenylethanol 
 
In summary, enzymatic reductions of prochiral ketones into the corresponding optically active 
alcohols generally proceed with high enantioselectivity and yields. The use of ADHs has therefore be 
proven to be a highly efficient method for the reduction of C=O bonds and can be successfully used as 
catalysts in preparative organic chemistry and on an industrial scale for the synthesis of chiral alcohols. 
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 Results and discussion 
 
 As previously discussed in chapter 2.2 to investigate the viability of the one-pot cascade 
process a study of each separate step has to be carried out first. The Pd-catalysed Suzuki cross-
coupling reaction is based on the method described in the literature.[23] The catalyst used is the 
previously studied water-soluble PdCl2/TPPTS whose activity and stability need yet to be tested in 
eutectic mixtures. The subsequent enantioselective bioreduction step is carried out to obtain the 
corresponding alcohol after the in-situ formation of the desired ketone. In addition, reaching complete 
conversion in the first step of the cascade is highly advisable, since the unreacted ketone is also a 
competitive substrate for the enzymatic reduction. 
 
 
 Development of the Suzuki cross-coupling reaction in a mixture of DES and buffer for 
the synthesis biarylketones 
 
 Suzuki cross-coupling reaction in a mixture of DES-buffer (4:1) 
 
 According to the reported Suzuki cross-coupling reaction in water,[23] the process was carried 
out with the following reaction conditions: 40 mM substrate concentration, catalyst loading of 4 
mol% PdCl2 and 5 mol% TPPTS at room temperature for 24 hours. Rather than using a mixture of 
water and isopropanol the aim was to design a comparable process with the reaction medium 
consisting of a DES-water mixture. For this, a choline chloride (ChCl) and glycerol-based (Gly) 
eutectic mixture was prepared (ChCl/Gly 1:2 w/w), and the reaction medium also contained 20 % 
v/v of water (Scheme 23). Likewise, a slight excess of sodium carbonate was added to ensure the 
basic pH required for the cross-coupling. As a result, the Suzuki cross-coupling reaction proceeded 
smoothly at room temperature in the presence of the homogeneously dissolved catalysts system. 
These preliminary attempts led to the formation of the desired biaryl ketone (5a) with high 
conversion (92%). This satisfying result was on par with the quantitative conversion obtained in 
the originally reported process with water and isopropanol. 
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Scheme 23. Suzuki cross-coupling reaction in a mixture of 1ChCl/2Gly and water at room temperature 
 
 Screening of different mixtures of DES and buffer 
 
 Finding suitable the DES-water mixture as the reaction medium for the Suzuki cross-coupling 
reaction, the coupling between 4’-bromoacetophenone (1b) and phenylboronic acid (2) to yield 4’-
acetylbiphenyl (5a) was selected as a benchmark reaction. Three additional choline chloride-based 
eutectic mixtures, namely 1ChCl/2H2O, 1ChCl/1Sorbitol and 1ChCl/2Urea were prepared by combining 
choline chloride with the opportune amount (w/w) of the second component (see experimental 
section for more details) generating the appropriate DES solution. 
 
Table 1. Suzuki cross-coupling reaction of 4’-bromoacetophenone (1b) and phenylboronic acid (2) in DES-
water mixtures at room temperature 
 
Entry DES T (°C) c (%) 
1 1ChCl/2Gly rt 92 
2 1ChCl/1Sorb rt 82 
3 1ChCl/2Urea rt 0 
4 1ChCl/2H2O rt 80 
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 The result clearly unveiled 1ChCl/2Gly as the optimal DES mixture giving high conversion of 
92% with respect to the formation of the ketone (Table 1, entry 1). On the other hand, the reaction 
did not work in 1ChCl/2Urea (entry 3) while 1ChCl/2H2O and 1ChCl/1Sorb displayed conversions higher 
than 80% (entries 4 and 2). An explanation for this unusual effect could be the potential inactivation 
of the palladium catalyst by urea. Similarly, sorbitol and water have a slightly negative impact on the 
reaction in comparison to the glycerol-containing eutectic mixture. From these results it can be 
concluded that hydroxy-groups are well tolerated while amide bonds might have a negative influence 
on the catalytic transformation. 
 
 Substrate scope of the cross-coupling reaction 
 
Next, the attention was aimed at the use of 1ChCl/2Gly and the substrate scope for the Suzuki 
cross-coupling reaction was studied. Accordingly, ortho-, meta-, para-biaryl and arylpyridine ketones 
were devised and arylbromides and arylboronic acids containing fluorine groups were also used to 
produce fluorinated biaryl analogues. As a result, the resulting ketones were classified into three 
groups according to the reactivity exhibited by their precursor reagents (Table 2): i) fluorinated biaryl 
ketones (entry 5), ii) unsubstituted biaryl ketones (entry 1-4) and iii) arylpyridine ketones (entry 6). 
 
 
Table 2. Substrate scope for the Suzuki cross-coupling reaction 
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Entry Product 
[Pd]/ligand 
[mol%] 
T (°C) 
Substrate 
concentration 
(mM) 
c (%) 
1 
 
4/5 rt 40 92 
2 
 
4/5 rt 40 84 
3 
 
4/5 rt 40 63 
4 
 
4/5 rt 40 83 
5 
 
4/5 rt 40 95 
6 
 
4/5 rt 40 50 
 
The fluorinated derivative (5f) reached a conversion of 95% due to high reactivity of the 
boronic acid bearing such electron-withdrawing groups (entry 5). On the other hand, the conversion 
of the pyridine-substituted biaryl ketone (5c) was lower than 60 % (entry 6). The nitrogen moiety again 
appears to have a negative impact on the conversion which was a further motivation to investigate 
thoroughly the process and improve the results. 
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 Effect of higher temperature and lower catalyst loading 
 
To explore the effect of parameters such as temperature and catalyst loading, the coupling 
between 4’-bromoacetophenone (1b) and phenylboronic acid (2) was taken as a model reaction taking 
place in 1ChCl/2Gly, demonstrated to be the most efficient DES mixture. 
An increase of reaction temperature to 70°C enabled quantitative conversion towards the 
compound 5a (>99%, entry 2). Remarkably, an identical result was obtained at the same temperature 
with a decreased catalyst loading set at only 1 mol% PdCl2 and 3 mol% TPPTS (entry 3).  
 
 
Table 3. Suzuki cross-coupling with different amounts of catalyst loading and higher reaction temperature 
 
Entry Product 
[Pd]/ligand 
[mol%] 
T (°C) 
Substrate 
concentration 
(mM) 
c (%) 
1 1ChCl/2Gly 4/5 rt 40 92 
2 1ChCl/2Gly 4/5 70 40 >99 
3 1ChCl/2Gly 1/3 70 40 >99 
 
 The optimised reactions conditions based on increased temperature were extended for the 
preparation of the previously described biaryl ketones and the conversion dramatically improved in 
all cases. Likewise, the challenging pyridine compound 5c required heating up to 100°C for a complete 
conversion (Table 4, entry 6). Since the pyridine compound had a lower tendency to be converted, 
these new results evidently confirmed that an increase of temperature could overcome such 
limitations of nitrogen-containing compounds.  
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Table 4. Suzuki cross-coupling reaction with reduced catalyst loading and higher reaction temperature 
Entry Product 
[Pd]/ligand 
[mol%] 
T (°C) 
Substrate 
concentration 
(mM) 
c (%) 
1 
 
1/3 70 40 >99 
2 
 
1/3 70 40 >99 
3 
 
1/3 70 40 >99 
4 
 
1/3 70 40 >99 
5 
 
1/3 70 40 >99 
6 
 
1/3 100 40 90 
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 Study of the substrate concentration 
 
After reaching excellent conversions in the previous study, higher substrate concentrations 
were investigated (Table 5, entries 7–11). Thus, it was found that concentrations of 100 mM or higher 
demanded heating to 100°C in the 1ChCl/2Gly-water mixture to reach complete conversion, with the 
upper limit being 200 mM. On the contrary, upon these conditions the analogue mixtures based on 
1ChCl/1Sorb and 1ChCl/2H2O led to poor conversions (<40%, entries 9–10) which resulted in discarding 
these DESs for further optimisation. Considering the structure of these mixtures, the unsatisfying 
effect caused by the use of water and sorbitol as second components could be explained by a different 
special structure and formation of hydrogen bonds. Physical properties such as viscosity, density and 
polarity, along with solubilising capacities are slightly different, a peculiarity that could present a 
disadvantage in their application as extraction and reaction media in this type of reactions.[79] 
To ensure an effective homogeneous mixture following an increased substrate concentration 
the decision was made to use an aqueous phosphate buffer at fixed pH 8.5 in place of sodium 
carbonate. A phosphate buffer ensured an invariable pH through the cross-coupling reaction, while a 
rather weak Na2CO3 base is not strong enough to keep the pH unchanged. 
 Finally, the parametrisation was also extended to other aryl halides. Thus, the aryl chloride 
turned out to be less reactive (65% conversion, Table 5, entry 7) meanwhile the iodine derivative 
enabled complete conversion at 200 mM and 100°C (entry 8). Following the satisfactory results, the 
reactions with bromine and iodine reagents were essayed with a catalyst load reduced tenfold (entries 
9–10). In the case of the aryl iodide the process worked efficiently (entry 9), and despite a slightly 
decreased conversion, the required low catalyst loading could be interesting from an economic point 
of view for large-scale reactions. 
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Table 5. Parametrisation of the Suzuki cross-coupling reaction of 1 and 2 in DES-buffer (4 :1) medium 
catalysed by PdCl2/TPPTS 
 
Entry X DES 
[Pd]/ligand 
[mol%] 
T (°C) 
Substrate 
concentration 
(mM) 
c (%) 
1 Br 1ChCl/2Gly 1/3 70 40 >99 
2 Br 1ChCl/2Gly 1/3 70 100 99 
3 Br 1ChCl/2Gly 1/3 100 200 >99 
4 Br 1ChCl/1Sorb 1/3 100 200 40 
5 Br 1ChCl/2H2O 1/3 100 200 35 
6 Br 1ChCl/2Gly 1/3 100 300 60 
7 Cl 1ChCl/2Gly 1/3 100 200 65 
8 I 1ChCl/2Gly 1/3 100 200 >99 
9 I 1ChCl/2Gly 0.1/0.3 100 200 92 
10 Br 1ChCl/2Gly 0.1/0.3 100 200 40 
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 As depicted in Table 6 the substrate scope of the Suzuki coupling under optimised conditions 
was extended for the total of 10 biaryl and arylpyridine ketones, some of them exhibiting different 
patterns of substitution. Thus, a set of 10 compounds was prepared by reacting appropriate aryl 
bromides and arylboronic acids. 
 
Table 6. Scope of the Suzuki cross-coupling reaction in DES-buffer medium under the optimised reaction 
conditions [200 mM substrate concentration, 1ChCl:2Gly-KPi buffer pH 8.5 (4:1), PdCl2 (1 mol%), TPPTS (3 
mol%), 70 °C or 100 °C, 24 h] 
 
Entry Product 
[Pd]/ligand 
[mol%] 
T (°C) 
Substrate concentration 
(mM) 
c (%) 
1a 
 
1/3 70 200 >99 
2 
 
1/3 70 200 >99 
3 
 
1/3 70 200 >99 
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Entry Product 
[Pd]/ligand 
[mol%] 
T (°C) 
Substrate concentration 
(mM) 
c (%) 
4 
 
1/3 70 200 >99 
5 
 
1/3 70 200 >99 
6a 
 
1/3 70 200 >99 
7 
 
1/3 70 200 >99 
8 
 
1/3 100 200 >99 
9a 
 
1/3 100 200 >99 
10 
 
1/3 100 200 >99 
[a] In these cases (entry 1, 6 and 9) biarylketones were synthesised at a preparative scale. After the reaction 
and following a simple workup (see experimental section for more information) no further column 
chromatography purification was required and the resulting products were isolated in high yields ranging from 
90 to 95%. 
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 The conversion to the biaryl ketones was measured by HPLC and product was quantitatively 
afforded in all cases. The resulting products were easily recovered from the reaction medium by 
adding saturated aqueous NH4Cl followed by an extraction with cyclopentylmethyl ether. The organic 
phases were then combined, dried over Na2SO4, filtered and concentrated under vacuum providing 
the crude product.  
 
 Bioreduction of biarylketones in a mixture of DES and buffer for the synthesis of biaryl 
alcohols 
 
Once assessed the conditions for the Suzuki cross-coupling in the first step of the cascade the 
aim was directed at the enzymatic reduction process by using a Codex® commercial kit of KREDs and 
two ADHs overexpressed in E. coli, namely the (R)-selective ADH from Lactobacillus kefir DSM 20587[80] 
and the ADH from Rhodococcus ruber DSM 44541[81] with opposite enantioselectivity. 
 
 Screening of alcohol dehydrogenases for the synthesis of the biaryl alcohol in a DES-buffer 
mixture 
 
The biaryl ketone 5a was initially tested with a set of engineered KREDs from Codexis, the (R)-
selective ADH from L. kefir and the (S)-selective ADH from R. ruber. In a typical experiment, 5a (5 mM) 
was incubated in the presence of a KRED (200% w/w) at 30°C and 250 rpm in a mixture of 1ChCl/2Gly 
buffer 1: 1.5 (containing 1.25mM MgSO4 and 1 mM NADP+) supplemented with isopropanol (i-PrOH, 
10% v/v) for cofactor recycling. The choice of this reaction medium composition, which contains about 
35% (v/v) of DES, was based on the decision preserve the stability of the enzymes. 
From the series of KREDs of the kit, most of the biocatalysts rendered biphenylethan-1-ol (6a) in 
quantitative conversion and perfect enantioselectivity (>99% ee, entries 1–17). 
 
 
 
 
 
 
 36 
 
Table 7. ADH-catalysed reduction of 4’-acetylbiphenyl (5a) in DES-buffer medium 
 
Entry KRED c (%) ee (%) 
1 P1-A04 >99 >99 (R) 
2 P1-B02 >99 99 (R) 
3 P1-B05 >99 >99 (R) 
4 P1-B10 >99 >99 (R) 
5 P1-H08 >99 98 (R) 
6 P2-G09 >99 >99 (S) 
7 P2-B02 >99 63 (S) 
8 P2-C02 >99 90 (S) 
9 P2-C11 >99 >99 (R) 
10 P2-D03 >99 93 (R) 
11 P2-D11 35 99 (R) 
12 P2-D12 95 95 (R) 
13 P2-G03 >99 >99 (R) 
14 P2-H07 >99 >99 (R) 
15 P3-B03 >99 >99 (S) 
16 P1-A12 >99 >99 (R) 
17 P3-H12 95 98 (S) 
18 L. kefir DSM 20587 >99 >99 (R) 
19 R. ruber DSM 44541 >99 >99 (S) 
 
 Complementary to the Codex® kit screening, the reactions with R. ruber and L. kefir (entries 
18–19) were carried out in a 15 mL falcon tube and 10 U of enzyme was added to a mixture of 
1ChCl:2Gly in phosphate buffer set at pH 7.0 containing 10% v/v isopropanol and the appropriate co-
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factor. At the end of the reaction the mixture was treated with saturated aqueous NH4Cl and extracted 
with ethyl acetate. The organic layers were then combined, filtered and concentrated under vacuum 
to provide the crude product with the yield in both cases higher than 95%. The conversion was 
measured on the achiral reverse-phase HPLC and it was demonstrated that the reaction worked 
efficiently in this reaction medium, forming both enantiomers of 6a in enantiomerically pure form 
(>99% ee). 
 
 
 Substrate scope of the enzymatic reduction  
 
Next, on the basis of the established enzymatic conditions in Table 7, the reduction of 
remaining ketones 5b–j was screened with the overexpressed ADHs from L. kefir and R. ruber along 
with four purified enzymes from the Codex® kit, in particular the (R)-selective KRED_P1-A04 and 
KRED_P2-H07 and the (S)-selective KRED_P2-G09 and KRED_P3-H12 (Table 8). The choice for these 
four biocatalysts was based on the results afforded in Table 7 with 5a, and also on the grounds of their 
excellent activity recently reported for the bioreduction of propiophenone in DES-buffer 1:1 
mixtures.[25] 
 
 
Table 8. ADH-catalysed reduction of biaryl ketones in DES-buffer medium 
 
Entry Ketone Enzyme Alcohol c (%) ee (%) 
1 5b P1-A04  >99 >99 (R) 
2 5b P2-G09 >99 >99 (S) 
3 5b P2-H07  >99 >99 (R) 
4 5b P3-H12  >99 >99 (S) 
5 5b L. kefir  23 n.d. 
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Entry Ketone Enzyme Alcohol c (%) ee (%) 
6a 5b R. ruber   95 >99 (S) 
7 5c P1-A04  >99 >99 (R) 
8 5c P2-G09 >99 >99 (S) 
9 5c P2-H07  >99 >99 (R) 
10 5c P3-H12  >99 >99 (S) 
11 5c L. kefir   >99 84 (R) 
12a 5c R. ruber   >99 >99 (S) 
13 5d P1-A04  >99 >99 (R) 
14 5d P2-G09 >99 92 (S) 
15 5d P2-H07  >99 >99 (R) 
16 5d P3-H12  >99 >99 (S) 
17a 5d L. kefir   >99 >99 (R) 
18 5d R. ruber   >99 >99 (S) 
19 5e P1-A04  
 
>99 >99 (R) 
20 5e P2-G09 >99 >99 (S) 
21 5e P2-H07  >99 >99 (R) 
22 5e P3-H12  >99 >99 (S) 
23 5e L. kefir   >99 >99 (R) 
24a 5e R. ruber   >99 >99 (S) 
25 5f P1-A04  >99 >99 (R) 
26 5f P2-G09  >99 67 (S) 
27 5f P2-H07  >99 >99 (R) 
28 5f P3-H12  >99 95 (S) 
29 5f L. kefir   >99 >99 (R) 
30a 5f R. ruber   >99 >99 (S) 
31 5g P1-A04  >99 >99 (R) 
32 5g P2-G09  >99 94 (S) 
33 5g P2-H07  >99 >99 (R) 
34 5g P3-H12  >99 >99 (S) 
35 5g L. kefir   >99 >99 (R) 
36a 5g R. ruber   >99 >99 (S) 
37 5h P1-A04  >99 >99 (R) 
38 5h P2-G09  >99 >99 (S) 
39 5h P2-H07  >99 >99 (R) 
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Entry Ketone Enzyme Alcohol c (%) ee (%) 
40 5h P3-H12  >99 >99 (S) 
41 5h L. kefir   >99 >99 (R) 
42a 5h R. ruber   >99 >99 (S) 
43 5i P1-A04  >99 >99 (R) 
44 5i P2-G09  95 >99 (S) 
45 5i P2-H07  >99 97 (R) 
46 5i P3-H12  >99 97 (S) 
47 5i L. kefir   94 96 (R) 
48a 5i R. ruber   >99 >99 (S) 
49 5j P1-A04  7 n.d. 
50 5j P2-G09  32 n.d. 
51 5j P2-H07  26 >99 (R) 
52 5j P3-H12  79 16 (S) 
53a 5j P1-B02  >99 >99 (S) 
54 5j P1-B05  >99 >99 (S) 
55 5j L. kefir   0 n.d. 
56 5j R. ruber   75 >99 (S) 
[a] These selected enantiomerically pure biaryl alcohols were synthesised at a preparative scale. At 
the end of the reaction the solution was quenched with NH4Cl and extracted with ethyl acetate. The organic 
layers were then combined, filtered and concentrated under vacuum to provide the crude product in high 
yields (>95%). 
 
All examples described that it was possible to access both enantiomers of the target alcohols 
after 24 hours with very high conversion (>99%) and enantioselectivity (99% ee). The only exception 
was the sterically hindered ortho-biaryl ketone 5j, which led to (R)-6j, however with lower conversion 
compared to the other substrates. Exceptionally, the biaryl ketone 5j was also screened with a 
different KRED from the kit, namely P1-B02, which was recently found to be very active towards 5j in 
aqueous medium.[82] Pleasantly, this biocatalyst made it possible to obtain (S)-6j with complete 
conversion and enantioselectivity (Table 8, entry 53). Interestingly, both L. kefir and R. ruber ADHs 
overexpressed in E. coli were very efficient in terms of reactivity and selectivity towards some of the 
substrates (c>99%, ee>99%). These results make these biocatalysts especially attractive for a 
hypothetical gram-scale process in comparison with the commercial purified ones limited by their high 
cost. 
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 Reducing the amount of isopropanol for the bioreduction process 
 
Isopropanol is critical for the bioreduction process as a co-substrate necessary for the 
regeneration of cofactors NADP+ or NAD+. In the previous reported cascade system the overall one-
pot process consisted of a mixture of equal amounts of water and isopropanol (v/v).[23] In that 
particular case isopropanol did not only act as a co-substrate in the cofactor regeneration system, but 
also as a co-solvent in the first step used to help dissolve the hydrophobic biaryl molecules.  
The current system consisting of a mixture of DES and water benefits from the excellent 
dissolving properties of the DES, which helps in the case of hardly water-soluble substrates, and can 
also be beneficial in particular in cases of high Km (Michaelis constant) values. In such examples it is 
not necessary to supplement additional amounts of isopropanol to the reaction medium.  
To outperform the generally suggested concentration of isopropanol in the medium, capped 
between 10 and 15 % v/v, the aim was to carry out the bioreduction reducing its amount to only 5 % 
v/v. The decrease in conversion was unfortunately observed (Table 9) as the medium certainly 
required substantial amounts of the co-substrate to push the equilibrium towards the product 
formation. Thus, it was concluded that isopropanol is not only necessary from a kinetic point of view, 
but considerable amounts are required to thermodynamically drive the reaction to completion and 
avoid the reduction of the formed acetone.  
Table 9. ADH-catalysed reduction of 4’-acetylbiphenyl (5a) with a decreased amount of isopropanol 
 
Entry Ketone Enzyme i-PrOH (%v/v) Conv. (%) 
1 5a R. ruber DSM 44541 10 >99 
2 5a R. ruber DSM 44541 5 43 
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 Increasing the concentration of the substrate for the bioreduction 
 
  
Scheme24. ADH-catalysed reduction of the biaryl ketone 5a at 75 mM concentration 
 
 An increase of the ketone concentration in the biocatalytic step leads to preferable reaction 
parameters for a manufacturing setting and for that reason the biotransformation was carried out 
with an increased substrate loading. Excellent solubilising properties of DESs, used at 35% v/v, 
therefore ensured a homogeneous reaction mixture for the selected bioreduction with the enzyme 
from R. ruber at 75 mM substrate concentration (Scheme 24), enabling comparable results to those 
obtained in the initial screenings at 5 mM. 
 Synthesis of biaryl alcohols in a one-pot cascade process 
 
With both catalytic steps validated and optimised in terms of reaction parameters, substrate 
concentration and composition of the reaction medium, the combination in a one-pot fashion with 
sequential steps was thoroughly monitored. At first, a Suzuki cross-coupling reaction was conducted 
at 200 mM substrate concentration in a DES-buffer 4:1 medium, followed by the in-situ enzymatic 
reduction of the transiently formed ketone with previous dilution to 75 mM with the DES-buffer 1:1 
medium containing isopropanol, enzyme and cofactor. Accordingly, and based on a recent study about 
the effect of water in the nanostructure of DES,[83] the coupling step was considered to be 
accomplished in a choline chloride/glycerol/water deep eutectic solvent mixture. Respectively, the 
medium for the bioreduction, containing approximately 50% H2O, should be considered an aqueous 
solution of DES components. 
A selection of four target alcohols was made to show the general applicability of the process, 
including examples of unsubstituted (6a), fluorinated (6g) and pyridyl derivatives (6d, e). The 
reductions were carried out utilising the two recombinant ADHs from L. kefir DSM 20587 and R. ruber 
DSM 44541, overexpressed in E. coli, which demonstrated to be promising biocatalysts in the initial 
screening. 
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Table 10. One-pot synthesis of biaryl alcohols by palladium-catalysed Suzuki cross-coupling followed by 
enzymatic reduction 
 
Entry 
Cross-coupling 
T (°C) 
Enzyme Product 
Overall 
conversion 
(%) 
Isolated 
Yield 
(%) 
ee 
(%) 
Absolute 
configuration 
1 100 L. kefir  6a 78 70 >99 (R) 
2 100 R. ruber  6a 86 80 >99 (S) 
3 100 L. kefir  6d 85 80 >99 (R) 
4 100 R. ruber  6d 90 85 >99 (S) 
5 100 L. kefir  6e 91 86 >99 (R) 
6 100 R. ruber  6e 92 84 >99 (S) 
7 70 R. ruber  6g 90 83 >99 (S) 
 
The bioreduction of the formed ketone intermediates generated both enantiomers of 6a with 
good conversion and >99% ee (Table 10, entry 1 and 2). Similar cascades were established to produce 
the biaryl alcohols 6d, 6e and 6g. The ADH from L. kefir DSM 20587 led to the formation of the 
corresponding (R)-enantiomer with >99% ee and conversions of up to 91% (entries 3 and 5). 
Meanwhile, the ADH from R. ruber DSM 44541 gave access to the (S)-counterparts with conversions 
over 90% (entries 4, 6 and 7).  
In all cases, the workup was identical to the single-step process previously described, and 
although having an additional step it was simple and straightforward. Specifically, after 48 hours of 
overall reaction time the mixture was supplemented with saturated NH4Cl and extracted with ethyl 
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acetate. The combined organic layers were dried over Na2SO4, filtered and concentrated under 
vacuum to provide the crude product. Further purification by flash chromatography (silica gel 60A˚, 
hexane-ethyl acetate 1: 1) provided the target biaryl alcohols in high yields (>80% with the exception 
of entry 1). 
 
 Conclusion 
 
A chemoenzymatic cascade consisting on a palladium-catalysed Suzuki cross-coupling 
followed by an enzymatic reduction mediated by alcohol dehydrogenases has been efficiently 
implemented in ad hoc mixtures of DESs and aqueous media. The two catalytic steps took place 
efficiently and the excellent enantioselectivity displayed by the biocatalysts enabled the preparation 
of both enantiomers of several chiral biaryl alcohols in enantiomerically pure form. Likewise, the 
presence of the neoteric solvent in the medium enabled to tackle the solubility hurdles of substrates 
aiding the biotransformation to be carried out at 75 mM concentration. Furthermore, the advantages 
of DESs being utilised as a reaction media are found to be of fundamental importance contributing to 
excellent catalytic performances of both reaction steps of the cascade. 
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3 Process design for enantioselective syntheses of bulky amines based on the 
use of chemocatalysts and transaminases  
 
 Introduction 
 
 The construction of chiral amine structures has raised interest in the field of drug 
development, as the related biaryl amines are key intermediates for the synthesis of a broad range of 
pharmaceuticals and natural products.[84] The presence of the biaryl amine moiety can be seen in a 
number of biologically active compounds such as Valsartan (hypertension), Telmisartan 
(hypertension), Boscalid (fungicide) and Odanacatib (osteoporosis). 
 
 
Scheme 25. Examples of drugs containing the biaryl amine moiety 
 
 The enantiomeric synthesis of chiral biaryl amine compounds can be carried out in a variety 
of chemical pathways which often involve the use of toxic materials, harsh reaction conditions, tedious 
work-ups and various purification steps. On the other hand, amine transaminases (ATAs) emerged as 
a highly valuable alternative catalytic “tool” for the formation of chiral amines, thus enabling novel 
perspectives for a green and sustainable synthetic access to this structural motif. For that reason, the 
biocatalytic process employing these enzymes has recently become of greater interests as an efficient 
method to produce compounds with the amine moiety by reversibly catalysing the transfer of an 
amine group from an amino donor to a ketone or aldehyde.  
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 The active site of the majority of wild-type ATAs consists of a large and a small binding pocket 
and in almost all cases the small binding pocket can accommodate only a methyl group.[85] For that 
reason biaryl ketones are not commonly used in enzymatic transamination reactions due to their size 
and inability to access the small binding pocket of most transaminases. To address this challenge, 
recent advances in protein engineering have enabled the conversion of a variety of sterically 
demanding ketones such as the rationally engineered (S)-selective ATA from V. fluvialis for the 
synthesis of the enantiomerically pure ortho-substituted biaryl amine.[5]  
 ATAs found in the environment were at first all (S)-specific until the discovery of Aspergillus 
terreus (Ate) and Arthrobacter (Ar) ATAs displaying the opposite (R)-enantiopreference.[86] Although 
attractive for their enantioselectivity, the (R)-selective ATAs have a less versatile substrate spectrum 
than their counterpart and so far, only the engineered enzymes have been able to accept highly bulky 
ketones.[87,88] The synthetic potential of (R)-selective ATAs has been investigated by the groups from 
Codexis and Merck & Co who successfully engineered the Arthrobacter ATA-117 applied for the large-
scale production of the antidiabetic drug Sitagliptin (Scheme 26).[19] This biocatalytic process is an 
excellent example of the implementation of biocatalysis in the pharmaceutical industry and has 
triggered enormous attention since its development. 
 
Scheme 26. Biocatalytic synthetic production of Sitagliptin reported by Savile et al[19]  
  
 The potential pharmaceutical applications for these chiral biaryl units was a motivation to 
search for new (R)-selective ATAs and expand the substrate scope within bulky prochiral substrates. 
Having in mind numerous advantages of biocatalytic one-pot reactions the idea was to include a 
reaction system consisting of a chemocatalysed synthesis of biaryl ketones followed by the biocatalytic 
transformation.  At first, the biaryl unit could be constructed through a palladium-catalysed Suzuki-
cross coupling reaction of monoaromatic ketones and boronic compounds.[89] Combining this process 
with the asymmetric reductive amination into a two steps reaction represents an elegant approach 
for the synthesis of these target biaryl amine molecules. A similar application of ATAs in a 
chemocatalytic process has been investigated by Bornscheuer’s group for the formation of biaryl 
amines.[90] Taking into account the importance on the environmental impact, the use of a right solvent 
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system is of crucial significance. Thus, having in mind the results from the previous chapter and the 
significance of Deep Eutectic Solvents, the aim was to investigate the use of this medium in 
combination with amine transaminases for the synthesis of enantiomerically pure biaryl amines. 
 
 Goals and motivation 
 
 Driven by the awareness of the use of bio-renewable and non-toxic solvents the interest 
increased to develop a chemoenzymatic multi-step one-pot process towards biaryl-substituted 
amines by combining a Suzuki cross-coupling reaction with an enzymatic transamination in DESs 
(Scheme 27). 
 
Scheme 27. Chemoenzymatic cascade towards chiral biaryl amines in a DES-buffer medium 
 
 The goal is to demonstrate the usefulness of the newly discovered ATAs in a process not very 
common with this class of enzymes due to their sensible nature and inefficient operational stability at 
high substrate concentrations, along with their incompatibility with metal catalysts and harsh 
conditions usually required for the cross-coupling reactions.[91] The palladium-catalysed Suzuki cross-
coupling promotes a C-C bond formation between halides and boronic acids, and although originally 
performed in organic solvents, recent research demonstrated its applicability in aqueous systems (see 
chapter 2). This discovery is unquestionably beneficial for amine transaminases that function ideally 
in aqueous systems. Thus, the DES-buffer mixtures projected for this one-pot process might be well-
tolerated by ATAs. Nevertheless, their activity and stability in DESs has yet to be determined. For the 
reason of being designed as a one-pot process particular attention has to be given to the reaction 
media to be highly compatible with both steps of the reaction.  
 Initially the two reactions need to be established separately to optimise the conditions 
suitable for both steps. The optimisation will not only include reaction parameters such as 
temperature and pH, but also the choice of the ideal amine donor, co-solvent and biocatalyst 
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formulation with the emphasis on the substrate concentration. Additionally, to access the target chiral 
biaryl-substituted amine molecules the biocatalysts will be improved by means of protein engineering. 
Thus, its effect on enzymatic stability and activity towards certain bulky substrates will be evaluated. 
After successfully optimising the two steps individually, both reactions will be studied in a one-pot 
process stabilising the settings for a concurrent process. 
 Among a few literature examples that cover biotransformations in DES and DES-buffer 
mixtures,[53] this is the first study that examines the application of amine transaminases in these 
neoteric solvents. 
 
 State of the art 
 
 Biocatalysis employing transaminases 
 
 Introduction to transaminases 
 
 Amino acids and amines are essential for living organisms as they play a key role in the 
nitrogen metabolism and are involved in a variety of other important complex functions.[92] These 
compounds are highly important in the food industry and various pharmaceutical applications are 
based on the structure of optically pure amines. They can differ structurally and account for important 
building blocks for the synthesis of drugs like antibiotics, antidiabetics, antihypertensives and many 
others (Scheme 28). 
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Scheme 28. Examples of pharmaceuticals containing chiral amine building blocks 
 
 Optically active amines can be prepared through a variety of classical methods (Scheme 29)[93] 
and the introduction of the amino group often results in the incorporation of its protected form, 
followed by subsequent deprotection steps. Numerous methodologies to access the amino group 
include chemical reactions such as asymmetric hydrogenation of acetamides and imines through the 
employment of transition metal catalysts,[94] or the asymmetric addition of nucleophiles to activated 
imines.[95] Chemical methods also include processes such as the asymmetric hydrogenation of 
imines[96] or the reductive amination of ketones.[97] Most commonly amines are prepared from 
alcohols by converting them into the corresponding halides or sulfonates.[98],[99] This is then followed 
by a nucleophilic introduction of the azide group and a subsequent reduction to yield the amine 
product. To introduce enantioselectivity some reactions generally include the use of chiral ligands, 
chiral auxiliaries or metal complexes.[100] Furthermore, chiral amines can be isolated from the racemic 
mixture by crystallising with diastereomeric salts of chiral carboxylic acids. Other methods for the 
synthesis of chiral amines include C-H amination of hydrocarbons and intramolecular hydroamination 
of aminoalkenes.[101] 
 
 
Scheme 29. Chemical methods for the synthesis of amines 
 
 Compared to chemical processes, enzymatic methods certainly represent an elegant 
alternative for the synthesis of chiral amines. Many enzymes can be used for their preparation, such 
as transaminases (ATAs), hydrolases, amine oxidases (AO), amino acid dehydrogenases (AmDHs), 
imine reductases (IREDs) (Scheme 30).[102]  
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Scheme 30. Biocatalytic routes to optically active amines 
 
 Amine transaminases (EC 2.6.1.18)  were first identified more than 50 years ago[103] as highly 
versatile biocatalysts for the synthesis of optically active amines or α-amino acids. They can be 
classified based on sequence similarities and a three-dimensional structure into six subgroups 
belonging to the fold class I and fold class IV. Another classification is based on their substrate 
specificity as they differ in their natural amine donor with respect to the transferred amino group. α-
transaminases require the presence of a carboxylic acid group in the position to the carbonyl 
functionality whether ω-transaminases accept any ketone or amine and therefore are much more 
useful and generally applied. [102] 
 Today more than 60 microbial transaminases have been discovered,[104] and approximately 20 
new transaminases have been recently identified mostly by means of genome mining and 
metagenomics.[105] The vast majority of ATAs exhibit (S)-selectivity with the enzyme originating from 
Vibrio fluvialis as the most intensively studied transaminase.[106] Recent technological advancements 
resulted in the identification of new enzymes with higher thermostability, broader substrate scope, 
and in particular those that exhibit (R)-selectivity.[88,107,108] 
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 Reaction mechanism 
 ATAs reversibly catalyse the transfer of an amino group from the amino donor to the carbonyl 
moiety of an amino acceptor (Scheme 31). 
 
 
Scheme 31. ATA-catalysed transamination reaction 
 
 
 
 In 1944 It was proposed that pyridoxal might be part of a coenzyme needed for the 
transamination reaction and that transaminases acted via two half-way reactions that interconverted 
pyridoxal and pyridoxamine.[109] Soon the co-enzyme was identified as pyridoxal 5'-phospate (PLP) or 
pyridoxamine 5'-phosphate (PMP). Later in 1955 the vitamin B6-based cofactor PLP was synthesised 
and it was found out to be an essential coenzyme for a variety of enzymes.[110]  
 
 The group transfer is mediated by PLP which plays a crucial role by forming a Schiff base with 
the active site lysine of the enzyme and helps transfer electron and ammonia between the amine 
donor and amino acceptor (Scheme 32).[111]  
 
 The reaction mechanism initially involves the transfer of the amino group to the PLP (1), 
disconnection from lysine and formation of an enzyme-bound PMP intermediate with a corresponding 
keto by-product. The subsequent step involves the transfer of the amine group from PMP to the amino 
acceptor (2), producing the corresponding amine and regenerating the cofactor to its initial state for 
another catalytic cycle. 
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Scheme 32. Reaction cycle of PLP-dependant transaminases for the asymmetric synthesis of amines[69] 
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 The production of chiral amines using ATAs can be carried out through mainly two different 
approaches, namely the kinetic resolution and asymmetric synthesis (Scheme 33). Compared to the 
resolution approach that yields a maximum of 50% yield, the synthetic approach is more convenient 
and can generate a theoretical yield of 100%.  
 
 
Scheme 33. Possible enzymatic routes to optically active amines using ATAs 
 
 By means of kinetic resolution one enantiomer is removed from the racemate with the 
enantiospecific transaminase leaving the other enantiomer, which can be extracted, in 
enantiomerically pure form. This method strongly favours product formation when α-ketoacids such 
as pyruvate are used as amino acceptors. Kinetic resolution is interesting to obtain the enantiomer of 
the opposite configuration and since most amine-TA show (S)-enantiopreference, it has also been an 
attractive method to prepare (R)-amines.  
 One of the limitations of the applications of ATAs is the substrate and product inhibition 
resulting from its reaciton mechanism (Scheme 32). Since two forms of the free enzyme are formed 
(E-PLP and E-PMP) the inhibition may be caused by the binding of substrates and products to the 
‘incorrect’ form of the enzyme (e.g. pyruvate and E-PLP) forming dead-end complexes.[112] A number 
of techniques have been investigated to remove the ketone from the reaction media to increase the 
product yield. Biphasic (aqueous/organic) reaction systems for the kinetic resolution demonstrated to 
be an efficient stategy for the removal of inhibiting ketones.[112] Alternatively, processes combining an 
enzyme-membrane reactor were developed to physically separate the enzymes from the organic 
solvent and simultaneously facilitate the removal of from the aqueous solution.[113] In the case of the 
formation of volatile ketone by-prodacts their removal could be performed using reduced 
pressure.[114] 
 In the asymmetric synthesis approach the enantiomerically pure amine is synthesised by 
transferring the amino group from the amine donor to the prochiral ketone. This reaction has been of 
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great interest as it can generate 100% theoretical yield, and particularly for that reason the applicative 
potential of ATAs has been thoroughly studied.[115]  
 Along with the substrate/product inhibition and their restricted substrate scope, a major 
hurdle in the asymmetric synthesis of chiral amines is the unfavourable reaction equilibrium since all 
steps in the mechanism are reversible.[69] As a result of these obstacles, the application of ATAs in 
organic chemistry has certain limitations and for their use in stereoselective synthesis several efficient 
strategies have been developed[104] which will be discussed in the following paragraphs. 
 
 Strategies for ATA-catalysed processes 
 
 A conventional approach in order to push the transamination reaction towards completion is 
to use an excess of co-substrate. This method has been developed for the transamination of 
acetophenone involving large excess of the inexpensive amine donor isopropylamine (1M) for the 
synthesis of 1-phenylethylamine (Scheme 34).[116] Although simple and rapid, this approach may be 
limited by substrate insolubility, enzyme inhibition and often incompatibility of this amine donor with 
certain ATAs. 
 
Scheme 34. ATA- catalysed transamination of acetophenone with isopropylamine amine donor[116] 
  
 Most ATAs rely on the use of alanine as the amine donor which implies the formation of 
pyruvate, thus several methods have been studied to remove the formed keto-acid by-product 
(Scheme 35).[106] One of today’s most widely use strategies was investigated for the first time by Kim 
and co-workers and involved the use of lactate dehydrogenase (LDH) for the reduction of pyruvate 
into lactate.[117] For an efficient process the NAD(P)H co-factor is required with the addition of a 
dehydrogenase enzyme such as formate dehydrogenase (FDH) or glucose dehydrogenase (GDH).[118] 
This thoroughly studied LDH/GDH system has been afterwards employed for the synthesis of many 
compounds.[115] 
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Scheme 35. Strategies to remove the co-product pyruvate with 1) amino acid dehydrogenase (AADH); 2) 
lactate dehydrogenase (LDH) in combination with glucose dehydrogenase (GDH); 3) pyruvate decarboxylase 
(PDC) 
 
 Pyruvate could alternatively be removed with the pyruvate decarboxylase (PCD) enzyme 
which does not require a co-factor recycling system and the equilibrium is shifted by the evaporation 
of the CO2 formed.[119]  
 Another elegant strategy is to use the amino acid dehydrogenase (AADH), in particular the 
alanine dehydrogenase (AlaDH) to recycle the formed pyruvate back to the corresponding alanine.[120] 
This system requires ammonia and NAD+ which can be easily regenerated using the previously 
described FDH or GDH co-factor recycling system.[121] Moreover, AlaDH was studied in the 
combination with alanine racemase (AlaR) as an efficient method to provide the regeneration of L-
alanine and its in-situ racemisation to obtain the opposite D-alanine isomer (Scheme 36). This strategy 
represents an effective way to use the readily available L-alanine as a starting material for (R)-selective 
ATAs that require the far more expensive D-alanine amine donor.[120] 
 
Scheme 36. Combining AlaDH and alanine racemase, the produced pyruvate is first converted into L-ala and 
then racemised 
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 Furthermore, pyruvate could be removed non-enzymatically through a process that implies 
treatment with H2O2.[122] Although this strategy doesn’t require any additional enzyme, it is restricted 
by the low stability of enzymes in the presence of hydrogen peroxide.  
 From an industrial point of view having isopropylamine as a low-cost amine donor is more 
desirable compared to alanine. This is an easily obtainable and cost-efficient chemical which is 
transformed into acetone during the transamination reaction. Moreover, acetone is easily removable 
under reduced pressure but can be also effectively in-situ removed by combining the process with 
alcohol dehydrogenases (ADH) to produce isopropanol.[123]  
 An alternative method to the equilibrium shifting process is the use of ‘’smart’’ co-substrates 
which spontaneously transform into a stable by-product with the result of pushing the equilibrium 
towards the products side. For this purpose, several diamine co-substrates are used to spontaneously 
cyclize or dimerize in a way to prevent the reverse reaction from occurring (Scheme 37).[124] 
 
Scheme 37. a) various different amine donor can be used to shift the reaction equilibrium. b) diamines such as 
but-2-ene-1,4-diamine and o-xylylenediamine can be used to displace the equilibrium by cyclisation 
 
 The use of whole cells or co-expression of multiple enzymes for the asymmetric synthesis of 
amines is an approach that might overcome most of the drawbacks presented by the previously 
mentioned methods including high costs of enzyme production and addition of high amounts of 
biomass in reaction mixtures.  
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Figure 1. Illustration of a whole-cell system that co-expresses three enzymes for the amination of 4-phenyl-2-
butanone[125]  
 
 An organism that co-expresses transaminases and enzymes for the pyruvate removal and co-
factor regeneration is a promising strategy for that purpose.[126] In certain cases the whole-cell 
biocatalysis improves the stability of ATAs as it was described in the study of Vibrio fluvialis-ATA whose 
chemical tolerance was enhanced with the multi-enzyme system.[127] Very recently a group of 
researchers from the TU Graz co-expressed a system for the production of ATAs, GDH and LDH (Figure 
1).[125] They demonstrated the use of E. coli cell-free extract for the amination of 4-phenyl-2-butanone 
achieving high yields and reaching high substrate loadings, comparable to industrially relevant 
conditions.  
 
 Improving ATAs performance 
 
 To expand the practical and economical application of ATAs in organic synthesis their stability 
issues and non-physiological conditions can be improved. Recent works on ATAs include the 
development of strategies to improve the thermostability, tolerance towards organic solvents and 
chemicals and storage stability.[104] This section focuses on different approaches that have been used 
to optimise the performance of ATAs. 
 
 Generation and discovery of new enzymes 
 
 The generation of novel biocatalysts relies on practically two strategies, namely the gene 
mining to identify new enzymes and protein engineering to mutate the wild-type enzymes.  
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 Isolation of wild-type enzymes and identification in sequence databases is often a tedious and 
time-consuming strategy but it is advantageous due to the enormous supply of sequences and 
genomes in public databases. Screening of ATAs can be classified into classical and computational 
methods. Using classical methods a high number of microorganisms were identified containing 
ATA.[128] This strategy allowed for the identification of ATAs in organisms such as Vibrio fluvialis JS17, 
Bacillus thuringiensis JS64, Anthrobacter sp. KNK 168, Pseudomonas sp. NCIMB 11753 and many 
others. With computational methods a vast number of genes have been deposited in databases which 
in turn allowed to identify novel enzymes such as the Chromobacterium violaceum and many (R)-
selective transaminases.[85] 
 The in-silico strategies complemented with the traditional approach for identifying enzymes 
through tests on microorganisms positively contributed to the discovery of enzymes with higher 
activity, desired enantiopreference and higher stability. Recently thermostable ATAs have been 
identified with operational temperatures over 60°C.[129] With the help of bioinformatic research new 
enzymes with a broader substrate spectrum were discovered. Many of these novel enzymes showed 
good activity towards isopropylamine and provided access to different chiral amines and α-amino 
acids.[130],[131],[108] 
 An increasing number of crystal structures and characterization of available ATAs made it 
possible to structure-orientate engineering studies with the aim to obtain improved 
transaminases.[104] Thus, having an improved understanding of the enzyme’s substrate binding 
allowed researchers to engineer a Vibrio fluvialis mutant able to convert bulky-bulky ketones through 
mutations of the small pocket of the active site.[132]  
 
 Biocatalyst formulation 
 
 Immobilization is a strategy often used to improve enzyme properties and facilitate their 
implementation at a larger scale. It is one of the most vastly used methods to increase their efficiency 
by improving their stability and recyclability, allowing for their employment in different solvents 
systems, at high pH and temperature and often increased substrate concentration.[133] The large-scale 
application of commercialized enzymes is often restricted by the use of expensive carrier materials, 
hence the need for effective and economical immobilization methods. Immobilization might also 
positively affect functional properties of enzymes as it was often demonstrated that the 
enantioselectivity of different enzymes could be improved.[3]  
 Immobilization techniques could reduce problems that transaminase encounter such as the 
product and substrate inhibition as a result of their reaction mechanism, or inactivation caused by 
 58 
 
various components of the reaction medium. Early attempts of transamination immobilization include 
the encapsulation of both commercially available enzymes as well as cell-free extracts in sol-gel matrix 
or chitosan beads.[134] These strategies allowed the catalyst to be reused, resulting in a lower effective 
enzyme loading. Furthermore, these methods showed activity even at pH 11 and no loss of conversion 
or enantioselectivity was observed. Additionally enzymes often retained their initial activity even after 
prolonged storage periods, which could be associated with the conformal stabilization of the enzyme 
following the immobilization.[134,135] Beside the use of immobilized enzymes in aqueous reaction 
systems, these formulations were active and stable in organic solvents. This study reported a 
successful immobilization of transaminases on a hydrophobic SEPABEADS EXE120 support which 
allowed for multiple rounds of enzyme use without any significant loss of activity.[136] This 
immobilization method was recently studied with the transaminase from Halomonas elongata in a 
continuous flow-biocatalysis setup.[137] 
 Applications of immobilized (S) and (R)-selective transaminases enabled high conversions in 
batch, but also in continuous flow processes. For that purpose ATAs were often immobilized on 
cellulose matrix,[138] polymeric resins,[139] methacrylated beads,[140] and MnO2 nanorods after being 
fused to an elastin-like polypeptide.[141] 
 An important aspect of enzyme immobilization is often their loss of activity, probably due to 
their structural change that leads to irreversible denaturation.[142] In order to be effective, the 
procedure of immobilisation should be fast, scalable and reproducible whilst maintaining the 
enzymatic activity. These supports should be mechanically stable, readily available and cost-effective 
in order to bring the process to industrial biocatalysis.  
 
 Lyophilisation is often an option employed when transamination reactions are carried out in 
organic solvent. This fairly straightforward strategy involves the removal of water molecules followed 
by rapid freezing which allows the protein structure to maintain its conformation and prevents 
denaturation. This is a stable biocatalyst formulation that often permits longer storage. 
 
 An alternative and certainly the most preferred biocatalyst formulation is the enzyme in its 
purified form. However, purification methods are often expensive and time consuming. Alternatively 
cell-free extracts (CFE) often show comparable activity to the purified form and are the most widely 
used formulation on laboratory scale due to its ease of production and low cost.[104] 
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 Medium engineering 
 
 Enzymes generally exhibit lower activity in organic solvents and a lot of effort has been put 
into the discovery of enzymes that are naturally stable in that reaction medium.[143] One option to 
achieve higher stability in organic solvents is to increase their activity by means of protein engineering. 
Additionally, applying reaction medium engineering is another possible strategy addressed to solve 
stability issues of transaminases as having a suitable and well-tolerated solvent is certainly an 
attractive advantage to improve their application for diverse chemical processes.  
 Certain solvents have been reported to have positive effects on enzymatic half-life.[144] The 
most studied were the additions of glycerol, methanol and DMSO and it was determined that they 
improved storage abilities of Chromobacterium violaceum ATA.[145]  
 
 The synthesis of chiral amines often involves the presence of highly apolar compounds, such 
as ketones or aromatic compounds and since biotransformations are typically carried out in aqueous 
systems they generally suffer from the poor solubility of reagents and products in water. To 
circumvent this problem organic solvents can be supplemented as co-solvents sometimes with the 
expense of enzyme stability generally limited in these media. For that reason, water-miscible co-
solvents are often used to increase the solubility of rather insoluble substrates such as bulky ketones 
or aromatic compounds.  
 Nonetheless, certain transaminases employed as crude enzyme preparations also worked in 
organic media without the need of being immobilized.[146] Nine transaminases accepted 
isopropylamine as amine donor and worked effectively in tert-butyl ether (MTBE). In that study the 
biocatalytic transformation in organic media showed advantages such as higher reaction rates (up to 
17‐fold), less tedious work‐up procedure (i.e. no basification and extraction required), possibility to 
recycle the enzyme and lack of substrate inhibition. 
 Efficient medium engineering evaluates the effect of co-solvents on the enzyme’s reaction 
rate as well as stability. In 2010 the group of N. J. Turner developed a convenient process development 
strategy as they evaluated various co-solvents and their effect on the transamination reaction. [147] 
Their effect was thoroughly studied with (R)- and (S)-stereospecific ATAs and it was demonstrated that 
the enzymes achieved higher activities with little amounts of DMSO (2.5-5% v/v) compared to the 
reaction with only buffer as the reaction medium.[148] The effect of various water-soluble and 
immiscible co-solvents was tested in the transamination reaction of 4-phenyl-2-butanone.[149] The 
presence of 15% of solvents such as DMSO and methanol significantly decreased the conversion, 
although the enantiomeric excess remained unchanged. However, low tolerance of wild-type enzymes 
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towards co-solvents was observed, a flaw which could be additionally improved by means of protein 
engineering.  
 
 Application of ATAs in bio- and chemoenzymatic cascade reactions 
 
 Having many properties in common with other enzymes ATAs often being employed in 
multiple-enzyme cascade reactions and combined with other biocatalysts. For that purpose ATAs are 
often present in associations with other enzymes such as lyases, transketolases and hydrolases. In 
particular, Smith et al describe an efficient biocatalytic route to chiral amino alcohols consisting of the 
combination of a transketolase with the transaminase from Chromobacterium violaceum for the 
synthesis of this important class of compounds (Scheme 38).[150] 
 
Scheme 38. Two-step biocatalytic synthesis of 2-amino-1,3-diols using transketolase (TKA) and amine 
transaminase from Chromobacterium violaceum 
 
 As described in section 3.3.1.1 amines are frequently synthesised from alcohols. Similarly, an 
artificial multienzyme network approach has been designed in the asymmetric amination of secondary 
alcohols to the corresponding α-chiral primary amines through the use of a multistep enzymatic 
system consisting of alcohol dehydrogenases (ADHs) and ATAs.[151]   
Another prominent example of the combination of biocatalysts is the synthesis of 3’‐
substituted cyclohexylamine derivatives (Scheme 39).[152] This asymmetric three-steps cascade starts 
with the formation of chiral centres with a C-C 6-oxocamphor hydrolase, followed by the esterification 
catalysed by a CAL-B lipase. Finally, the ketone is transformed into the corresponding amine using an 
(R)- or (S)-selective amine transaminase to obtain cis- and trans- diastereomers in optically pure forms. 
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Scheme 39. Diastereoselective synthesis of 2-(3-aminocyclohexyl)acetic acid methyl ester derivatives via a 
three-step cascade process employing a C-C hydrolase OCH, lipase CALB and an amine transaminase 
 
 Apart from the ability to produce optically pure amine compounds, ATAs have been effectively 
used to obtain highly-valuable non-natural amino acids. For that purpose an ATA from Paracoccus 
denitrificans PD1222 has been successfully coupled with threonine deaminase in a one-pot system to 
obtain L-homoalanine.[153] Furthermore, a one-pot two-step cascade consisting of a kinetic resolution 
and subsequent stereoselective amination catalysed by two enantiocomplementary ATAs was also 
described. The resulting amines were obtained with up to quantitative conversion and excellent 
enantioselectivities giving optically pure pharmacologically relevant amines.[154] The combination of 
ATAs and deaminases was also described in a study in 2008 as a multienzymatic process for the 
synthesis of a CGRP receptors antagonist was developed. The synthetic route consisted of an amino 
acid deaminase followed by an (R)-selective transaminase to prepare the key intermediate needed for 
the synthesis of the target drug. 
 ATA-catalysed reactions have been successfully integrated with various chemical 
transformations resulting in a successful combination of chemoenzymatic processes for the synthesis 
of beneficial compounds. Beside for the already mentioned synthesis of Sitagliptin, ATAs have been 
successfully applied for the preparation of Rivastigmine, a drug for the treatment of Alzheimer’s 
disease.[155] This highly stereoselective chemoenzymatic process was developed via a four step 
procedure using the enzyme from Vibrio fluvialis for the synthesis of (S)-Rivastigmine with an overall 
isolated yield of 71 %, whereas (R)-enantiomer was obtained with complementary ATA-117. 
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 More recently, an excellent example of a one-pot chemoenzymatic cascade was described for 
the total synthesis of capsaicinoids (Scheme 40).[156] The overall environmentally friendly process 
consisted of a few possible routes starting from lignin-derived compounds, involved different catalytic 
steps and described the compatibility of biocatalysts with heterogeneous metal catalysts. The process 
consisted of three steps, namely the production of vanillin (74), the formation of the aminated 
compound (5e) and the production of amide (78), with the possibility to achieve each of them by 
either chemo- or bio-catalysis. For this synthesis of Capsaicin analogues, the steps were combined in 
a one-pot fashion without any protection and purification needed, which resulted in a more efficient, 
sustainable and economical route. 
 
Scheme 40. Total synthesis of Capsaicin analogues describing the compatibility of chemoenzymatic methods[156] 
ATAs have been successfully applied in the chemoenzymatic synthetic route towards the 
preparation of Janus kinase 2 (JAK2) inhibitor AZD1480 to construct the key chiral amine using a two-
phase reaction mixture to avoid enzyme inhibition. Similar chemoenzymatic processes have been 
developed for a number of pharmaceutically relevant compounds, intermediates and APIs. For 
instance the preparation of the drug to treat insomnia was prepared in a nine-steps three-enzyme 
system process using ATAs to prepare chiral lactams from prochiral ketones.[157] 
 These examples highlight the applicability of amine transaminases for the preparation of 
amines on both laboratory and industrial scale. Moreover, recent technological advancements in the 
fields of enzyme discovery, protein engineering and process optimisations allowed biocatalysis to 
prevail as a promising strategy in organic synthesis for an efficient production of valuable 
pharmaceuticals.   
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Results and discussion 
 
 The previous chapter described the synthesis of biaryl alcohols by means of a Suzuki cross-
coupling and subsequent bioreduction catalysed by KREDs of the transiently formed ketones. In regard 
to the process development of that research a similar pattern takes place for the multi-step synthesis 
of biaryl amines. Referring to the previous project the use of DESs allowed to tackle the solubility 
hurdles and reach concentrations of 200 mM for the coupling step and 75 mM for the later 
bioreduction. Having that in mind, it is necessary to evaluate the stability of transaminases in these 
solvents, and above all to find a reaction mixture suitable for both steps of the cascade. After 
optimising the first step of the cascade, the focus is switched to the biotransformation process with 
the goal to select the appropriate transaminases and the efficient amine donor system. Finally, both 
processes are combined in a one-pot multistep sequence for the synthesis of bulky amines. 
 
 Development of the Suzuki cross-coupling reaction in a mixture of DES and buffer for 
the synthesis of biarylamines 
 
 
Scheme 41. Suzuki cross-coupling reaction of 4’-bromoacetophenone (1b) and phenylboronic acid (2) 
 
 Taking into account the excellent properties of the 1ChCl/2Gly DES mixture based on the 
previous research from chapter 2, the same composition was tested along with other water-miscible 
co-solvents in order to find the reaction media suitable for both steps of the cascade. For this, 
equimolar amounts of 4’-bromoacetophenone (1b) and phenylboronic acid (2) were added at 40 mM 
in a mixture of water and the individual co-solvent at room temperature (Scheme 41). As depicted in 
Scheme 42, the measured conversions towards the compound 5a were very high (≥90%) at 50% of i-
PrOH, THF and 1ChCl/2Gly respectively, whereas the reaction did not work at all at 50% of DMSO. 
When the concentration of these co-solvents was lowered to 10 % v/v, there was no improvement in 
the formation of the biaryl ketone. On the contrary, 10 % v/v co-solvent concentration seemed to 
generate lower results, probably caused by inefficient solubility of the rather apolar substrate 1b at 
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such a high-water content. The reaction with 10 % DMSO slightly improved compared to higher 
amounts of this co-solvent. A rather low 30 % conversion in that case was by all means too low to 
progress with the choice of this co-solvent.  
 Based on the knowledge gained in the previous chapters 1ChCl/2Gly turned up to be a suitable 
candidate for the one-pot process. Furthermore, the first step of the process could be effectively 
accomplished up to 200 mM substrate concentration in a DES-water 4:1 mixture at temperatures 
ranging from 70 to 100 °C (see chapter 2). Nonetheless, it will still be necessary to investigate the 
feasibility of the transamination step in Deep Eutectic Solvents along with the above mentioned i-PrOH 
and THF for their use as co-solvents in the one-pot cascade process. 
 
 
Scheme 42. Effect of co-solvent on the Suzuki cross-coupling reaction for the synthesis of 4’-acetylbiphenyl 5a 
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 Transamination reactions employing ω-transaminases 
 
 In the joint project with Aline Telzerow from the University of TU Graz, using data mining, six 
new amine transaminases cloned from different organisms were available and supplied.[158] Five of 
these available ATAs were demonstrated to be (R)-selective and will be studied in the enzymatic 
transamination reaction of ketones and bulky substrates (Table 11). 
 
 
Figure 2. SDS-PAGE of the crude extracts of five new (R)-selective ATAs 
 
Table 11. The enzymatic volumetric activity of the new (R)-selective ATAs identified by Aline Telzerow[158] 
Entry Enzyme Organism of origin Activity (U/ml lysate) 
1 EX-wt Exophiala xenobiotica 16.9 
2 Esi Exophiala sideris 6.42 
3 Pac Pseudonocardia acaciae 4.2 
4 Shi Shinella 13.21 
5 Tja Tetrasphaera japonica 3.04 
 
The amount of overexpression of the five (R)-selective ATAs was studied via the SDS-PAGE 
analysis (Figure 2). Furthermore, the acetophenone assay was used to measure the enzymatic 
performance and confirmed highest activities in EX-wt and Shi amine transaminases (Table 11). 
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Furthermore, the industrial partner DSM provided four amine transaminases, namely the 
ATAs from Vibrio fluvialis (Vf-ATA)[159], Chromobacterium violaceum (Cv-ATA)[160], Aspergillus terreus 
(Ate-ATA)[161] and its mutated variant Ate-ATA_T274S (unpublished) (Table 12). 
 
Table 12. The enzymatic volumetric activity of the ATAs from DSM 
Entry Enzyme Activity (U/ml lysate) 
1 Vf-ATA 51.8 
2 Cv-ATA 42.3 
3 Ate-ATA 28.2 
4 Ate-ATA_T274S 44.4 
 
 The initial screening strategy involved the selection of the preferred amine donor for the 
amination of simple monoaryl ketones (1a and 1b). The ATAs provided from DSM showed great 
conversion ranging from 68 -99 % towards the selected ketones with excellent enantioselectivity 
(Table 13). The course of the reaction could be easily followed by thin-layer chromatography (TLC) 
analysis (chloroform/methanol/acetic acid, 12:2:1) as the amines had an evidently lower Rf (~0.3) 
compared to the ketone starting material (~0.9). Simple staining with ninhydrin was sufficient to 
visualise the obtained aromatic amines as distinct purple spots. 
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Table 13. Enzymatic asymmetric amination of mono aryl ketones using ATAs from DSM 
 
Entry Substrate Amine donor Enzyme c (%) ee (%) 
1 1a L-alanine Vf-ATA >99 >99 (S) 
2 1b L-alanine Vf-ATA 90 >99 (S) 
3 1a L-alanine Cv-ATA 90 >99 (S) 
4 1b L-alanine Cv-ATA 68 >99 (S) 
5 1a D-alanine Ate-ATA 98 >99 (R) 
6 1b D-alanine Ate-ATA 93 >99 (R) 
7 1a D-alanine Ate-ATA_T274S >99 >99 (R) 
8 1b D-alanine Ate-ATA_T274S 95 >99 (R) 
 
 The selection of the appropriate amine donor is a crucial parameter, and although the use of 
isopropylamine seems a good alternative from the economical perspective, its use is restricted only 
to certain ATAs. For that reason, the biotransformation is often achieved through the use of other 
amine donors such as L-alanine. Although being fairly cheap and readily available, the use of L-alanine 
is limited to (S)-selective transaminases, while the (R)-selective ATAs demand for the more expensive 
D-alanine enantiomer. For that reason, the choice of a suitable amine donor poses a challenging and 
necessary task. 
 As Ate-TA and ATA_T274S are known to have no trouble accepting isopropylamine as the 
amine donor, the favoured amine donor for the five recently identified ATAs had yet to be identified. 
For that purpose, the biotransformation was tested under the simplest reaction conditions comparing 
the performance using isopropylamine and alanine as the amine donors.  
 The obtained results displayed very low conversion in most cases with isopropylamine and 
certain enzymes did not accept this amine donor at all (Table 14). Contrarily, D-alanine was revealed 
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to be the amine donor of choice for the five recently discovered transaminases as a considerably 
higher conversion was achieved with all five enzymes to obtain the monoaryl amines 7a and 7b (Table 
15). 
 
Table 14. Enzymatic asymmetric amination of monoaromatic ketones using new (R)-selective ATAs with 
isopropylamine amine donor 
 
Entry Substrate Amine donor Enzyme c (%) 
1 1b i-PrNH2 Esi 0 
2 1a i-PrNH2 Esi 0 
3 1b i-PrNH2 EX-wt 16 
4 1a i-PrNH2 EX-wt <5 
5 1b i-PrNH2 Pac 32 
6 1a i-PrNH2 Pac 23 
7 1b i-PrNH2 Shi 20 
8 1a i-PrNH2 Shi <5 
9 1b i-PrNH2 Tja 0 
19 1a i-PrNH2 Tja <5 
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Table 15. Enzymatic asymmetric amination of monoaromatic ketones using new (R)-selective ATAs with D-
alanine amine donor 
 
Entry Substrate Amine donor Enzyme c (%) ee (%) 
1 1a D-alanine Esi 5 >99 (R) 
2 1b D-alanine Esi 18 >99 (R) 
3 1a D-alanine EX-wt 15 >99 (R) 
4 1b D-alanine EX-wt >99 >99 (R) 
5 1a D-alanine Pac 42 >99 (R) 
6 1b D-alanine Pac 45 >99 (R) 
7 1a D-alanine Shi 51 >99 (R) 
8 1b D-alanine Shi 95 >99 (R) 
9 1a D-alanine Tja 10 >99 (R) 
10 1b D-alanine Tja 13 >99 (R) 
 
 In order to achieve the goal of the one-pot cascade process towards the bulky biaryl amine 
the joined ATAs were tested for the conversion of the 4’-acetylbiphenyl (5a). After thorough 
parameterization encompassing not only the involved enzymes and cofactors but also pH, amino 
donor and co-solvent, the enzymatic system worked efficiently according to the following reaction 
setup: 5a (20 mM) in 100 mM phosphate buffer pH 7.5, supplemented with PLP (1 mM), NAD+ (0.1 
mM), glucose (60 mM), D-alanine (6.5 equivalents), DMSO (5% v/v) and 8 U of ATA were used. After 
24 h of incubation at 30 °C and 250 rpm, the TLC analysis (chloroform/methanol/acetic acid, 12:2:1) 
followed by ninhydrin staining revealed the formation of the amine. Further validation was needed 
and the subsequent HPLC analyses confirmed the production of the corresponding biaryl amine (R)-
8a in enantiomerically pure form (>99% ee, Table 16, entry 2) with a conversion of 83% using the EX-
wt enzyme. On the other hand, the Shi ATA was able to convert the 4’-acetylbiphenyl to the respective 
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chiral biaryl amine with a conversion of 17 % (Table 16, entry 4). These positive results highlighted the 
possibility to use of EX-wt in a one-pot system for the synthesis of bulky biaryl amines.  
 It is also worth noting that although the other enzymes (entry 1, 3, 5-9) effortlessly converted 
the mono aryl substrates with relatively high conversions (Table 13, 15), they were unable to accept 
the bulky biaryl ketone and convert it into the corresponding amine under the identical reaction 
conditions. 
 
Table 16. Enzymatic asymmetric amination of 4’-acetylbiphenyl using the available ATAs 
 
Entry Enzyme c (%) ee (%) 
1 Esi 0  n.d. 
2 EX-wt 83  ≥99 (R) 
3 Pac 0  n.d. 
4 Shi 17  ≥99 (R) 
5 Tja 0  n.d. 
6 Vf-ATA 0  n.d. 
7 Cv-ATA 0  n.d. 
8 Ate-ATA 0  n.d. 
9 Ate-ATA_T274S 0  n.d. 
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 (R)-selective amine transaminase from Exophiala xenobiotica for the synthesis bulky 
biaryl amines 
 
 To identify new (R)-selective ATAs that expand the substrate scope within previously 
inaccessible bulky substrates several sequences from literature were used for sequence-based 
similarity searches against the NCBI database. Exophiala xenobiotica-ATA (EX-ωTA) was chosen based 
on the habitat of its host organism. The black yeast E. xenobiotica was isolated from environments 
that were associated with toxic, aromatic xenobiotics such as oil sludge, creosote-treated railway tie, 
soil polluted by gasoline or brown coal rich in phenolic compounds.[162] The hypothesis was that the 
presence and density of so many different aromatic compounds in the habitat of E. xenobiotica might 
have led to a natural evolution of its transaminase to accept some substrates that other ATAs do not 
tolerate. 
 Encouraged by the latest result of the bioamination of the compound 5a the substrate scope 
was explored employing a panel of ortho-, meta-, para-biaryl and arylpyridine ketones, some of them 
exhibiting different patterns of substitution at the phenyl moiety next to the carbonyl group (Scheme 
43). Additionally, the protein crystal structure of the wild type enzyme (Figure 3) was obtained which 
enabled structure-guided protein engineering. As a result, five variants were prepared with EX-STA 
and EX-STA5 being the best ones in terms of stability and activity towards various biaryl ketones. 
 
 
Figure 3. Crystal structure of the EX-ꞷTA dimer (chain A in orange, chain B in turquoise), PLP is indicated in 
yellow. The figure was provided by Aline Telzerow and prepared using the program PyMOL 
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Scheme 43. Substrate scope of biaryl ketones for the enzymatic transamination reaction 
 
 While none of the variants showed detectable catalysis toward the ortho-biaryl ketone 5j 
(Table 17, entry 10), a remarkable activity was observed for meta- and para-biaryl ketones. Formation 
of the amine was clearly visible via TLC analysis (chloroform/methanol/acetic acid, 12:2:1) followed 
by staining with ninhydrin, and further confirmed by HPLC measurement.  In particular, the 
unsubstituted arylpyridine ketones 5c-e rendered conversions higher than 70% (entries 8-10). The 
inactivity toward 4’-phenylpropiophenone (5b, entry 2) unveiled the size restrictions of EX-ωTA in the 
small binding pocket, which cannot accommodate substituents larger than a methyl group.  
 Fluorine atoms on different positions on the aromatic group in ketones 5f-h had a negative 
impact on the conversion which was attributed to the strong electron-withdrawing effect of fluorine 
(entries 6-8).  
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Table 17. Substrate scope of EX-wt and its variants 
 
Entry Substrate EX-wt EX-STA EX-STA5 ee (%) 
1 5a 83 45 45 >99 (R) 
2 5b - - - n.d. 
3 5c 72 >99 80 >99 (R) 
4 5d 82 >99 95 >99 (R) 
5 5e 85 >99 70 >99 (R) 
6 5f 25 72 55 >99 (R) 
7 5g 21 40 30 >99 (R) 
8 5h 25 30 24 >99 (R) 
9 5i 38 85 85 >99 (R) 
10 5j - - - n.d. 
 
 
Figure 4. The black yeast E. xenobiotica, isolated from harsh and toxic environments, was able to accept bulky 
substrates that other known ATAs are unable to tolerate 
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 In conclusion, the EX-ωTA displayed perfect asymmetric induction in the reductive amination 
of the carbonyl group of the biaryl ketones, leading to the (R)-enantiomer of each amine with >99% 
ee. These results already underline the high potential of this enzyme for the synthesis of chiral biaryl 
amine building blocks of various pharmaceutical intermediates and chemical compounds. 
 
 Optimisation of the transamination reaction 
 
 Taking the EX-STA-catalysed transamination of 5d as a model reaction (Table 17, entry 4), 
several process parameters were investigated on an analytical scale. In detail, the formulation of the 
biocatalyst, the amino donor, the concentration of substrate and the enzyme loading were assessed.  
 As described in the previous sections, a major limitation in the asymmetric synthesis starting 
from prostereogenic ketones is the product inhibition and the unfavourable thermodynamic 
equilibrium. Many studies addressed this issue and a number of methods have been developed to 
shift the equilibrium towards the desired amination reaction.[106,120,163] One of the suggested methods 
implies the use of the preferred amine donor in excessive amounts. From the economical aspect it is 
desirable to lower the amount of the amine donor and find the lowest quantity necessary to efficiently 
carry out the reaction. For that purpose, the amount of the amine donor was investigated as original 
protocols suggested the use of 12 equivalents of D-alanine.[116] It was then demonstrated that the 
reaction ran smoothly with 7 equivalents of D-alanine in regards to the substrate.  
 Moreover, the analysis of the enzyme formulation displayed that the engineered enzymes EX-
5, EX-STA and EX-STA5 retained their activity as a lyophilised powder in contrast to the wild type whose 
activity dropped dramatically (Scheme 44). These findings were beneficial for the preparative-scale 
and cascade reactions and further confirmed the advantages of protein engineering. 
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Scheme 44. Study of the performance of EX-ωTA and its variants in different formulations for the 
transamination of the biaryl ketone 5d 
 
 In addition, the same model reaction was used to investigate the possibility of having 
isopropylamine as the amine donor with the engineered variants using the lyophilised formulation. 
Pleasantly these enzymes accepted isopropylamine although with lower conversions than those 
measured with alanine (Scheme 45). This feature again demonstrates the benefits of protein 
engineering as the possibility to use isopropylamine heavily broadens the spectrum of possible 
reactions. To complement these studies a kinetic analysis was carried out and it was demonstrated 
that the transamination of the compound 5d fully took place after only 3 hours of reaction time 
(Scheme 46). This significantly reduces the duration of the biotransformation and the entire cascade 
as this step was usually carried out for 24 hours.  
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Scheme 45. Enzymatic transamination of the compound 5d catalysed by lyophilised EX-ωTA and its variants 
using isopropylamine (1M) as amino donor compared to the use of D-alanine 
 
 Furthermore, the enzymatic reaction worked efficiently at up to 75 mM substrate 
concentration (Scheme 46) which was a substantial increase from the previously tested reactions at 
concentrations that barely reached 20 mM.  
 Another optimisation study was aimed to investigate the lowest amount of enzyme required 
for the biotransformation which was thus carried out in the range of 1 - 4 U per mg of substrate 
(Scheme 48).  
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 Reducing the amount of enzyme starting from 4 U per mg of substrate gradually showed a 
decrease of conversion. Thus, 4 U per mg of substrate was defined as optimally the lowest enzyme 
loading necessary to successfully carry out the biotransformation reaction (Scheme 47). This finding 
is a considerable improvement over the previously used 8 U per mg substrate as it heavily reduces the 
necessary amount of enzyme and facilitates the upscaling of the process. 
 
 
 
Scheme 46. Study of the kinetics for the transamination of 5d catalysed by lyophilised EX-STA  
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Scheme 47. Enzymatic transamination of 5d catalysed by lyophilised EX-STA at different substrate loadings 
 
 
Scheme 48. Enzymatic transamination of 5d catalysed by lyophilised EX-STA at different enzyme loadings 
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 To illustrate the synthetic applicability of the new ATA, a preparative-scale biotransformation 
was carried out. The target biotransformation was accomplished at a 100 mg-scale and 75 mM of the 
compound 5d to afford the enantiomerically pure (R)-8d in excellent isolated yield (96%) after 
extractive workup and without the need for further purification of the crude product (Scheme 49). 
 
Scheme 49. Preparative-scale transamination of 5d catalysed by EX-STA 
 
 Activity of EX-ωTA in DES and other co-solvents 
 
 In order for the transaminases to be suitable for the one-pot process a key challenge was to 
determine if the enzyme is active in the solvents already tested for the Suzuki cross-coupling reaction 
step. Accordingly, the bioamination of the biaryl ketone 5d was investigated as a benchmark reaction 
with the mutant EX-STA, the variant leading to the highest conversions. The biotransformation was 
conducted under the previously optimised reaction setup, namely based on the use of alanine as 
amino donor and the LDH/GDH recycling system. As deduced from Table 18, the presence of THF and 
i-PrOH was harmful for the enzyme, resulting in a conversion being very low at 15% of co-solvent 
(entries 2 and 4). Conversely, the ATA remained very active in both DMSO and 1ChCl/2Gly with 
conversions almost quantitative at 15% of co-solvent (entries 5-8). An increase to 25% DES decreased 
the enzymatic performance by 40% (entry 9) while the activity of the ATA in DES-buffer 1:1 was 
negligible (entry 10). In conclusion, the variant exhibited perfect enantioselectivity regardless of the 
co-solvent and its ratio, with the resulting amine (R)-8d displaying >99% ee in all cases. 
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Table 18. Effect of co-solvent on the conversion of the EX-STA-catalysed bioamination of biaryl ketone 5d 
 
Entry Co-solvent (%) c (%) ee (%) 
1 THF (5%) 8 >99 (R) 
2 THF (15%) - n.d. 
3 i-PrOH (5%) 64 >99 (R) 
4 i-PrOH (15%) <5 n.d. 
5 DMSO (5%) >99 >99 (R) 
6 DMSO (15%) >99 >99 (R) 
7 1ChCl/2Gly (5%) >99 >99 (R) 
8 1ChCl/2Gly (15%) 95 >99 (R) 
9 1ChCl/2Gly (25%) 60 >99 (R) 
10 1ChCl/2Gly (50%) <5 n.d. 
 
 
 ATA-catalysed bioamination of phenylacetone in different DES-buffer media 
 
 For a better understanding of the unveiled stability of ATAs in DES-buffer mixtures the study 
was extended to enzymes from the Codexis commercial kit, also overexpressed in E. coli.[164] 
Furthermore the enzymes utilized were the (S)-selective ATAs from Chromobacterium violaceum 
(Cv),[160] (S)-Arthrobacter (ArS),[165] the (R)-selective ATAs from (R)-Arthrobacter (ArR)[86] and its 
evolved variant ArRmut11.[19] For this study, phenylacetone (1c) was selected as a substrate, which 
had been efficiently converted for those ATAs in conventional aqueous medium.[166] 
 Four choline chloride-based eutectic mixtures, namely 1ChCl/2Gly, 1ChCl/2H2O, 1ChCl/1Sorb 
and 1ChCl/2Urea were screened at variable water content (Table 19). In a typical experiment aimed 
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at evaluating the enzymatic performance, 1c (30 mM) was incubated in a mixture (1 mM PLP and 1 M 
isopropylamine) of DES and potassium phosphate buffer 100 mM at pH 7.0, 30 °C and 250 rpm during 
24 hours. The first conclusion was that the DES-buffer mixtures resulted in being a suitable reaction 
media for both purified and overexpressed ATAs at 25% or 50% (w/w) DES. Conversely, the 
commercial purified enzymes led to very high conversions in the four media tested (entries 1-4). 
Indeed, the conversion values were almost identical to those reported in aqueous buffer solution,[166] 
and in the case of ATA-256 the conversion even increased from 57% to 90-95% in the neoteric mixtures 
(entry 3).  
 With regards to the overexpressed enzymes, the transaminase from C. violaceum and ArS-TA 
were less active in 1ChCl/2H2O, 1ChCl/1Sorb and 1ChCl/2Urea meanwhile they exhibited comparable 
activities in 1ChCl/2Gly to those in aqueous buffer (entries 5-6). On the other hand, the enzymes from 
ArR and ArRmut11 led to good conversion in all the DES-buffer mixtures, especially in the case of the 
ATA from ArRmut11. For the particular case of 1ChCl/2Gly, a further increase to 75% (w/w) DES proved 
to be harmless for ATAs with changes in the conversion rate lower than 5%.  
 It is worth noting the excellent tolerance of DESs by ATAs, far greater than organic solvents.[167] 
The unexpected stability of ATAs in DESs could be explained following a recent study in which the DES 
hydration tolerance was investigated and the presence of water in its nanostructured domains was 
discussed.[83] 
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Table 19. Effect of different DESs-buffer media on the conversion of the ATA-catalysed bioamination of 
phenylacetone 
 
  Buffer 1ChCl/2Gly 1ChCl/2H2O 1ChCl/1Sorb 1ChCl/2Urea 
Entry Enzyme  
25% 
DES 
50% 
DES 
75% 
DES 
25% 
DES 
50% 
DES 
25% 
DES 
50% 
DES 
25% 
DES 
50% 
DES 
1 ATA-237 95 98 93 93 90 90 93 88 91 88 
2 ATA-251 95 97 92 92 93 90 >99 91 95 86 
3 ATA-256 57 95 95 95 91 92 85 88 90 85 
4 ATA-P1-G06 95 95 95 92 95 90 96 91 95 90 
5 Cv 91 94 90 85 5 30 12 15 <5 <5 
6 ArS 64 45 42 40 10 25 10 35 <5 <5 
7 ArR 91 55 60 72 50 80 85 90 70 65 
8 ArRmut11 >99 95 95 95 90 80 73 95 85 90 
 
 Inhibition studies 
 
 After both reaction steps of the cascade have been studied separately, the focus was to 
investigate the potential inhibitory effects of the remaining reagents from the Suzuki cross-coupling 
reaction on the biocatalytic system (Scheme 50). Thus, the transamination of the compound 5d under 
the optimised setup (Table 18, entry 8) was subjected to deferent reaction parameters namely the 
impact of the formed catalyst [Pd(TPPTS)2Cl2], the ligand TPPTS and boronic acid on this enzymatic 
step. 
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Scheme 50. Study of the potential inhibitory effect of the cross-coupling reagents on the biocatalytic system 
 
 The EX-STA enzyme variant tolerated concentrations of TPPTS to up to 10 mol% (Scheme 51). 
The ligand in the solution started to have a negative impact on the enzymatic activity only at 
concentrations above 10 mol % which in turn generated only 45% of the amine product at 22 mol % 
concentration. On the other hand the palladium complex did not have such an unfavourable impact, 
as 1 mol% of [Pd(TPPTS)2Cl2] inhibited the enzyme slightly, resulting in a conversion of the 
biotransformation of 81% at that concentration (Scheme 52). Doubling the amount of catalyst 
gradually decreased the effectiveness of the biocatalytic step, as 3 mol% of the complex resulted in a 
67 % final conversion.  
 Lastly, the boronic acid component was well-tolerated by the enzyme reaching concentrations 
of 50 mol% for a nearly complete conversion (Scheme 53). 
 
Scheme 51. Enzyme activity at different concentrations of TPPTS 
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Scheme 52. Enzyme activity at different concentrations of the palladium complex 
 
 
 
Scheme 53. Enzyme activity at different concentrations of boronic acid 
  
 The presence of the boronic acid and the TPPTS salt in the solution however should not pose 
a problem to the enzymatic step since the reported Suzuki cross-coupling occurs quantitatively from 
equimolar amounts of these species, thus leading to their full consumption prior to the addition of the 
enzyme in the one-pot process. 
 
0
10
20
30
40
50
60
70
80
90
100
110
0 1 2 3
C
o
n
ve
rs
io
n
 %
mol % concentration
[Pd(TPPTS)2Cl2]
0
10
20
30
40
50
60
70
80
90
100
110
0 20 40 60 80 100 120 140 160
C
o
n
ve
rs
io
n
 %
mol % concentration
Boronic acid
 85 
 
 Synthesis of biaryl amines in a one-pot cascade process 
 
 The impact of the Suzuki cross-coupling components and co-solvents on ATAs was essential 
to setup the chemoenzymatic cascade in a sequential fashion. Attention had to be given to the 
concentration of the starting components and temperature as the first step was carried out at 100 °C 
and 200 mM while the enzymatic step on the other hand is limited to the ketone concentration of 75 
mM and works efficiently only at temperatures lower than 50 °C. Likewise, although the first step is 
accomplished at 80% (w/w) DES, the EX-STA only tolerates 15% of this solvent (Table 18, entry 8).  
With these premises, the first step was efficiently conducted at 100 °C in DES-water 4:1. Once 
the reaction was completed, the mixture containing 4’-acetylbiphenyl (5a) was diluted to 75 mM with 
the aqueous buffer for the bioamination and supplemented with EX-STA, LDH, GDH, glucose, the 
cofactors and the amino donor. After 24 h of incubation at 30 °C and 250 rpm, the resulting 1-([1,1'-
biphenyl]-4-yl)ethanamine (8a) was produced with a conversion of 15%. A plausible explanation for 
this low conversion was presumably the high content of DES during the bioamination step. Actually, 
the dilution of the DES-water 4:1 mixture from 200 mM to 75 mM results in a medium containing 
approximately 30% DES. Considering the previous studies (Table 18) over 15% of DES v/v had negative 
effect on the enzyme activity. Accordingly, the dilution of the reaction mixture containing the 
transiently biaryl ketone was fixed at 50 mM, resulting in a final 20% of DES for the biotransformation. 
As expected, the conversion for 8a increased up to 30%. Further dilution to 25 mM, which results in 
10% of DES, led to an optimised conversion of 45% (Table 20, entry 1).  
 In addition to the EXE-STA variant, the cascade was tested with the wild-type enzyme, which 
had previously exhibited the highest conversion in the single bioamination of 8a (c= 83%, Table 16, 
entry 2). However, upon the optimal cascade setup described above (25 mM concentration in the 
biotransformation) the conversion to the desired amine dropped to only 35% (Table 20, entry 2). 
Nonetheless, encouraged by the potential of this dual catalytic system, the methodology was 
extended to other substrates with both EX-STA and EX-wt. Thus, the initial metal-catalysed step 
proceeded quantitatively in all cases, leading to the formation of 3’-acetylbiphenyl 5i and methyl 
pyridylphenyl ketones 5c-e.  The subsequent transamination step proceeded according to the 
optimised conditions and the conversion of ketones to their respective amines was confirmed via TLC 
analysis (chloroform/methanol/acetic acid, 12:2:1). The immediate appearance of purple spots 
followed by ninhydrin staining indicated the formation of the desired products. According to the HPLC 
analysis EX-STA converted quantitatively (c >95%) the resulting ketones into the corresponding (R)-
biaryl amines 8c-e,i with >99% ee (Table 20, entries 3, 5, 7, 9). Conversely, as a result of its poor 
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stability in the DES-buffer medium, the EX-wt displayed very low product formation (Table 20, entries 
6, 8, 10) and even no conversions at all (Table 20, entry 4).  
 Although originally engineered to have a higher enzymatic activity and a larger binding pocket, 
the EX-STA variant turned out to be more stable than the wild type enzyme in DES-buffer mixtures, a 
feature that made it possible to carry out an efficient one-pot cascade process. 
Table 20. One-pot synthesis of enantiomerically pure biaryl amines by palladium-catalysed Suzuki cross-
coupling followed by enzymatic transamination in a DES-buffer mixture 
 
Entry Enzyme Product c (%) Isolated yield (%) ee (%) 
1 EX-STA 
 
45 32 >99 (R) 
2 EX-wt 
 
35 n.d. >99 (R) 
3 EX-STA 
 
95 85 >99 (R) 
4 EX-wt 
 
- n.d. n.d. 
5 EX-STA  >99 85 >99 (R) 
6 EX-wt  20 n.d. >99 (R) 
7 EX-STA  >99 88 >99 (R) 
8 EX-wt  10 n.d. n.d. 
9 EX-STA  >99 90 >99 (R) 
10 EX-wt  5 n.d. n.d. 
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 Conclusion 
 
 A chemoenzymatic cascade consisting of a palladium-catalysed Suzuki cross-coupling followed 
by an enzymatic transamination mediated by ω-transaminases has been efficiently implemented in 
ad hoc mixtures of DESs and aqueous media. 
 At first a suitable (R)-selective ATA which naturally converts biaryl ketones to the 
corresponding enantiomerically pure amines has been identified, followed by accurate protein 
engineering that improved the biocatalysts activity and stability, allowing for a preparative-scale biaryl 
amine synthesis. 
 
Figure 5. Illustration of a one-pot synthesis of biaryl amines in the mixture of DESs and aqueous media 
 
 Furthermore, the advantages of the reaction the medium allowed the cross-coupling step to 
proceed smoothly at high substrate concentration. The ATAs exhibited good stability and catalytic 
performance at high percentages of DES (up to 75%) which allowed the two processes to be effectively 
combined after thorough reaction optimisation resulting in a successful sequential one-pot process. 
This unprecedented enzymatic activity of ATAs is an excellent proof of concept of the practical value 
of biorenewable solvents for synthetic chemists.  
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4 Summary 
  
Among several achievements realised throughout this research, the highlight is certainly the use of 
Deep eutectic solvents for one-pot chemoenzymatic cascades. Amine transaminases and alcohol 
dehydrogenases displayed praiseworthy performances in these neoteric solvents for the synthesis of 
bulky chiral compounds.  
Besides the broadening of the substrate scope, a variety of of different enzymes has been tested for 
both cascade reactions. For the chemoenzymatic ketone reduction a number of commercially 
available ADHs was first screened in an individual process, followed by its combination with the 
chemical step resulting in a successful one-pot reaction.  
Contrarily to ADHs, for the ATA catalysed reactions there were no reported enzymes able to accept 
such demanding biaryl substrates. It was thus inevitable to screen for ATAs that would work with these 
challenging compounds, leading to the discovery of two enzymes that could naturally convert the 
bulky ketones. The (R)-selective transaminase from Exophiala xenobiotica showed exceptional results 
for this purpose and the acquisition of its crystal structure enabled to explain the substrate 
acceptance, thus making it possible to further improve its performance by means of protein 
engineering.  
The substrate scope for both enzymatic processes was in principle closely related and consisted of 
ortho-, meta- and para-biaryl and arylpyridine ketones, some of them exhibiting different patterns of 
substitution. A first process development by conductive small-scale experiments for the Suzuki cross-
coupling was successful with the best performing model substrate. Consequently, intensive process 
optimisation led to lower utilization of the metal catalyst and allowed a higher substrate loading with 
the biotransformations being carried out in the range of 25-75 mM substrate concentration. 
Besides the possibility to reach high substrate concentration the unique propeties of DESs allowed to 
obtain chiral amines and alcohols in good yields (70 – 90 %) and a very high enantiomeric excess (>99 
%). 
These results highlight the value of nature’s biodiversity as an ever-increasing source of new genomes 
and metagenomes to identify unprecedented catalytic activities which can lead to novel robust 
biocatalysts. Furthermore medium engineering was demonstrated to be a valuable solution for the 
optimisation of chemical transformations and biocatalytic reactions with the possibility to overcome 
a set of hurdles and and reach improvement of the overall process.  
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5 Experimental section 
 
 Materials and general methods 
 
Enzymes 
Codex® KRED Screening Kit was purchased from Codexis. 
 
Codex® Transaminase Screening Kit (ATASK-000250) was purchased from Codexis. 
 
The (S)-alcohol dehydrogenase from Rhodococcus ruber DSM 44541[81] was provided as a cell-free 
extract (CFE) by InnoSyn. The total protein concentration is about 46 mg/ml with a good expression 
level of the ADH in the soluble fraction. The activity determined spectrophotometrically at pH 6.0 with 
acetone and NADH as substrates was 225 U/ml or 4.85 U/mg total protein, respectively. 
 
The (R)-alcohol dehydrogenase from Lactobacillus kefir DSM 20587[80] was provided as a cell-free 
extract (CFE) by the Industrial Organic Chemistry and Biotechnology group in Bielefeld. The 
determination of the protein amount revealed ca. 22 mg/mL. The activity of the enzyme is about 1468 
U/mL. The activities for both enzymes were measured by the above-mentioned groups referring to 
the activity for acetophenone following the appropriate assay known in the literature.[168] 
 
LDH (Lactate dehydrogenase) from rabbit muscle (Sigma-Aldrich, Type II, ammonium sulfate 
suspension, 800-1,200 U mg-1 protein). 
 
GDH (Glucose dehydrogenase) from Bacillus megaterium was expressed in Escherichia coli. The 
activity was determined as 1884 U mL-1 according to the assay described in the literature.[169] 
 
E. xenobiotica ATA gene codon-optimised for expression in Escherichia coli was ordered from 
Geneart/LifeTech (Vienna, Austria). 
 
The (S)-selective ω-TA from Chromobacterium violaceum (Cv-TA) and Vibrio fluvialis (Vf-ATA), and the 
(R)-selective ω-TA from Aspergillus terreus (Ate-ATA) and its mutated variant (Ate-ATA_T274S) were 
provided as a cell-free extracts (CFE) by DSM. Other ω-TAs were provided by InnoSyn B.V. (Geleen, 
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The Netherlands) or, when stated, were expressed in Escherichia coli and the activity was measured 
spectrophotometrically. 
 
Transaminases from Arthrobacter sp. [ArR (pEG23), ArS (pEG29) and ArRmut11 (pEG90)] were 
overexpressed in E.coli and used and lyophilised cells. The protein content of these four transaminases 
was established by the Pierce’s method (mg protein/mg catalyst) according to the manufacturer’s 
instructions: ArS (0.37), Cv (0.31), ArRmut11 (0.38), ArR (0.19). 
 
Reagents 
The ligand TPPTS (Triphenylphosphine-3,3',3''-trisulfonic acid trisodium salt hydrate, tech. 85%) was 
purchased from Alfa Aesar. 1-(Biphenyl-4-yl)ethanone (5a) was purchased from Merck Schuchardt. 
Palladium(II) chloride was purchased from TCI. Arylbromides (1a,b,f-j and 3c-e) and phenylboronic 
acids (2a,b,f-j and 4c-e) were purchased from Sigma Aldrich. D-(+)-glucose was purchased from VWR. 
D-alanine, PLP (Pyridoxal 5′-phosphate hydrate) and NAD+ were purchased from Sigma Aldrich. 
 
Protein expression and purification: 
After transformation of E. coli BL21-Gold(DE3) (Stratagene, La Jolla, CA, USA), the cells were grown at 
37 °C in terrific broth medium supplemented with ampicillin (Amp: 100 μg mL-1). Expression was 
induced with 0.1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) at an OD600 between 0.6-0.8 and 
carried out at 25 °C overnight. The cells were harvested at 4000 x g for 15 min and resuspended in 
buffer (50 mM KPi buffer, pH 7.5, 0.1 mM PLP). The cells were disrupted by sonication (Branson 
Sonifier S-250, 6 min, 80% duty cycle, 70% output) and centrifuged at 50000 x g for 1 h. The cleared 
lysates were filtered through 0.45 μm syringe filters. The protein concentration of the lysate was 
determined by Bradford protein assay. The expression and solubility of the proteins was analyzed by 
SDS-PAGE (NuPAGE Bis-Tris PreCast Gels/Life Technologies). The protein was frozen and stored at -20 
°C until further use. 
 
Spectrophotometric activity assay 
The activity of the ATA variants was determined with an adjusted acetophenone photometric assay. 
The substrate phenylethylamine is converted to acetophenone, which can be detected 
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spectrophotometrically at 300 nm. The absorbance increases with rising product concentration. To 
measure the activities of the ATA variants, reactions were set up in 1 mL volume with 100 mM KPi 
buffer pH 7.5 containing 0.1 mM PLP, 5 mM phenylethylamine and 5 mM pyruvic acid. For the 
reaction, 50 μg to 250 μg of total protein were used. The production of acetophenone was measured 
for several minutes at 300 nm at 30 °C. The volumetric activity in U mL-1 and the specific activity in U 
mg-1 total protein of the enzyme samples was calculated using the Beer-Lambert law with the molar 
extinction coefficient of acetophenone ε300 = 0.28 cm2 μmol-1. 
 
NMR 
1H-NMR and proton-decoupled 13C-NMR spectra (CDCl3) were obtained using a Bruker DPX-300 (1H, 
300.13 MHz and 13C, 75.5 MHz) spectrometer using the δ scale (ppm) for chemical shifts. Calibration 
was made on the signal of the solvent (13C: CDCl3, 77.16; 1H: CDCl3, 7.26).[170]  
 
Optical activity  
Optical rotations were measured using a Perkin-Elmer 241 polarimeter and are quoted in units of 10-
1deg cm2 g-1.  
 
HPLC for conversion (c) and enantiomeric excess (ee) determination 
The determination of conversion (c) of ketones, amines and alcohols was measured at the following 
settings: 
Conversion was determined monitoring and comparing the integrated areas of the product with the 
starting material in the HPLC chromatogram. 
HPLC Method for 5a-b, 5f-j, 6a-b, 6f-j, 7a-c, 8a-b, 8f-j (Method A): HPLC analyses were carried out in 
an Agilent chromatographic system, using a reversed phase column (Zorbax Eclipse XDB-C18, RR, 1.8 
μm, 4.6 x 50 mm, Agilent) and acetonitrile (MeCN) and 0.1% trifluoroacetic acid (TFA) in water as 
solvents. Samples were eluted with three linear gradients from 10% to 60% MeCN during 5.70 min, 
followed by another from 60% to 100% MeCN during 0.5 min and a third gradient from 100% to 10% 
MeCN during 1.90 min, at flow rate of 2 ml/min. Detection and spectral characterization of peaks were 
performed at 220 nm with a diode array detector and ChemStation Rev.B.03.01 software (Agilent).  
HPLC Method for 5c-e, 6c-e, 8c-e (Method B): HPLC analyses (for 5c-e) were carried out in an Agilent 
chromatographic system, using a reversed phase column (Zorbax Eclipse XDB-C18, RR, 1.8 μm, 4.6 x 
50 mm, Agilent) and acetonitrile (MeCN) and 0.1% triethylamine (Et3N) in water as solvents. Samples 
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were eluted with three linear gradients from 10% to 60% MeCN during 5.70 min, followed by another 
from 60% to 100% MeCN during 0.5 min and a third gradient from 100% to 10% MeCN during 1.90 
min, at flow rate of 1.50 ml/min. Detection and spectral characterization of peaks were performed at 
278 nm with a diode array detector and ChemStation Rev.B.03.01 software (Agilent). 
 
The determination of enantiomeric excess was measured at the following settings: 
HPLC analyses to determine the enantiomeric excess were performed on a Hewlett Packard 1100 LC 
liquid chromatograph using hexane/isopropanol mixtures and 0.8 mL/min flow. Detection of peaks 
(UV absorption) was performed at 210 and 278 nm on normal-phase AD-H or OD-H columns. 
 
Column chromatography 
The column-chromatographic purification was carried out with Merck® Silica Gel 60 (0.04-0.063 nm) 
as the stationary phase and different proportions of ethyl acetate and Hexane were used as mobile 
phases.  
 
Thin Layer Chromatography (TLC) 
Glass TLC plates coated with silica were used. To detect the substances, fluorescence quenching was 
used under UV light at the wavelength of 254 nm. The detection of alcohols was determined with 
using the permanganate staining procedure. To follow the formation of the amine products the TLC 
plates were stained with ninhydrin resulting in the formation of purple or orange spots after heating. 
 
APCI+-MS 
High resolution mass spectra were recorded on a Bruker Impact II instrument. 
 
Preparation of DESs 
Deep Eutectic Solvents ChCl-Gly (1:2 w/w), ChCl-H2O (1:2 w/w), ChCl-Sorb (1:1 w/w) and ChCl-Urea 
(1:2 w/w) were prepared by adding choline chloride to a round-bottom flask followed by the addition 
of the second component. The mixture was then gently heated under stirring at 60-80 °C for 1 hour. 
The corresponding individual components were homogeneously dissolved and a clear solution was 
obtained signalling the completion of the process. For simplicity purposes the DES mixtures in the text 
were expressed as follows: 1ChCl/2Gly, 1ChCl/2H2O, 1ChCl/1Sorb and 1ChCl/2Urea. 
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 Pd-catalysed Suzuki cross-coupling reaction 
 
 Study of different Deep Eutectic Solvents 
 
 
 At first, a suspension of PdCl2 (2.8 mg; 0.016 mmol; 4 mol %) and TPPTS (11.3 mg; 0.020 mmol; 
5 mol %) in 1.0 mL of phosphate buffer 150 mM pH 8.5 was prepared. After 30 min the resulting 
catalyst solution was added to a mixture consisting of 4’-bromoacetophenone (1b, 0.389 mmol), 
boronic acid (2, 0.389 mmol), DES (8.0 mL) and phosphate buffer 150 mM pH 8.5 (1.0 mL). The pH was 
adjusted to 8.5 by adding aqueous 3 N NaOH and the reaction mixture stirred at room temperature 
for 24 h. After this time, the reaction was quenched with saturated aqueous NH4Cl (10 mL) and 
extracted with ethyl acetate (2 × 20 mL). The combined organic layers were combined, dried with 
NaSO4, filtered and concentrated under vacuum to provide the crude product 5a. The degree of 
conversion (c) was determined via HPLC and the results obtained in these reactions are shown in Table 
21. 
 
 
Table 21. Screening of different DESs to obtain the ketone 5a 
Entry DES c (%) 
1 1ChCl/2Gly 92 
2 1ChCl/1Sorb 82 
3 1ChCl/2Urea 0 
4 1ChCl/2H2O 80 
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 Study of amount of catalyst and temperature 
 
 It was performed following the procedure detailed above. The degree of conversion (c) of 
each reaction was determined from HPLC analysis of the crude material. The results obtained in 
these reactions are shown in Table 22. 
 
 
Table 22. Screening of amount of catalyst and temperature to obtain the ketone 5a 
 
Entry 
[Pd]/ligand 
[mol%] 
T (°C) c (%) 
1 4/5 rt 92 
2 1/3 rt 78 
3 1/3 70 >99 
 
 
 Synthesis of biarylketones in DES-Buffer medium after process optimisation  
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General procedure for the preparation of biaryl ketones: 
 At first, a suspension of PdCl2 (3.5 mg; 0.02 mmol; 1 mol%) and TPPTS (34 mg; 0.06 mmol; 3 
mol%) in 1 mL of phosphate buffer 150 mM pH 8.5 was prepared. After 30 min the resulting catalyst 
solution was added to a mixture, consisting of arylbromide (1 or 3, 1.945 mmol; 1 eq, 200 mM), 
boronic acid (2 or 4, 1.945 mmol; 1 eq, 200 mM), DES (8 mL) and phosphate buffer 150 mM pH 8.5 (1 
mL). The pH was adjusted to 8.5 by dropwise addition of aq 3 N NaOH and the reaction mixture was 
heated according to the substrate of choice for 24 h. Then, 20 mL of aq saturated NH4Cl was added 
and extracted with ethyl acetate (2x20 mL). The combined organic layers were combined, dried with 
Na2SO4, filtered and concentrated under vacuum providing the crude product (5 a-j).  
 
 Synthesis of 1-([1,1'-biphenyl]-4-yl)ethanone (5a) 
 
At first, a suspension of PdCl2 (3.5 mg; 0.02 mmol; 1 mol%) and TPPTS (34 mg; 
0.06 mmol; 3 mol%) in 1 mL of phosphate buffer 150 mM pH 8.5 was prepared. 
After 30 min the resulting catalyst solution was added to a mixture, consisting of 
4’-bromoacetophenone (386 mg, 1.945 mmol; 1 eq, 200 mM), phenylboronic 
acid (2, 237,76 mg, 1.945 mmol; 1 eq, 200 mM), DES (8 mL) and phosphate buffer 150 mM pH 8.5 (1 
mL). The pH was adjusted to 8.5 by dropwise addition of aq 3 N NaOH and the reaction mixture was 
heated to 70 °C for 24 h. Then, 20 mL of aq saturated NH4Cl was added and extracted with ethyl 
acetate (2x20 mL). The combined organic layers were combined, dried with Na2SO4, filtered and 
concentrated under vacuum providing the crude product. With further purification by flash 
chromatography (silica gel 60 Å, hexane-ethyl acetate 14: 1) a white solid was obtained. 
1H NMR (500 MHz, CDCl3) δ (ppm): 2.64 (s, 3H), 7.43 – 7.38 (m, 1H), 7.51 – 7.45 (m, 2H), 7.65 – 7.61 
(m, 2H), 7.71 – 7.67 (m, 2H), 8.07 – 8.01 (m, 2H). These spectroscopic data are in good agreement with 
the characterized compound in the literature.[23] 
RP-HPLC (Method A): tR = 5.8 min 
 
 Synthesis of 1-([1,1'-biphenyl]-4-yl)propan-1-one (5b) 
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At first, a suspension of PdCl2 (3.5 mg; 0.02 mmol; 1 mol%) and TPPTS (34 mg; 
0.06 mmol; 3 mol%) in 1 mL of phosphate buffer 150 mM pH 8.5 was prepared. 
After 30 min the resulting catalyst solution was added to a mixture, consisting 
of 4-bromopropiophenone (414,42 mg, 1.945 mmol; 1 eq, 200 mM), 
phenylboronic acid (2, 237,8 mg, 1.945 mmol; 1 eq, 200 mM), DES (8 mL) and phosphate buffer 150 
mM pH 8.5 (1 mL). The pH was adjusted to 8.5 by dropwise addition of aq 3 N NaOH and the reaction 
mixture was heated to 70 °C for 24 h. Then, 20 mL of aq saturated NH4Cl was added and extracted 
with ethyl acetate (2x20 mL). The combined organic layers were combined, dried with Na2SO4, filtered 
and concentrated under vacuum providing the crude product. With further purification by flash 
chromatography (silica gel 60 Å, hexane-ethyl acetate 14: 1) a white solid was obtained. 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.26 (t, J 7.5 Hz, 3H), 3.04 (q, J 7.5 Hz, 2H), 7.37-7.51 (m, 3H), 7.60-
7.72 (m, 4H), 8.04 (d, J 8.4 Hz, 2H). These spectroscopic data are in good agreement with the 
characterized compound in the literature.[171] 
RP-HPLC (Method A): tR = 6.5 min 
 
 Synthesis of 1-(4-(pyridin-2-yl)phenyl)ethanone (5c) 
 
At first, a suspension of PdCl2 (3.5 mg; 0.02 mmol; 1 mol%) and TPPTS (34 mg; 
0.06 mmol; 3 mol%) in 1 mL of phosphate buffer 150 mM pH 8.5 was prepared. 
After 30 min the resulting catalyst solution was added to a mixture, consisting 
of 2-bromopyridine (307,3 mg, 1.945 mmol; 1 eq, 200 mM), 4-
acetylphenylboronic acid (2, 318,9 mg, 1.945 mmol; 1 eq, 200 mM), DES (8 mL) and phosphate buffer 
150 mM pH 8.5 (1 mL). The pH was adjusted to 8.5 by dropwise addition of aq 3 N NaOH and the 
reaction mixture was heated to 100 °C for 24 h. Then, 20 mL of aq saturated NH4Cl was added and 
extracted with ethyl acetate (2x20 mL). The combined organic layers were combined, dried with 
Na2SO4, filtered and concentrated under vacuum providing the crude product. With further 
purification by flash chromatography (silica gel 60 Å, hexane-ethyl acetate 3: 1) a yellow solid was 
obtained.  
1H NMR (300 MHz, CDCl3) δ (ppm): 2.64 (s, 3H), 7.28 (q, J 3.9 Hz, 1H), 7.71 (d, J 8.4 Hz, 1H), 7.79 (d, J 
4.8 Hz, 1H), 8.04-8.11 (m, 4H), 8.72 (d, J 4.8 Hz, 1H). These spectroscopic data are in good agreement 
with the characterized compound in the literature. [172] 
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RP-HPLC (Method B): tR = 5.6 min 
 
 Synthesis of 1-(4-(pyridin-3-yl)phenyl)ethanone (5d) 
 
At first, a suspension of PdCl2 (3.5 mg; 0.02 mmol; 1 mol%) and TPPTS (34 mg; 
0.06 mmol; 3 mol%) in 1 mL of phosphate buffer 150 mM pH 8.5 was prepared. 
After 30 min the resulting catalyst solution was added to a mixture, consisting of 
3-bromopyridine (307,3 mg, 1.945 mmol; 1 eq, 200 mM), 4-acetylphenylboronic 
acid (2, 318,9 mg, 1.945 mmol; 1 eq, 200 mM), DES (8 mL) and phosphate buffer 
150 mM pH 8.5 (1 mL). The pH was adjusted to 8.5 by dropwise addition of aq 3 N NaOH and the 
reaction mixture was heated to 100 °C for 24 h. Then, 20 mL of aq saturated NH4Cl was added and 
extracted with ethyl acetate (2x20 mL). The combined organic layers were combined, dried with 
Na2SO4, filtered and concentrated under vacuum providing the crude product. With further 
purification by flash chromatography (silica gel 60 Å, hexane-ethyl acetate 3: 1) a white solid was 
obtained. 
1H NMR (300 MHz, CDCl3) δ (ppm): 2.65 (s, 3H), 7.40 (dd, J 8.1 and 4.8 Hz, 1H), 7.68 (d, J 8.4 Hz, 1H), 
7.91 (dt, J 7.8 and 2.1 Hz, 1H), 8.07 (d, J 8.4 Hz, 2H), 8.65 (dd, J 4.8 and 1.5 Hz, 1H), 8.88 (d, J 2.1 Hz, 
1H). These spectroscopic data are in good agreement with the characterized compound in the 
literature. [173] 
RP-HPLC (Method B): tR = 3.8 min 
 
 Synthesis of 1-(4-(pyridin-4-yl)phenyl)ethanone (5e) 
 
At first, a suspension of PdCl2 (3.5 mg; 0.02 mmol; 1 mol%) and TPPTS (34 mg; 
0.06 mmol; 3 mol%) in 1 mL of phosphate buffer 150 mM pH 8.5 was prepared. 
After 30 min the resulting catalyst solution was added to a mixture, consisting 
of 4-bromopyridine hydrochloride (378,2 mg, 1.945 mmol; 1 eq, 200 mM), 4-
acetylphenylboronic acid (318,9 mg, 1.945 mmol; 1 eq, 200 mM), DES (8 mL) 
and phosphate buffer 150 mM pH 8.5 (1 mL). The pH was adjusted to 8.5 by dropwise addition of aq 
3 N NaOH and the reaction mixture was heated to 100 °C for 24 h. Then, 20 mL of aq saturated NH4Cl 
was added and extracted with ethyl acetate (2x20 mL). The combined organic layers were combined, 
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dried with Na2SO4, filtered and concentrated under vacuum providing the crude product. With further 
purification by flash chromatography (silica gel 60 Å, hexane-ethyl acetate 1: 2) a white solid was 
obtained. 
1H NMR (300 MHz, CDCl3) δ (ppm): 2.66 (s, 3H), 7.53 (d, J 6.0 Hz, 2H), 7.73 (d, J 8.4 Hz, 2H), 8.07 (d, J 
8.4 Hz, 2H), 8.70 (d, J 6.0 Hz, 2H), 8.65 (dd, J 4.8 and 1.5 Hz, 1H), 8.88 (d, J 2.1 Hz, 1H). These 
spectroscopic data are in good agreement with the characterized compound in the literature. [174] 
RP-HPLC (Method B): tR = 3.8 min 
 
 Synthesis of 1-(3',4'-difluoro-[1,1'-biphenyl]-4-yl)ethanone (5f) 
 
At first, a suspension of PdCl2 (3.5 mg; 0.02 mmol; 1 mol%) and TPPTS (34 mg; 
0.06 mmol; 3 mol%) in 1 mL of phosphate buffer 150 mM pH 8.5 was prepared. 
After 30 min the resulting catalyst solution was added to a mixture, consisting 
of 4’-bromoacetophenone (386 mg, 1.945 mmol; 1 eq, 200 mM), 3,4-
difluorophenylboronic acid (306,4 mg, 1.945 mmol; 1 eq, 200 mM), DES (8 mL) 
and phosphate buffer 150 mM pH 8.5 (1 mL). The pH was adjusted to 8.5 by dropwise addition of aq 
3 N NaOH and the reaction mixture was heated to 70 °C for 24 h. Then, 20 mL of aq saturated NH4Cl 
was added and extracted with ethyl acetate (2x20 mL). The combined organic layers were combined, 
dried with Na2SO4, filtered and concentrated under vacuum providing the crude product. With further 
purification by flash chromatography (silica gel 60 Å, hexane-ethyl acetate 8: 1) a white solid was 
obtained. 
1H NMR (300 MHz, CDCl3) δ (ppm): 2.63 (s, 3H), 7.18-7.46 (m, 3H), 7.60 (d, J 8.1 Hz, 2H), 8.01 (d, J 8.1 
Hz, 2H), 8.70 (d, J 6.0 Hz, 2H), 8.65 (dd, J 4.8 and 1.5 Hz, 1H), 8.88 (d, J 2.1 Hz, 1H). These spectroscopic 
data are in good agreement with the characterized compound in the literature.[175] 
RP-HPLC (Method A): tR = 6.0 min 
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 Synthesis of 1-(4'-fluoro-3'-methyl-[1,1'-biphenyl]-4-yl)ethanone (5g) 
 
At first, a suspension of PdCl2 (3.5 mg; 0.02 mmol; 1 mol%) and TPPTS (34 mg; 
0.06 mmol; 3 mol%) in 1 mL of phosphate buffer 150 mM pH 8.5 was prepared. 
After 30 min the resulting catalyst solution was added to a mixture, consisting 
of 4’-bromoacetophenone (386 mg, 1.945 mmol; 1 eq, 200 mM), 4-fluoro-3-
methylphenylboronic acid (299,4 mg, 1.945 mmol; 1 eq, 200 mM), DES (8 mL) 
and phosphate buffer 150 mM pH 8.5 (1 mL). The pH was adjusted to 8.5 by dropwise addition of aq 
3 N NaOH and the reaction mixture was heated to 70 °C for 24 h. Then, 20 mL of aq saturated NH4Cl 
was added and extracted with ethyl acetate (2x20 mL). The combined organic layers were combined, 
dried with Na2SO4, filtered and concentrated under vacuum providing the crude product. With further 
purification by flash chromatography (silica gel 60 Å, hexane-ethyl acetate 8: 1) a white solid was 
obtained. 
1H NMR (300 MHz, CDCl3) δ (ppm): 2.35 (d, J 1.8 Hz, 3H), 2.64 (s, 3H), 7.09 (t, J 9.0 Hz, 1H), 7.36-7.47 
(m, 2H), 7.62 (d, J 8.4 Hz, 2H), 8.01 (d, J 8.4 Hz, 2H). These spectroscopic data are in good agreement 
with the characterized compound in the literature. [176] 
RP-HPLC (Method A): tR = 6.4 min 
 
 Synthesis of 1-(5'-fluoro-2'-methoxy-[1,1'-biphenyl]-4-yl)ethanone (5h) 
 
At first, a suspension of PdCl2 (3.5 mg; 0.02 mmol; 1 mol%) and TPPTS (34 mg; 
0.06 mmol; 3 mol%) in 1 mL of phosphate buffer 150 mM pH 8.5 was prepared. 
After 30 min the resulting catalyst solution was added to a mixture, consisting of 
4’-bromoacetophenone (386 mg, 1.945 mmol; 1 eq, 200 mM), 5-Fluoro-2-
methoxyphenylboronic acid (330,6 mg, 1.945 mmol; 1 eq, 200 mM), DES (8 mL) 
and phosphate buffer 150 mM pH 8.5 (1 mL). The pH was adjusted to 8.5 by dropwise addition of aq 
3 N NaOH and the reaction mixture was heated to 70 °C for 24 h. Then, 20 mL of aq saturated NH4Cl 
was added and extracted with ethyl acetate (2x20 mL). The combined organic layers were combined, 
dried with Na2SO4, filtered and concentrated under vacuum providing the crude product. With further 
purification by flash chromatography (silica gel 60 Å, hexane-ethyl acetate 8: 1) a white solid was 
obtained (Mp: 113-115 °C). 
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1H NMR (300 MHz, CDCl3) δ (ppm): 2.63 (s, 3H), 3.79 (s, 3H), 6.87-6.92 (m, 1H), 7.00-7.08 (m, 2H), 7.61 
(d, J 8.4 Hz, 2H), 8.01 (d, J 8.4 Hz, 2H).  
 
13C NMR (CDCl3, 75.5 MHz):  26.68 (CH3), 56.19 (CH3), 112.40 (CH, d, JCF= 8 Hz), 115.22 (CH, d, JCF= 23 
Hz), 117.27 (CH, d, JCF= 23 Hz), 128.17 (2CH), 129.61 (2CH), 130.63 (C, d, JCF= 7 Hz), 135.86 (C), 142.35 
(C), 152.26 (C), 157.08 (C, d, JCF= 239 Hz), 197.80 (C) 
 
MS (APCI+, m/z): 245 [(M+H)+, 100%]. 
RP-HPLC (Method A): tR = 5.9 min 
 
 Synthesis of 1-([1,1'-biphenyl]-3-yl)ethanone (5i) 
 
At first, a suspension of PdCl2 (3.5 mg; 0.02 mmol; 1 mol%) and TPPTS (34 mg; 0.06 
mmol; 3 mol%) in 1 mL of phosphate buffer 150 mM pH 8.5 was prepared. After 
30 min the resulting catalyst solution was added to a mixture, consisting of 3’-
bromoacetophenone (386 mg, 1.945 mmol; 1 eq, 200 mM), phenylboronic acid (2, 
237,76 mg, 1.945 mmol; 1 eq, 200 mM), DES (8 mL) and phosphate buffer 150 mM pH 8.5 (1 mL). The 
pH was adjusted to 8.5 by dropwise addition of aq 3 N NaOH and the reaction mixture was heated to 
70 °C for 24 h. Then, 20 mL of aq saturated NH4Cl was added and extracted with ethyl acetate (2x20 
mL). The combined organic layers were combined, dried with Na2SO4, filtered and concentrated under 
vacuum providing the crude product. With further purification by flash chromatography (silica gel 60 
Å, hexane-ethyl acetate 14: 1) a yellowish oil was obtained. 
1H NMR (300 MHz, CDCl3) δ (ppm): 2.66 (s, 3H), 7.35-7.57 (4H, m), 7.60-7.65 (2H, m), 7.79 (dt, J 7.8 
and 1.5 Hz, 1H), 7.94 (dt, J 7.8 and 1.5 Hz, 1H), 8.21 (t, J 4.8 Hz, 1H). These spectroscopic data are in 
good agreement with the characterized compound in the literature.[172] 
HPLC (Method A): tR = 5.9 min 
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 Synthesis of 1-([1,1'-biphenyl]-2-yl)ethanone (5j) 
 
At first, a suspension of PdCl2 (3.5 mg; 0.02 mmol; 1 mol%) and TPPTS (34 mg; 0.06 
mmol; 3 mol%) in 1 mL of phosphate buffer 150 mM pH 8.5 was prepared. After 30 min 
the resulting catalyst solution was added to a mixture, consisting of 2’-
bromoacetophenone (386 mg, 1.945 mmol; 1 eq, 200 mM), phenylboronic acid (2, 
237,76 mg, 1.945 mmol; 1 eq, 200 mM), DES (8 mL) and phosphate buffer 150 mM pH 
8.5 (1 mL). The pH was adjusted to 8.5 by dropwise addition of aq 3 N NaOH and the reaction mixture 
was heated to 70 °C for 24 h. Then, 20 mL of aq saturated NH4Cl was added and extracted with ethyl 
acetate (2x20 mL). The combined organic layers were combined, dried with Na2SO4, filtered and 
concentrated under vacuum providing the crude product. With further purification by flash 
chromatography (silica gel 60 Å, hexane-ethyl acetate 14: 1) a yellowish oil was obtained. 
1H NMR (300 MHz, CDCl3) δ (ppm): 2.01 (s, 3H), 7.32-7.36 (2H, m), 7.37-7.46 (5H, m), 7.47-7.61 (m, 
2H). These spectroscopic data are in good agreement with the characterized compound in the 
literature.[177] 
HPLC (Method A): tR = 5.7 min 
 
 
 Reduction of the products from the Suzuki cross-coupling reaction using NaBH4 
 
 
General procedure for the reduction of biaryl ketones using sodium borohydride 
 After dissolving the biaryl ketone (5 a-j, 0.1 mmol) in methanol (2 mL), sodium borohydride 
(0.3 mmol) is added and the reaction is stirred for 24 hours at room temperature. The product (6 a-j) 
is then washed with water (10 mL) and the reaction mixture extracted with ethyl acetate (3x 10 mL). 
The organic layers are combined, dried with Na2SO4, filtered and concentrated under vacuum 
providing the final racemic alcohol. 
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 Synthesis of racemic -1-([1,1'-biphenyl]-4-yl)ethanol (6a) 
 
The title compound was obtained according to the general procedure (Yield 
>95%). 
 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.52 (d, J 6.6 Hz, 3H), 1.70 (brs, OH), 4.88 (q, 
J 6.6 Hz, 1H), 7.32-7.38 (m, 1H), 7.40-7.48 (m, 4H), 7.58 (d, J 8.1 Hz, 4H). These spectroscopic data are 
in good agreement with those previously published.[172] 
NP-HPLC: (OD, hexane/isopropanol 95:5 v/v, 0.8 mL/min, 258 nm) tR = 15.4 min (S), 16.9 min (R) 
 
HPLC separation for both enantiomers of compound (±)-6a 
 
 
 Synthesis of racemic - 1-([1,1'-biphenyl]-4-yl)propan-1-ol (6b) 
 
 The title compound was obtained according to the general procedure (Yield 
>95%). 
1H NMR (300 MHz, CDCl3) δ (ppm): 0.97 (d, J 6.3 Hz, 3H), 1.74-1.97 (m, 2H+OH), 
4.68 (t, J 6.3 Hz, 1H), 7.33-7.51 (m, 5H), 7.57-7.65 (m, 4H). These spectroscopic 
data are in good agreement with those previously published.[172] 
NP-HPLC: (OD, hexane/isopropanol 97:3 v/v, 0.8 mL/min, 258 nm) tR = 22.3 min (S), 23.3 min (R) 
 
HPLC separation for both enantiomers of compound (±)-6b 
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 Synthesis of racemic - 1-(4-(pyridin-2-yl)phenyl)ethanol (6c) 
 
 The title compound was obtained according to the general procedure (Yield 
>95%). 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.53 (d, J 6.6 Hz, 3H), 2.11 (brs, OH), 4.96 (q, 
J 6.6 Hz, 1H), 7.20-7.26 (m, 1H), 7.43-7.58 (m, 3H), 7.70-7.79 (m, 2H), 7.96 (d, J 
8.1 Hz, 2H), 8.68 (d, J 4.8 Hz, 1H). These spectroscopic data are in good agreement with those 
previously published.[172] 
NP-HPLC: (OD, hexane/isopropanol 75:25 v/v, 0.8 mL/min, 258 nm) tR = 8.9 min (S), 13.9 min (R) 
 
HPLC separation for both enantiomers of compound (±)-6c 
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 Synthesis of racemic - 1-(4-(pyridin-3-yl)phenyl)ethanol (6d) 
 
 The title compound was obtained according to the general procedure (Yield 
>95%). 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.52 (d, J 6.6 Hz, 3H), 3.39 (brs, OH), 4.93 (q, 
J 6.6 Hz, 1H), 7.34 (dd, J 8.1 and 4.8 Hz, 1H), 7.43-7.51 (m, 4H), 7.83 (dt, J 4.8 and 
1.8 Hz, 1H), 8.50-8.54 (m, 2H) 
13C NMR (75.5 MHz, CDCl3):  25.37 (CH3), 69.90 (CH),123.75 (CH), 126.45 (2CH), 127.31 (2CH), 134.51 
(CH), 136.59 (2C), 146.52 (C), 148.15 (CH), 148.22 (CH)  
MS (APCI+, m/z): 200 [(M+H)+, 100%].  
NP-HPLC:  (AD-H, hexane/isopropanol 90:19 v/v, 0.8 mL/min, 258 nm) tR = 26.8 min (S), 28.9 min (R) 
 
HPLC separation for both enantiomers of compound (±)-6d 
 
 
 
 Synthesis of racemic- 1-(4-(pyridin-4-yl)phenyl)ethanol (6e) 
 
 The title compound was obtained according to the general procedure (Yield 
>95%). 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.54 (d, J 6.6 Hz, 3H), 2.48 (brs, OH), 4.98 (q, 
J 6.6 Hz, 1H), 7.47-7.5 (m, 4H), 7.63 (d, J 8.4 Hz, 2H), 8.53 (d, J 6.3 Hz, 1H). These 
spectroscopic data are in good agreement with those previously published.[178] 
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NP-HPLC: (AD-H, hexane/isopropanol 75:25 v/v, 0.8 mL/min, 258 nm) tR = 10.9 min (S), 13.7 min (R) 
 
HPLC separation for both enantiomers of compound (±)-6e 
 
 
 Synthesis of racemic - 1-(3',4'-difluoro-[1,1'-biphenyl]-4-yl)ethanol (6f) 
 
 The title compound was obtained according to the general procedure (Yield 
>95%). 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.60 (d, J 6.6 Hz, 3H), 2.16 (brs, OH), 5.02 
(q, J 6.6 Hz, 1H), 7.23-77 (m, 3H), 7.51 (d, J 8.4 Hz, 2H), 7.58 (d, J 8.4 Hz, 2H). 
13C NMR (75.5 MHz, CDCl3):  25.21 (CH3), 70.04 (CH), 115.84 (CH, d, JCF= 17 Hz), 117.51 (CH, d, JCF= 17 
Hz), 122.93 (CH, dd, JCF= 6 and 2 Hz), 126.02 (2CH), 127.04 (2CH), 137.90 (C, d, JCF= 5 Hz), 138.29 (C), 
145.44 (C), 148.52 (C, dd, JCF= 45 and 12 Hz), 151.81 (C, dd, JCF= 44 and 12 Hz). 
MS (APCI+, m/z): 235 [(M+H)+, 100%] 
NP-HPLC: (AD-H, hexane/isopropanol 98:2 v/v, 0.8 mL/min, 258 nm) tR = 33.5 min (S), 35.7 min (R) 
 
HPLC separation for both enantiomers of compound (±)-6f 
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 Synthesis of racemic- 1-(4'-fluoro-3'-methyl-[1,1'-biphenyl]-4-yl)ethanol (6g) 
 
 The title compound was obtained according to the general procedure (Yield 
>95%). 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.53 (d, J 6.3 Hz, 3H), 1.91 (brs, OH), 2.34 
(s ,3H), 4.94 (q, J 6.3 Hz, 1H), 7.06 (t, J 9.0 Hz, 1H), 7.31-7.47 (m, 4H), 7.51 (d, J 
8.1 Hz, 2H). 
13C NMR (75.5 MHz, CDCl3):  14.68 (CH3), 25.15 (CH3), 70.14 (CH), 115.25 (CH, d, JCF= 22 Hz), 125.02 
(C, d, JCF= 17 Hz), 125.85 (2CH), 127.09 (2CH), 130.13 (CH, d, JCF= 5 Hz), 136.37 (C), 139.66 (C), 144.66 
(C), 161.03 (C, d, JCF= 245 Hz). 
MS (APCI+, m/z): 231 [(M+H)+, 100%]. 
NP-HPLC: (AD-H, hexane/isopropanol 98:2 v/v, 0.8 mL/min, 258 nm) tR = 24.7 min (S), 27.0 min (R) 
 
HPLC separation for both enantiomers of compound (±)-6g 
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 Synthesis of racemic - 1-(5'-fluoro-2'-methoxy-[1,1'-biphenyl]-4-yl)ethanol (6h) 
 
 The title compound was obtained according to the general procedure (Yield 
>95%). 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.54 (d, J 6.6 Hz, 3H), 1.97 (brs, OH), 3.78 (s 
,3H), 4.93 (q, J 6.6 Hz, 1H), 6.86-6.94 (m, 1H), 6.95-7.08 (m, 2H), 7.42 (d, J 8.4 Hz, 
2H), 7.51 (d, J 8.4 Hz, 2H); 
13C NMR (75.5 MHz, CDCl3):  25.18 (CH3), 56.30 (CH3), 70.33 (CH), 112.39 (CH, d, JCF= 7 Hz), 114.39 
(CH, d, JCF= 23 Hz), 117.45 (CH, d, JCF= 23 Hz), 125.35 (2CH), 129.62 (2CH), 131.77 (C, d, JCF= 7 Hz), 
136.74 (C), 145.02 (C), 152.77 (C), 157.24 (C, d, JCF= 239 Hz);  
MS (APCI+, m/z): 247 [(M+H)+, 100%]. 
NP-HPLC: (AD-H, hexane/isopropanol 98:2 v/v, 0.8 mL/min, 258 nm) tR = 35.0 min (R), 40.2 min (S) 
 
HPLC separation for both enantiomers of compound (±)-6h 
 
 
 Synthesis of racemic - 1-([1,1'-biphenyl]-3-yl)ethanol (6i) 
 
 The title compound was obtained according to the general procedure (Yield 
>95%). 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.55 (d, J 6.3 Hz, 3H), 1.89 (brs, OH), 4.99 (q, J 
6.3 Hz, 1H), 7.32-7.55 (m, 6H), 7.57-7.64 (m, 3H). These spectroscopic data are in 
good agreement with those previously reported.[172] 
NP-HPLC: (AD-H, hexane/isopropanol 98:2 v/v, 0.8 mL/min, 258 nm) tR = 32.1 min (R), 35.4 min (S) 
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HPLC separation for both enantiomers of compound (±)-6i 
 
 
 
 Synthesis of racemic - 1-([1,1'-biphenyl]-2-yl)ethanol (6j) 
 
 The title compound was obtained according to the general procedure (Yield >95%). 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.42 (d, J 6.3 Hz, 3H), 1.69 (brs, OH), 4.98 (q, J 6.3 
Hz, 1H), 7.21 (dd, J 7.5 and 1.5 Hz, 1H), 7.28-7.35 (m, 3H), 7.37-7.45 (m, 4H), 7.68 (d, J 
7.8 Hz, 1H). These spectroscopic data are in good agreement with those previously 
reported.[172] 
 
NP-HPLC: (OD, hexane/isopropanol 99:1 v/v, 0.8 mL/min, 258 nm) tR = 11.1 min (R), 12.1 min (S). 
 
HPLC separation for both enantiomers of compound (±)-6j 
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 Enzymatic reduction of biaryl ketones in a DES-buffer mixture 
 
 
 
General procedure for the bioreduction of biaryl ketones in a DES-buffer mixture: 
 In a 2.0 mL Eppendorf tube, ketone (5 a-j,5 mM) and purified KRED (1.0 mg) were added to a 
1ChCl:2Gly (215 mL)/125 mM KH2PO4 buffer pH 7.0 (325 mL) mixture (containing 1.25 mM MgSO4, 
1mM NADP+), and i-PrOH (60 mL, 10% v/v). For L. kefir reactions, 15 U of ADH and KPi buffer 50 mM 
pH 7.0 were used, the mixture containing 1 mM MgCl2 and 1 mM NADP+; For R. ruber reactions, 5 U 
of ADH and KPi buffer 50 mM pH 7.0 were used, the mixture containing 1 mM NAD+. In all the cases, 
the reaction mixture was shaken at 30 °C and 250 rpm for 24 h. To determine the conversion, 10 mL 
of the mixture were diluted with 90 mL of Milli-Q water and analysed by achiral reverse phase. The 
mixture was then extracted with AcOEt (2x500 mL) and aq saturated NH4Cl (110 mL), the organic layers 
separated by centrifugation (120 sec, 1300 rpm), combined and dried over Na2SO4. The enantiomeric 
excess of alcohols (6 a-j) was measured by chiral HPLC. 
 
 Synthesis of (S)-1-([1,1'-biphenyl]-4-yl)ethanol (6a) 
 
 In a 15 mL Falcon tube, 5a (5 mM) and ADH from Rhodococcus ruber (10 U) were 
added to a 1ChCl:2Gly (2.15 mL)/50 mM KH2PO4 buffer pH 7.0 (3.25 mL) mixture 
(containing 1 mM NAD+), and i-PrOH (600 µL). The reaction was shaken at 30 °C 
and 250 rpm for 24 h. To determine the conversion, 10 µL of the mixture were 
diluted with 90 µL of Milli-Q water and analysed by achiral reverse phase with previous centrifuging 
and filtering of the sample. Then, the mixture was treated with aq saturated NH4Cl (1 × 10 mL) and 
extracted with ethyl acetate (2 × 5 mL), the organic layers combined, filtered and concentrated under 
vacuum to provide the crude product (S)-6a (yield >95%) as a colourless oil. 
 
[α]D20 −58.5 (c 0.2, CHCl3), ee >99%. Lit. [172] for (S)-6a: [α]D20 −44.1 (c 0.97, CHCl3), ee >99%. 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.52 (d, J 6.6 Hz, 3H), 1.70 (brs, OH), 4.88 (q, J 6.6 Hz, 1H), 7.32-
7.38 (m, 1H), 7.40-7.48 (m, 4H), 7.58 (d, J 8.1 Hz, 4H). 
 110 
 
NP-HPLC: (OD, hexane/isopropanol 95:5 v/v, 0.8 mL/min, 258 nm) tR = 15.4 min (S). 
 
Compound (S)-6a in >99% ee after bioreduction with R.ruber 
 
 
 Synthesis of (S)-1-([1,1'-biphenyl]-4-yl)propan-1-ol (6b) 
 
 In a 15 mL Falcon tube, 5b (5 mM) and ADH from Rhodococcus ruber (10 U) 
were added to a 1ChCl:2Gly (2.15 mL)/50 mM KH2PO4 buffer pH 7.0 (3.25 mL) 
mixture (containing 1 mM NAD+), and i-PrOH (600 µL). The reaction was shaken 
at 30 °C and 250 rpm for 24 h. To determine the conversion, 10 µL of the mixture 
were diluted with 90 µL of Milli-Q water and analysed by achiral reverse phase with previous 
centrifuging and filtering of the sample. Then, the mixture was treated with aq saturated NH4Cl (1 × 
10 mL) and extracted with ethyl acetate (2 × 5 mL), the organic layers combined, filtered and 
concentrated under vacuum to provide the crude product (S)-6b (yield >95%) as a white solid. 
 
[α]D20 −22.1 (c 0.2, CHCl3), ee >99%. Lit.[172] for (S)-6b: [α]D20 −13.0 (c 0.98, CHCl3), ee = 36%. 
1H NMR (300 MHz, CDCl3) δ (ppm): 0.97 (d, J 6.3 Hz, 3H), 1.74-1.97 (m, 2H+OH), 4.68 (t, J 6.3 Hz, 1H), 
7.33-7.51 (m, 5H), 7.57-7.65 (m, 4H). 
 
NP-HPLC: (OD, hexane/isopropanol 97:3 v/v, 0.8 mL/min, 258 nm) tR = 22.3 min (S). 
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Compound (S)-6b in >99% ee after bioreduction with R.ruber 
 
 
 Synthesis of (S)-1-(4-(pyridin-2-yl)phenyl)ethanol (6c) 
 
 In a 15 mL Falcon tube, 5c (5 mM) and ADH from Rhodococcus ruber (10 U) were 
added to a 1ChCl:2Gly (2.15 mL mL)/50 mM KH2PO4 buffer pH 7.0 (3.25 mL) 
mixture (containing 1 mM NAD+), and i-PrOH (600 µL). The reaction was shaken 
at 30 °C and 250 rpm for 24 h. To determine the conversion, 10 µL of the mixture 
were diluted with 90 µL of Milli-Q water and analysed by achiral reverse phase 
with previous centrifuging and filtering of the sample. Then, the mixture was treated with aq saturated 
NH4Cl (1 × 10 mL) and extracted with ethyl acetate (2 × 5 mL), the organic layers combined, filtered 
and concentrated under vacuum to provide the crude product (S)-6c (yield >95%) as a colourless oil. 
 
[α]D20 −70.5 (c 0.2, CHCl3), ee >99%. Lit.[172] for (S)-6c: [α]D20 −42.2 (c 0.82, CHCl3), ee = 93%. 
 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.53 (d, J 6.6 Hz, 3H), 2.11 (brs, OH), 4.96 (q, J 6.6 Hz, 1H), 7.20-
7.26 (m, 1H), 7.43-7.58 (m, 3H), 7.70-7.79 (m, 2H), 7.96 (d, J 8.1 Hz, 2H), 8.68 (d, J 4.8 Hz, 1H). 
 
NP-HPLC: (OD, hexane/isopropanol 75:25 v/v, 0.8 mL/min, 258 nm) tR = 8.9 min (S). 
Compound (S)-6c in >99% ee after bioreduction with R. ruber 
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 Synthesis of (R)-1-(4-(pyridin-3-yl)phenyl)ethanol (6d) 
 
 In a 15 mL Falcon tube, 5d (5 mM) and ADH from L. kefir (30 U) were added to a 
1ChCl:2Gly (2.15 mL mL)/50 mM KH2PO4 buffer pH 7.0 (3.25 mL) mixture 
(containing 1 mM MgCl2 and 1 mM NADP+), and i-PrOH (600 µL). The reaction 
was shaken at 30 °C and 250 rpm for 24 h. To determine the conversion, 10 µL of 
the mixture were diluted with 90 µL of Milli-Q water and analysed by achiral reverse phase with 
previous centrifuging and filtering of the sample. Then, the mixture was treated with aq saturated 
NH4Cl (1 × 10 mL) and extracted with ethyl acetate (2 × 5 mL), the organic layers combined, filtered 
and concentrated under vacuum to provide the crude product (R)-6d (yield >95%) as a white solid. 
Mp: 108-110 °C 
[α]D20 +21.5 (c 0.2, CHCl3), ee >99%. 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.52 (d, J 6.6 Hz, 3H), 3.39 (brs, OH), 4.93 (q, J 6.6 Hz, 1H), 7.34 (dd, 
J 8.1 and 4.8 Hz, 1H), 7.43-7.51 (m, 4H), 7.83 (dt, J 4.8 and 1.8 Hz, 1H), 8.50-8.54 (m, 2H). 
13C NMR (75.5 MHz, CDCl3):  25.37 (CH3), 69.90 (CH),123.75 (CH), 126.45 (2CH), 127.31 (2CH), 134.51 
(CH), 136.59 (2C), 146.52 (C), 148.15 (CH), 148.22 (CH). 
MS (APCI+, m/z): 200 [(M+H)+, 100%]. 
NP-HPLC: (AD-H, hexane/isopropanol 90:19 v/v, 0.8 mL/min, 258 nm) tR = 28.9 min (R). 
 
Compound (R)-6d in >99% ee after bioreduction with L. kefir 
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 Synthesis of (S)-1-(4-(pyridin-4-yl)phenyl)ethanol (6e) 
 
 In a 15.0 mL Falcon tube, 5e (5 mM) and ADH from Rhodococcus ruber (10 U) 
were added to a 1ChCl:2Gly (2.15 mL)/50 mM KH2PO4 buffer pH 7.0 (3.25 mL) 
mixture (containing 1 mM NAD+), and i-PrOH (600 µL). The reaction was shaken 
at 30 °C and 250 rpm for 24 h. To determine the conversion, 10 µL of the mixture 
were diluted with 90 µL of Milli-Q water and analysed by achiral reverse phase 
with previous centrifuging and filtering of the sample. Then, the mixture was treated with aq saturated 
NH4Cl (1 × 10 mL) and extracted with ethyl acetate (2 × 5 mL), the organic layers combined, filtered 
and concentrated under vacuum to provide the crude product (S)-6e (yield >95%) as a white oil. 
[α]D20 −41.0 (c 0.2, CHCl3), ee >99%;  
1H NMR (300 MHz, CDCl3) δ (ppm): 1.54 (d, J 6.6 Hz, 3H), 2.48 (brs, OH), 4.98 (q, J 6.6 Hz, 1H), 7.47-7.5 
(m, 4H), 7.63 (d, J 8.4 Hz, 2H), 8.53 (d, J 6.3 Hz, 1H). 
NP-HPLC: (AD-H, hexane/isopropanol 75:25 v/v, 0.8 mL/min, 258 nm) tR = 10.9 min (S) 
 
 
Compound (S)-6e in >99% ee after bioreduction with R. ruber 
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 Synthesis of (S)-1-(3',4'-difluoro-[1,1'-biphenyl]-4-yl)ethanol (6f) 
 
 In a 15.0 mL Falcon tube, 5f (5 mM) and ADH from Rhodococcus ruber (10 U) 
were added to a 1ChCl:2Gly (2.15 mL)/50 mM KH2PO4 buffer pH 7.0 (3.25 mL) 
mixture (containing 1 mM NAD+), and i-PrOH (600 µL). The reaction was 
shaken at 30 °C and 250 rpm for 24 h. To determine the conversion, 10 µL of 
the mixture were diluted with 90 µL of Milli-Q water and analysed by achiral 
reverse phase with previous centrifuging and filtering of the sample. Then, the mixture was treated 
with aq saturated NH4Cl (1 × 10 mL) and extracted with ethyl acetate (2 × 5 mL), the organic layers 
combined, filtered and concentrated under vacuum to provide the crude product (S)-6f (yield >95%) 
as a colourless oil. 
 
[α]D20 −24.5 (c 0.2, CHCl3), ee >99%. 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.60 (d, J 6.6 Hz, 3H), 2.16 (brs, OH), 5.02 (q, J 6.6 Hz, 1H), 7.23-77 
(m, 3H), 7.51 (d, J 8.4 Hz, 2H), 7.58 (d, J 8.4 Hz, 2H). 
13C NMR (75.5 MHz, CDCl3):  25.21 (CH3), 70.04 (CH), 115.84 (CH, d, JCF= 17 Hz), 117.51 (CH, d, JCF= 17 
Hz), 122.93 (CH, dd, JCF= 6 and 2 Hz), 126.02 (2CH), 127.04 (2CH), 137.90 (C, d, JCF= 5 Hz), 138.29 (C), 
145.44 (C), 148.52 (C, dd, JCF= 45 and 12 Hz), 151.81 (C, dd, JCF= 44 and 12 Hz). 
MS (APCI+, m/z): 235 [(M+H)+, 100%]. 
NP-HPLC: (AD-H, hexane/isopropanol 98:2 v/v, 0.8 mL/min, 258 nm) tR = 33.5 min (S). 
 
Compound (S)-6f in >99% ee after bioreduction with R. ruber 
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 Synthesis of (S)-1-(4'-fluoro-3'-methyl-[1,1'-biphenyl]-4-yl)ethanol (6g) 
 
 In a 15.0 mL Falcon tube, 5g (5 mM) and ADH from Rhodococcus ruber (10 U) 
were added to a 1ChCl:2Gly (2.15 mL)/50 mM KH2PO4 buffer pH 7.0 (3.25 mL) 
mixture (containing 1 mM NAD+), and i-PrOH (600 µL). The reaction was 
shaken at 30 °C and 250 rpm for 24 h. To determine the conversion, 10 µL of 
the mixture were diluted with 90 µL of Milli-Q water and analysed by achiral 
reverse phase with previous centrifuging and filtering of the sample. Then, the mixture was treated 
with aq saturated NH4Cl (1 × 10 mL) and extracted with ethyl acetate (2 × 5 mL), the organic layers 
combined, filtered and concentrated under vacuum to provide the crude product (S)-6g (yield >95%) 
as a white solid. 
Mp: 59-61 °C. 
[α]D20 −17.0 (c 0.2, CHCl3), ee >99% (S). 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.53 (d, J 6.3 Hz, 3H), 1.91 (brs, OH), 2.34 (s ,3H), 4.94 (q, J 6.3 Hz, 
1H), 7.06 (t, J 9.0 Hz, 1H), 7.31-7.47 (m, 4H), 7.51 (d, J 8.1 Hz, 2H). 
13C NMR (75.5 MHz, CDCl3):  14.68 (CH3), 25.15 (CH3), 70.14 (CH), 115.25 (CH, d, JCF= 22 Hz), 125.02 
(C, d, JCF= 17 Hz), 125.85 (2CH), 127.09 (2CH), 130.13 (CH, d, JCF= 5 Hz), 136.37 (C), 139.66 (C), 144.66 
(C), 161.03 (C, d, JCF= 245 Hz). 
MS (APCI+, m/z): 231 [(M+H)+, 100%]. 
NP-HPLC: (AD-H, hexane/isopropanol 98:2 v/v, 0.8 mL/min, 258 nm) tR = 24.7 min (S). 
 
Compound (S)-6g in >99% ee after bioreduction with R. ruber 
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 Synthesis of (S)-1-(5'-fluoro-2'-methoxy-[1,1'-biphenyl]-4-yl)ethanol (6h) 
 
 In a 15.0 mL Falcon tube, 5h (5 mM) and ADH from Rhodococcus ruber (10 U) 
were added to a 1ChCl:2Gly (2.15 mL)/50 mM KH2PO4 buffer pH 7.0 (3.25 mL) 
mixture (containing 1 mM NAD+), and i-PrOH (600 µL). The reaction was shaken 
at 30 °C and 250 rpm for 24 h. To determine the conversion, 10 µL of the mixture 
were diluted with 90 µL of Milli-Q water and analysed by achiral reverse phase 
with previous centrifuging and filtering of the sample. Then, the mixture was treated with aq saturated 
NH4Cl (1 × 10 mL) and extracted with ethyl acetate (2 × 5 mL), the organic layers combined, filtered 
and concentrated under vacuum to provide the crude product (S)-6h (yield >95%).  
Brownish oil; [α]D20 −23.5 (c 0.2, CHCl3), ee >99%.  
1H NMR (300 MHz, CDCl3) δ (ppm): 1.54 (d, J 6.6 Hz, 3H), 1.97 (brs, OH), 3.78 (s ,3H), 4.93 (q, J 6.6 Hz, 
1H), 6.86-6.94 (m, 1H), 6.95-7.08 (m, 2H), 7.42 (d, J 8.4 Hz, 2H), 7.51 (d, J 8.4 Hz, 2H). 
13C NMR (75.5 MHz, CDCl3):  25.18 (CH3), 56.30 (CH3), 70.33 (CH), 112.39 (CH, d, JCF= 7 Hz), 114.39 
(CH, d, JCF= 23 Hz), 117.45 (CH, d, JCF= 23 Hz), 125.35 (2CH), 129.62 (2CH), 131.77 (C, d, JCF= 7 Hz), 
136.74 (C), 145.02 (C), 152.77 (C), 157.24 (C, d, JCF= 239 Hz). 
MS (APCI+, m/z): 247 [(M+H)+, 100%]. 
NP-HPLC: (AD-H, hexane/isopropanol 98:2 v/v, 0.8 mL/min, 258 nm) tR = 40.2 min (S). 
 
 
Compound (S)-6h in >99% ee after bioreduction with R. ruber 
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 Synthesis of (S)-1-([1,1'-biphenyl]-3-yl)ethanol (6i) 
 
 In a 15.0 mL Falcon tube, 5i (5 mM) and ADH from Rhodococcus ruber (10 U) were 
added to a 1ChCl:2Gly (2.15 mL)/50 mM KH2PO4 buffer pH 7.0 (3.25 mL) mixture 
(containing 1 mM NAD+), and i-PrOH (600 µL). The reaction was shaken at 30 °C 
and 250 rpm for 24 h. To determine the conversion, 10 µL of the mixture were 
diluted with 90 µL of Milli-Q water and analysed by achiral reverse phase with previous centrifuging 
and filtering of the sample. Then, the mixture was treated with aq saturated NH4Cl (1 × 10 mL) and 
extracted with ethyl acetate (2 × 5 mL), the organic layers combined, filtered and concentrated under 
vacuum to provide the crude product (S)-6i (yield >95%) as a colourless oil. 
[α]D20 -26.5 (c 0.2, CHCl3), ee >99%. Lit.[172] for (S)-6i: [α]D20 −38.0 (c 1.09, CHCl3), ee = 98%. 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.55 (d, J 6.3 Hz, 3H), 1.89 (brs, OH), 4.99 (q, J 6.3 Hz, 1H), 7.32-
7.55 (m, 6H), 7.57-7.64 (m, 3H). 
NP-HPLC: (AD-H, hexane/isopropanol 98:2 v/v, 0.8 mL/min, 258 nm) tR = 35.4 min (S). 
 
 
Compound (S)-6i in >99% ee after bioreduction with R. ruber 
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 Synthesis of (R)-1-([1,1'-biphenyl]-2-yl)ethanol (6j) 
 
In a 15 mL Falcon tube, 5j (5 mM) and KRED-P2-H07 (10 mg) were added to a 1ChCl:2Gly 
(2.15 mL)/125 mM KH2PO4 buffer pH 7.0 (3.25 mL) mixture (containing 1.25 mM MgSO4 
and 1 mM NAD+), and i-PrOH (600 µL). The reaction was shaken at 30 °C and 250 rpm 
for 24 h. To determine the conversion, 10 µL of the mixture were diluted with 90 µL of 
Milli-Q water and analysed by achiral reverse phase with previous centrifuging and 
filtering of the sample. Then, the mixture was treated with aq saturated NH4Cl (1 × 10 mL) and 
extracted with ethyl acetate (2 × 5 mL), the organic layers combined, filtered and concentrated under 
vacuum to provide the crude product (S)-6j (yield >95%) as a colourless oil. 
[α]D22 -29.5 (c 0.20, CHCl3), ee >99%. Lit.[172] for (S)-6j: [α]D20 -26.5 (c 1.00, CHCl3), ee 45%. 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.42 (d, J 6.3 Hz, 3H), 1.69 (brs, OH), 4.98 (q, J 6.3 Hz, 1H), 7.21 
(dd, J 7.5 and 1.5 Hz, 1H), 7.28-7.35 (m, 3H), 7.37-7.45 (m, 4H), 7.68 (d, J 7.8 Hz, 1H). 
NP-HPLC: (OD, hexane/isopropanol 99:1 v/v, 0.8 mL/min, 258 nm) tR = 10.8 min (R) 
 
 
Compound (R)-6j in >99% ee after bioreduction with KRED-P2-H07 
 
 
 
 
 
 
 
 119 
 
 Preparative-scale synthesis of biaryl alcohols in a one-pot sequential process 
 
 
 
General procedure for the synthesis of biaryl alcohols in a one-pot sequential process: 
 A suspension of PdCl2 (3.5 mg; 0.02 mmol; 1 mol%) and TPPTS (34 mg; 0.06 mmol; 3 mol%) in 
1 mL of phosphate buffer 150 mM pH 8.5 was prepared. After 30 min the resulting catalyst solution 
was added to a mixture, consisting of arylbromide (1 or 3, 1.945 mmol), phenylboronic acid (2 or 4, 
1.945 mmol), 1ChCl:2Gly (8 mL) and phosphate buffer 150 mM pH 8.5 (1 mL). Then, the pH was 
adjusted to 8.5 by dropwise addition of aq 3 N NaOH and the reaction mixture was stirred at 70 °C or 
100 °C for 24 h. To prepare the (S)-alcohol after cooling at rt, KPi buffer pH 8.5 (6.05 mL), i-PrOH (1.95 
mL), NAD+ (1 mM) and ADH from R. ruber DSM 44541 (360 U) were added and the mixture stirred for 
24 h at 30 °C. To prepare the (R)-alcohol after cooling at rt, KPi buffer 150 mM pH 8.5 (6.05 mL), i-
PrOH (1.95 mL), NADP+ (1 mM), MgCl2 (1 mM) and ADH from L. kefir DSM 20587 (690 U) were added 
and the mixture stirred for 24 h at 30 °C. Finally, saturated aq NH4Cl (25 mL) was added and the 
reaction mixture was extracted with ethyl acetate (3x40 mL). The combined organic layers were dried 
over Na2SO4, filtered and concentrated under vacuum to provide the crude product (6). Further 
purification by flash chromatography (silica gel 60 Å, hexane-ethyl acetate 1: 1) yielded the final 
alcohol in high yields (70-86 %). 
 
 Synthesis of (S)- 1-(4-(pyridin-3-yl)phenyl)ethanol (6d) 
 
A suspension of PdCl2 (3.5 mg; 0.02 mmol; 1 mol%) and TPPTS (34 mg; 0.06 mmol; 
3 mol%) in 1 mL of phosphate buffer 150 mM pH 8.5 was prepared. After 30 min 
the resulting catalyst solution was added to a mixture, consisting of 3-
bromopyridine (307,3 mg, 1.945 mmol), 4-acetylphenylboronic acid (318,9 mg, 
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1.945 mmol), 1ChCl:2Gly (8 mL) and phosphate buffer 150 mM pH 8.5 (1 mL). Then, the pH was 
adjusted to 8.5 by dropwise addition of aq 3 N NaOH and the reaction mixture was stirred at 100 °C 
for 24 h. After cooling to rt, phosphate buffer 150 mM pH 8.5 (6.05 mL), i-PrOH (1.95 mL, 11% v/v), 
NAD+ (1 mM) and ADH from Rhodococcus ruber DSM 44541 (360 U) were added. After stirring for 
another 24 h at 30°C, saturated aq NH4Cl (25 mL) was added and extracted with ethyl acetate (3x40 
mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under vacuum 
to provide the crude product. Further purification by flash chromatography (silica gel 60 Å, hexane-
ethyl acetate 1: 1) yielded 364 mg of (S)-6d as a yellowish oil (85 %). 
 
 
Scheme 54. In process HPLC monitoring for the preparation scale experiment of 6d 
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 Synthesis of (S)-1-([1,1'-biphenyl]-4-yl)ethanol (6a) 
 
A suspension of PdCl2 (3.5 mg; 0.02 mmol; 1 mol%) and TPPTS (34 mg; 0.06 mmol; 
3 mol%) in 1 mL of phosphate buffer 150 mM pH 8.5 was prepared. After 30 min 
the resulting catalyst solution was added to a mixture, consisting of 4’-
bromoacetophenone (387,1 mg, 1.945 mmol), 4-acetylphenylboronic acid (318,9 
mg, 1.945 mmol), 1ChCl:2Gly (8 mL) and phosphate buffer 150 mM pH 8.5 (1 mL). 
Then, the pH was adjusted to 8.5 by dropwise addition of aq 3 N NaOH and the reaction mixture was 
stirred at 70 °C for 24 h. After cooling to rt, phosphate buffer 150 mM pH 8.5 (6.05 mL), i-PrOH (1.95 
mL, 11% v/v), NAD+ (1 mM) and ADH from R. ruber DSM 44541 (360 U) were added. After stirring for 
another 24 h at 30°C, aq saturated NH4Cl (25 mL) was added and extracted with ethyl acetate (3x40 
mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under vacuum 
to provide the crude product. Further purification by flash chromatography (silica gel 60 Å, hexane-
ethyl acetate 1: 1) yielded 270 mg of (S)-6a as a yellowish oil (70 %). 
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Scheme 55. In process HPLC monitoring for the preparation scale experiment of 6a 
 
 
 
 Synthesis of (R)- 1-(4-(pyridin-4-yl)phenyl)ethanol (6e) 
 
A suspension of PdCl2 (3.5 mg; 0.02 mmol; 1 mol%) and TPPTS (34 mg; 0.06 
mmol; 3 mol%) in 1 mL of phosphate buffer 150 mM pH 8.5 was prepared. After 
30 min the resulting catalyst solution was added to a mixture, consisting of 4-
bromopyridine (377,1 mg, 1.945 mmol), 4-acetylphenylboronic acid (318,9 mg, 
1.945 mmol), 1ChCl:2Gly (8 mL) and phosphate buffer 150 mM pH 8.5 (1 mL). 
Then, the pH was adjusted to 8.5 by dropwise addition of aq 3 N NaOH and the reaction mixture was 
stirred at 100 °C for 24 h. After cooling to rt, phosphate buffer 150 mM pH 8.5 (6.05 mL), i-PrOH (1.95 
mL, 11% v/v), NAD+ (1 mM) and ADH from L. kefir DSM 20587 (690 U) were added. After stirring for 
another 24 h at 30°C, aq saturated NH4Cl (25 mL) was added and extracted with ethyl acetate (3x40 
mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under vacuum 
to provide the crude product. Further purification by flash chromatography (silica gel 60 Å, hexane-
ethyl acetate 1: 1) yielded 332 mg of (R)-6e as a white oil (86 %).  
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Scheme 56. In process HPLC monitoring for the preparation scale experiment of 6e 
 
 Synthesis of (S)- 1-(4'-fluoro-3'-methyl-[1,1'-biphenyl]-4-yl)ethanol (6g) 
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A suspension of PdCl2 (3.5 mg; 0.02 mmol; 1 mol%) and TPPTS (34 mg; 0.06 
mmol; 3 mol%) in 1 mL of phosphate buffer 150 mM pH 8.5 was prepared. 
After 30 min the resulting catalyst solution was added to a mixture, consisting 
of 4-fluoro-3-methylphenylboronic acid (300 mg, 1.945 mmol), 4’-
bromoacetophenone (387,1 mg, 1.945 mmol), 1ChCl:2Gly (8 mL) and 
phosphate buffer 150 mM pH 8.5 (1 mL). Then, the pH was adjusted to 8.5 by dropwise addition of aq 
3 N NaOH and the reaction mixture was stirred at 70 °C for 24 h. After cooling to rt, phosphate buffer 
150 mM pH 8.5 (6.05 mL), i-PrOH (1.95 mL, 11% v/v), NAD+ (1 mM) and ADH from R. ruber DSM 44541 
(360 U) were added. After stirring for another 24 h at 30°C, aq saturated NH4Cl (25 mL) was added and 
extracted with ethyl acetate (3x40 mL). The combined organic layers were dried over Na2SO4, filtered 
and concentrated under vacuum to provide the crude product. Further purification by flash 
chromatography (silica gel 60 Å, hexane-ethyl acetate 1: 1) yielded 371 mg of (S)-6g as a white oil (83 
%). 
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Scheme 57. In process HPLC monitoring for the preparation scale experiment of 6g 
 
 
 
 Optimisation of the Pd-catalysed Suzuki cross-coupling reaction for the one-pot 
synthesis of biaryl amines  
 
 Study of different solvents  
 
General procedure: 
 At first, a suspension of PdCl2 (3.5 mg; 0.02 mmol; 1 mol%) and TPPTS (34 mg; 0.06 mmol; 3 
mol%) in 1 mL of phosphate buffer 150 mM pH 8.5 was prepared. After 30 min the resulting catalyst 
solution was added to a mixture, consisting of 4’-bromoacetophenone (1b, 0.389 mmol; 1 eq, 40 mM), 
phenylboronic acid (2, 0.389 mmol; 1 eq, 40 mM), sodium carbonate (0.97 mmol, 2.5 eq), co-solvent 
and phosphate buffer 150 mM pH 8.5. The reaction mixture was stirred at room temperature for 24 
h. Then, 20 mL of aq saturated NH4Cl was added and extracted with ethyl acetate (2x20 mL). The 
combined organic layers were combined, dried with Na2SO4, filtered and concentrated under vacuum 
providing the crude product ketone 5a. 
 
OH
F
6g (standard)
OH
F
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Table 23. Effect of co-solvent on the Suzuki cross-coupling reaction of 4’-bromoacetophenone (1b) and 
phenylboronic acid (2) 
 
Entry co-solvent (%) c (%) 
1 i-PrOH (10%) 91  
2 i-PrOH (50%) 95 
3 THF (10%) 85 
4 THF (50%) 96 
5 1ChCl/2Gly (50%) 90 
6 1ChCl/2Gly (80%) 93 
7 1ChCl/2Gly (100%) 85 
8 DMSO (10%) 30 
 
 
 Cross-coupling reaction in a DES-buffer mixture 
 
General procedure under the optimised reaction conditions: 
 At first, a suspension of PdCl2 (3.5 mg; 0.02 mmol; 1 mol%) and TPPTS (34 mg; 0.06 mmol; 3 
mol%) in 1 mL of phosphate buffer 150 mM pH 8.5 was prepared. After 30 min the resulting catalyst 
solution was added to a mixture, consisting of arylbromide (1 or 3, 1.945 mmol; 1 eq, 200 mM), 
boronic acid (2 or 4, 1.945 mmol; 1 eq, 200 mM), sodium carbonate (2.5 eq, 4.9 mmol), DES (8 mL) 
and phosphate buffer 150 mM pH 8.5 (1 mL). The reaction mixture was heated according to the 
substrate of choice for 24 h. Then, 20 mL of aq saturated NH4Cl was added and extracted with ethyl 
acetate (2x20 mL). The combined organic layers were combined, dried with Na2SO4, filtered and 
concentrated under vacuum providing the crude product (5 a-j).  
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Table 24. Scope of the Suzuki cross-coupling reaction in DES-buffer medium under the optimised reaction 
conditions 
 
Entry Product 
[Pd]/ligand 
[mol%] 
T (°C) 
Substrate 
concentration 
(mM) 
c (%) 
1 
 
1/3 70 200 >99 
2 
 
1/3 70 200 >99 
3 
 
1/3 100 200 >99 
4 
 
1/3 100 200 >99 
5 
 
1/3 100 200 >99 
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6 
 
1/3 70 200 >99 
7 
 
1/3 70 200 >99 
8 
 
1/3 70 200 >99 
9 
 
1/3 70 200 >99 
10 
 
1/3 70 200 >99 
 
 
 Synthesis of racemic amine standards 
 
 
 
General procedure for the synthesis of racemic amine standards 8a,f-i: 
 Ammonium formate (300 mg) and zinc (150 mg) were added to a solution of 80 mg ketone 
(5a,f-i) in 1.5 mL of ethanol and the mixture was stirred overnight at 80 °C under nitrogen. Then, the 
reaction mixture was cooled at room temperature, filtered through Celite and washed with ethanol. 
The solvent was removed under vacuum to obtain an oily crude, followed by the addition of 10 mL of 
aqueous 1 N HCl and washing with diethyl ether (2 × 20 mL). The aqueous layer was basified to pH 10 
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with aqueous 10 N NaOH and extracted with ethyl acetate (3 × 5 mL). The organic layer was washed 
with 10 mL of brine and dried over Na2SO4. Further concentration on a rotary evaporator afforded the 
corresponding biaryl amine 8a, f-i (25-30% yield). 
 
 
 
 
General procedure for the synthesis of racemic amine standards 8c-e: 
 Et3N (2 eq) and MsCl (2 eq) were added to a solution of alcohol 6c-e (0.4 mmol, beforehand 
obtained by reducing the corresponding ketone 5c-e with NaBH4) in 3.0 mL of dichloromethane and 
the mixture was stirred overnight at room temperature. Then, the solvent was removed and NaN3 (10 
eq) and anhydrous DMF (3 mL) were added, the resulting mixture being stirred at 70 °C for 24 h. 
Further evaporation of the solvent under reduced pressure afforded a crude which was purified by 
flash chromatography (EtOAc/hexane mixtures). Finally, to a suspension of the previous azido 
compound and Pd-C 10% (25 mg) in a round-bottom flask, a H2 balloon was connected and 
deoxygenated MeOH (1.5 mL) was carefully added. The resulting mixture was stirred at room 
temperature for 24 h. After this time, the mixture was filtered through Celite® and the solvent 
evaporated under reduced pressure to afford the corresponding biaryl amine 8c-e in high yield (70-
75%). 
 
 Synthesis of rac-1-([1,1'-biphenyl]-4-yl)ethanamine (8a) 
 
The title compound was obtained with the general procedure according to the 
substrate in question. 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.47 (d, J 6.6 Hz, 3H), 1.85 (brs, NH2), 4.21 (q, 
J 6.6 Hz, 1H), 7.29-7.41 (m, 1H), 7.43-7.49 (m, 4H), 7.53-7.65 (m, 4H). These 
spectroscopic data are in good agreement with those previously published.[179] 
MS (APCI+, m/z): 198 [(M+H)+, 100%]. 
NP-HPLC (AD-H, hexane/isopropanol 90:10 v/v, 0.8 mL/min, 258 nm) tR = 7.2 min (R), 8.3 min (S) 
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HPLC separation for both enantiomers of (±)-8a as Boc derivative 
 
 
 
 Synthesis of rac-1-(4-(pyridin-2-yl)phenyl)ethanamine (8c) 
 
The title compound was obtained with the general procedure according to the 
substrate in question. 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.42 (d, J 6.6 Hz, 3H), 2.66 (brs, NH2), 4.16 (q, 
J 6.6 Hz, 1H), 7.16-7.21  (m, 1H), 7.45 (d, J 8.1 Hz, 2H), 7.70-7.76 (m, 2H), 7.95 (d, 
J 8.1 Hz, 2H), 8.68 (d, J 4.8 Hz, 1H). 
13C NMR (75.5 MHz, CDCl3):  25.25 (CH3), 51.05 (CH), 120.39 (CH), 121.98 (CH), 126.17 (2CH), 127.07 
(2CH), 136.70 (CH), 138.07 (C), 147.92 (C), 149.61 (CH), 157.20 (C). 
MS (APCI+, m/z): 199 [(M+H)+, 100%]. 
NP-HPLC (AD-H, hexane/isopropanol 75:25 v/v, 0.8 mL/min, 258 nm) tR = 6.3 min (R), 7.9 min (S) 
 
HPLC separation for both enantiomers of (±)-8c as Boc derivative 
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 Synthesis of rac-1-(4-(pyridin-3-yl)phenyl)ethanamine (8d) 
 
The title compound was obtained with the general procedure according to the 
substrate in question. 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.43 (d, J 6.6 Hz, 3H), 2.11 (brs, NH2), 4.18 (q, 
J 6.6 Hz, 1H), 7.34 (dd, J 8.1 and 4.8 Hz, 1H), 7.45 (d, J 8.1 Hz, 2H),  7.55 (d, J 8.1 
Hz, 2H),  7.87 (dt, J 7.8 and 2.1 Hz, 1H), 8.56 (dd, J 4.5 and 1.5 Hz, 1H), 8.83 (d, J 
1.2 Hz, 1H). 
13C NMR (75.5 MHz, CDCl3):  25.60 (CH3), 50.98 (CH), 123.57 (CH), 126.49 (2CH), 127.24 (2CH), 134.29 
(CH), 136.31 (C), 136.41 (C),147.63 (C), 148.11 (CH), 148.23 (CH). 
MS (APCI+, m/z): 199 [(M+H)+, 100%]. 
NP-HPLC (AD-H, hexane/isopropanol 75:25 v/v, 0.8 mL/min, 258 nm) tR = 8.1 min (S), 8.7 min (R 
 
HPLC separation for both enantiomers of (±)-8d as Boc derivative
 
 
 Synthesis of rac-1-(4-(pyridin-4-yl)phenyl)ethanamine (8e) 
 
The title compound was obtained with the general procedure according to the 
substrate in question. 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.41 (d, J 6.6 Hz, 3H), 1.85 (brs, NH2), 4.18 (q, 
J 6.6 Hz, 1H), 7.40-7.48 (m, 4H), 7.60 (d, J 8.1 Hz, 2H), 8.63 (d, J 4.8 Hz, 1H). 
13C NMR (75.5 MHz, CDCl3):  25.70 (CH3), 51.00 (CH), 121.48 (2CH), 126.55 (2CH), 127.10 (2CH), 
136.62 (C), 148.05 (C), 148.78 (C), 150.22 (2CH). 
MS (APCI+, m/z): 199 [(M+H)+, 100%]. 
NP-HPLC (AD-H, hexane/isopropanol 75:25 v/v, 0.8 mL/min, 258 nm) tR = 10.5 min (R), 11.5 min (S). 
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HPLC separation for both enantiomers of (±)-8e as Boc derivative 
 
 
 
 
 Synthesis of rac-1-(3',4'-difluoro-[1,1'-biphenyl]-4-yl)ethanamine (8f) 
 
The title compound was obtained with the general procedure according to the 
substrate in question. 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.59 (d, J 6.6 Hz, 3H), 3.78 (brs, NH2), 4.31 
(q, J 6.6 Hz, 1H), 7.26-7.73 (m, 9H). 
13C NMR (75.5 MHz, CDCl3):  24.69 (CH3), 50.89 (CH), 115.84 (CH, d, JCF= 17 Hz), 117.51 (CH, d, JCF= 17 
Hz), 122.83 (CH, dd, JCF= 6 and 2 Hz), 126.55 (2CH), 127.08 (2CH), 129.35 (C, d, JCF= 12 Hz), 137.95 (C), 
145.63 (C), 148.52 (C, dd, JCF= 45 and 12 Hz), 151.81 (C, dd, JCF= 44 and 12 Hz). 
MS (APCI+, m/z): 234 [(M+H)+, 100%]. 
NP-HPLC (AD-H, hexane/isopropanol 95:5 v/v, 0.8 mL/min, 258 nm) tR = 8.4 min (R), 9.6 min (S) 
 
HPLC separation for both enantiomers of (±)-8f as Boc derivative
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 Synthesis of rac-1-(4'-fluoro-3'-methyl-[1,1'-biphenyl]-4-yl)ethanamine (8g) 
 
The title compound was obtained with the general procedure according to the 
substrate in question. 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.45 (d, J 6.6 Hz, 3H), 1.84 (brs, NH2), 2.36 
(s, 3H), 4.19 (q, J 6.6 Hz, 1H), 7.08 (t, J 8.4 Hz, 1H), 7.31-7.48 (m, 4H), 7.52 (d, J 
8.1 Hz, 1H). 
13C NMR (75.5 MHz, CDCl3):  14.69 (CH3,d, JCF= 3 Hz), 25.63 (CH3), 51.03 (CH), 115.22 (CH, d, JCF= 22 
Hz), 125.52 (C, d, JCF= 17 Hz), 126.18 (2CH), 127.09 (2CH), 130.11 (CH, d, JCF= 5 Hz), 136.78 (C, d, JCF= 4 
Hz), 139.04 (C), 146.56 (C), 160.98 (C, d, JCF= 245 Hz). 
MS (APCI+, m/z): 230 [(M+H)+, 100%]. 
NP-HPLC (AD-H, hexane/isopropanol 90:10 v/v, 0.8 mL/min, 258 nm) tR = 6.8 min (R), 7.8 min (S). 
 
HPLC separation for both enantiomers of (±)-8g as Boc derivative
 
 
 
 Synthesis of rac-1-(5'-fluoro-2'-methoxy-[1,1'-biphenyl]-4-yl)ethanamine (8h) 
 
The title compound was obtained with the general procedure according to the 
substrate in question. 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.59 (d, J 6.6 Hz, 3H), 3.80 (s, 3H), 4.67 (q, J 
6.6 Hz, 1H), 6.92 (dd, J 9.0 and 4.5 Hz, 1H), 6.99-7.09 (m, 2H), 7.39 (d, J 8.1 Hz, 
1H), 7.56 (d, J 8.1 Hz, 1H). 
13C NMR (75.5 MHz, CDCl3):  25.66 (CH3), 56.28 (CH3), 60.99 (CH), 112.43 (CH, d, JCF= 7 Hz), 114.35 
(CH, d, JCF= 23 Hz), 117.45 (CH, d, JCF= 23 Hz), 126.25 (2CH), 129.85 (2CH), 131.42 (C, d, JCF= 7 Hz), 
137.37 (C), 140.08 (C), 152.75 (C), 157.23 (C, d, JCF= 239 Hz). 
MS (APCI+, m/z): 246 [(M+H)+, 100%]. 
NP-HPLC (AD-H, hexane/isopropanol 90:10 v/v, 0.8 mL/min, 258 nm) tR = 7.8 min (S), 8.6 min (R) 
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HPLC separation for both enantiomers of (±)-8h as Boc derivative 
 
 
 
 
 Synthesis of rac-1-([1,1'-biphenyl]-3-yl)ethanamine (8i) 
 
The title compound was obtained with the general procedure according to the 
substrate in question. 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.47 (d, J 6.6 Hz, 3H), 1.78 (brs, NH2), 4.21 (q, J 
6.6 Hz, 1H), 7.35-7.43 (m, 2H), 7.44-7.54 (m, 4H), 7.60-7.68 (m, 2H). 
13C NMR (75.5 MHz, CDCl3):  25.86 (CH3), 51.53 (CH), 124.73 (CH), 125.78 (C), 127.27 (2CH), 127.32 
(2CH), 128.79 (2CH), 128.97 (2CH), 141.49 (C), 148.34 (C). 
MS (APCI+, m/z): 198 [(M+H)+, 100%]. 
NP-HPLC (AD-H, hexane/isopropanol 90:10 v/v, 0.8 mL/min, 258 nm) tR = 6.2 min (R), 7.4 min (S) 
 
HPLC separation for both enantiomers of (±)-8i as Boc derivative 
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 Synthesis of enantiopure amine standards 
 
 
General procedure: 
 In a 15 mL reaction tube, ketone (5a,f-i, 0.25 mmol) and ADH from R. ruber (16 U) were added 
to a i-PrOH (5 mL)/50 mM KPi buffer pH 7.0 (5 mL) mixture (1 mM NAD+). The reaction was shaken at 
30 °C and 250 rpm for 24 h. The mixture was extracted with ethyl acetate (2 × 10 mL), the organic 
layers combined, dried over Na2SO4, filtered and concentrated under vacuum to provide the 
corresponding (S)-alcohol (6a,f-i, ee >99%). Then, the corresponding (S)-alcohol (6a,f-i, 0.25 mmol) 
and diphenyl phosphoryl azide (DPPA, 0.30 mmol) were dissolved in dry toluene (0.4 mL). The mixture 
was cooled to 0 °C under N2, and DBU (0.30 mmol) was added. The reaction was stirred for 2 h at 0 °C 
and then at 20 °C for 16 h. The resulting mixture was washed with H2O (2 × 5 mL) and aqueous 1N HCl 
(5 mL). The organic layer was concentrated under reduced pressure and purified by flash 
chromatography (EtOAc/hexane mixtures). Finally, to a suspension containing the resulting azide 
compound and Pd-C 10% (10 mg) in a 25 mL round-bottom flask a H2 balloon was connected and 
deoxygenated MeOH (1.0 mL) carefully added. The resulting suspension was stirred at room 
temperature for 24 h. After this time, the reaction mixture was filtered through Celite® and the solvent 
evaporated under reduced pressure to afford the corresponding (R)-biaryl amine as a colorless oil 
(8a,f-i, ee = 97%, yield = 50-70%). 
 
 Synthesis of (R)-1-([1,1'-biphenyl]-4-yl)ethanamine (8a) 
 
The title compound was obtained with the general procedure. 
[α]D18 +18.7 (c 0.5, CHCl3), ee = 99% for (R)-8a. 
NP-HPLC (AD-H, hexane/isopropanol 90:10 v/v, 0.8 mL/min, 258 nm) tR = 7.2 min 
(R). 
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HPLC chromatogram of compound (R)-8a in >99% ee 
 
 
 
 Synthesis of (R)-1-(4-(pyridin-2-yl)phenyl)ethanamine (8c) 
 
The title compound was obtained with the general procedure. 
[α]D18 +20.7 (c 1.3, CHCl3), ee = 99% for (R)-8c. 
NP-HPLC (AD-H, hexane/isopropanol 75:25 v/v, 0.8 mL/min, 258 nm) tR = 6.3 min 
(R. 
 
HPLC chromatogram of compound (R)-8c in >99% ee 
 
 
 
 Synthesis of (R)-1-(4-(pyridin-3-yl)phenyl)ethanamine (8d) 
 
The title compound was obtained with the general procedure. 
[α]D18 +24.5 (c 1.0, CHCl3), ee = 99% for (R)-8d. 
NP-HPLC (AD-H, hexane/isopropanol 75:25 v/v, 0.8 mL/min, 258 nm) tR = 8.7 min 
(R) 
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HPLC chromatogram of compound (R)-8d in >99% ee 
 
 
 
 Synthesis of (R)-1-(4-(pyridin-4-yl)phenyl)ethanamine (8e) 
 
The title compound was obtained with the general procedure. 
[α]D18 +23.3 (c 1.0, CHCl3), ee = 99% for (R)-8e. 
NP-HPLC (AD-H, hexane/isopropanol 75:25 v/v, 0.8 mL/min, 258 nm) tR = 10.5 
min (R). 
 
 
HPLC chromatogram of compound (R)-8e in >99% ee 
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 Synthesis of (R)-1-(3',4'-difluoro-[1,1'-biphenyl]-4-yl)ethanamine (8f) 
 
The title compound was obtained with the general procedure. 
[α]D18 +21.0 (c 1.1, CHCl3), ee = 97% for (R)-8f. 
NP-HPLC (AD-H, hexane/isopropanol 95:5 v/v, 0.8 mL/min, 258 nm) tR = 8.4 
min (R). 
 
HPLC chromatogram of compound (R)-8f in >99% ee 
 
 
 
 Synthesis of (R)-1-(4'-fluoro-3'-methyl-[1,1'-biphenyl]-4-yl)ethanamine (8g) 
 
The title compound was obtained with the general procedure. 
[α]D18 +39.4 (c 0.8, CHCl3), ee = 97% for (R)-8g. 
NP-HPLC (AD-H, hexane/isopropanol 90:10 v/v, 0.8 mL/min, 258 nm) tR = 6.8 
min (R) 
 
HPLC chromatogram of compound (R)-8g in >99% ee 
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 Synthesis of (R)-1-(5'-fluoro-2'-methoxy-[1,1'-biphenyl]-4-yl)ethanamine (8h) 
 
The title compound was obtained with the general procedure. 
[α]D18 +34.7 (c 1.1, CHCl3), ee 97% for (R)-8h. 
NP-HPLC (AD-H, hexane/isopropanol 90:10 v/v, 0.8 mL/min, 258 nm) tR = 8.6 
min (R) 
 
HPLC chromatogram of compound (R)-8h in >99% ee 
 
 
 
 Synthesis of (R)-1-([1,1'-biphenyl]-3-yl)ethanamine (8i) 
 
The title compound was obtained with the general procedure. 
[α]D18 +25.2 (c 1.0, CHCl3), ee >99% for (R)-8i. 
NP-HPLC (AD-H, hexane/isopropanol 90:10 v/v, 0.8 mL/min, 258 nm) tR = 6.2 min 
(R) 
 
 
HPLC chromatogram of compound (R)-8i in >99% ee 
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 Enzymatic transamination of ketones  
 
 Screening of monoaryl ketones with alanine as amine donor 
 
 
General procedure for the screening of monoaryl ketones using alanine as amine donor:  
 The ketone (20 mM) was first dissolved in DMSO (32 μL, 5% v/v) in a 2 mL reaction tube 
(Eppendorf). Then ATA lysate (8 U), potassium phosphate buffer (KPi) 100 mM pH 7.5, 1 mM PLP, 0.1 
mM NAD+, D-glucose (57 mM), D-alanine (130 mM), LDH (90 U) and GDH (30 U) were added. The 
reaction was shaken at 30 °C and 250 rpm for 24 h. To determine the conversion, 10 μL of the mixture 
were diluted with 90 μL of DMSO and analysed by achiral reverse phase with previous centrifuging 
and filtering of the sample. To determine the enantiomeric excess the reaction was quenched by 
addition of aqueous 10 N NaOH (400 μL). The mixture was then extracted with ethyl acetate (2 × 500 
μL) and the organic layers were separated by centrifugation (90 s, 13000 rpm), combined and dried 
over Na2SO4. 
 
 Synthesis of α-methylbenzylamine (7a) 
 
The title compound was obtained according to the general procedure. 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.24 (d, J 6.5 Hz, 3H), 4.25 (q, J 6.5 Hz, 1H), 7.28 
(m, 2H), 7.30 (m, 1H), 7.33-7.45 (m, 2H). 
NP-HPLC (OJ-H, hexane/isopropanol 90:10 v/v, 0.8 mL/min, 258 nm) tR = 7.54 min 
(S), 8.54 min (R). 
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HPLC separation for both enantiomers of compound (±)-7a 
 
 
Table 25. Screening of various ATAs to obtain the monoaryl amine 7a 
Entry Enzyme c (%) ee (%) 
1 Vf ≥ 99 ≥99 (S) 
2 Cv 90 ≥99 (S) 
3 Ate 98 98 (R) 
4 Ate-TA_T274S ≥ 99 ≥99 (R) 
5 Esi 5  ≥99 (R) 
6 EX-wt 15  ≥99 (R) 
7 Pac 42 ≥99 (R) 
8 Shi 51  ≥99 (R) 
9 Tja 10  ≥99 (R) 
 
 
 
 
 
 
 
 
 142 
 
 Synthesis of 4-bromo-α-methylbenzylamine (7b) 
 
The title compound was obtained according to the general procedure. 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.20 (d, J 6.6 Hz, 3H), 4.32 (q, J 6.6 Hz, 1H), 
7.30 (ddd, J 8.3, 2H), 7.45 (ddd, J = 8.3, 2H). 
NP-HPLC (OJ-H, hexane/isopropanol 90:10 v/v, 0.8 mL/min, 258 nm) tR = 8.4 
min (S), 8.89 min (R). 
 
HPLC separation for both enantiomers of compound (±)-7b 
 
 
 
Table 26. Screening of various ATAs to obtain the monoaryl amine 7b 
Entry Enzyme c (%) ee (%) 
1 Vf 90 ≥99 (S) 
2 Cv 68 ≥99 (S) 
3 Ate 93 ≥99 (R) 
4 Ate-TA_T274S 95 ≥99 (R) 
5 Esi 18 ≥99 (R) 
6 EX-wt >99 ≥99 (R) 
7 Pac 45 ≥99 (R) 
8 Shi 95 ≥99 (R) 
9 Tja 13 ≥99 (R) 
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 Screening of monoaryl ketones with isopropylamine as amine donor 
 
 
General procedure for the synthesis of monoaryl amines with isopropylamine as amine donor: 
 In a 2 mL reaction tube, ketone (20 mM) was first dissolved in DMSO (32 μL, 5% v/v) and then 
ATA lysate (8 U), KPi buffer 100 mM pH 7.5, 1 M isopropylamine and 1 mM PLP were added. The 
reaction was shaken at 30 °C and 250 rpm for 24 h. To determine the conversion, 10 μL of the mixture 
were diluted with 90 μL DMSO and analysed by achiral reverse phase with previous centrifuging and 
filtering of the sample. To determine the enantiomeric excess the reaction was quenched by addition 
of aqueous 10 N NaOH (400 μL). The mixture was then extracted with ethyl acetate (2 × 500μL) and 
the organic layers were separated by centrifugation (90 s, 13000 rpm), combined and dried over 
Na2SO4.  
 
 Synthesis of α-methylbenzylamine (7a) 
 
 The title compound was obtained according to the general procedure. 
 
 
 
Table 27. Screening of various ATAs to obtain the monoaryl amine 7a 
Entry Enzyme c (%) ee (%) 
1 Esi <5 n.d. 
2 EX-wt 0  n.d. 
3 Pac 23  n.d. 
4 Shi <5  n.d. 
5 Tja <5  n.d. 
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 Synthesis of 4-bromo-α-methylbenzylamine (7b) 
 
 The title compound was obtained according to the general procedure. 
 
 
 
Table 28. Screening of various ATAs to obtain the monoaryl amine 7b 
Entry Enzyme c (%) ee (%) 
1 Esi 16 n.d. 
2 EX-wt 0  n.d. 
3 Pac 32  n.d. 
4 Shi 20  n.d. 
5 Tja 0  n.d. 
 
 
 Synthesis of (R)-1-([1,1'-biphenyl]-4-yl)ethanamine (8a) with alanine as amine donor 
 
 The ketone (5a, 20 mM) was first dissolved in DMSO (32 μL, 5% v/v) in a 2 mL 
reaction tube (Eppendorf). Then EX-TA lysate (8 U), potassium phosphate buffer 
(KPi) 100 mM pH 7.5, 1 mM PLP, 0.1 mM NAD+, D-glucose (57 mM), D-alanine 
(130 mM), LDH (90 U) and GDH (30 U) were added. The reaction was shaken at 
30 °C and 250 rpm for 24 h. To determine the conversion, 10 µL of the mixture were diluted with 90 
µL of DMSO and analysed by achiral reverse phase with previous centrifuging and filtering of the 
sample. To determine the enantiomeric excess the reaction was quenched by addition of aqueous 10 
N NaOH (400 μL). The mixture was then extracted with ethyl acetate (2 × 500 µL) and the organic layers 
were separated by centrifugation (90 s, 13000 rpm), combined and dried over Na2SO4. The 
enantiomeric excess of amines was measured by chiral HPLC. 
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Table 29. Screening of different transaminases to obtain 5a 
Entry Enzyme c (%) ee (%) 
1 Vf-ATA 0 n.d. 
2 Cv-ATA 0 n.d. 
3 Ate-ATA 0 n.d. 
4 Ate-ATA_T274S 0 n.d. 
5 Esi 0 n.d. 
6 EX-wt 83 ≥99 (R) 
7 Pac 0 n.d. 
8 Shi 17 ≥99 (R) 
9 Tja 0 n.d. 
 
 
 Synthesis of (R)-1-([1,1'-biphenyl]-4-yl)ethanamine (8a) with isopropylamine as amine 
donor 
 
 In a 2 mL reaction tube, ketone (5a, 20 mM) was first dissolved in DMSO (32 μL, 
5% v/v) and then ATA lysate (8 U), KPi buffer 100 mM pH 7.5, 1 M isopropylamine 
and 1 mM PLP were added. The reaction was shaken at 30 °C and 250 rpm for 24 
h. To determine the conversion, 10 µL of the mixture were diluted with 90 µL 
DMSO and analysed by achiral reverse phase with previous centrifuging and filtering of the sample. 
To determine the enantiomeric excess the reaction was quenched by addition of aqueous 10 N NaOH 
(400 μL). The mixture was then extracted with ethyl acetate (2 × 500µL) and the organic layers were 
separated by centrifugation (90 s, 13000 rpm), combined and dried over Na2SO4. The enantiomeric 
excess of amines was measured by chiral HPLC. 
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Table 30. Screening of various ATAs to obtain 8a 
Entry Enzyme c (%) ee (%) 
1 Vf 0 n.d. 
2 Cv 0 n.d. 
3 Ate 0 n.d. 
4 Ate-TA_T274S 0 n.d. 
5 Esi 0 n.d. 
6 EX-wt 83 ≥99 (R) 
7 Pac 0 n.d. 
8 Shi 17 ≥99 (R) 
9 Tja 0 n.d. 
 
 Synthesis of biaryl amines 8a-j with alanine as amine donor 
 
 
 
General procedure for the screening of biaryl ketones (8a-j) with alanine as amine donor:  
 The ketone (20 mM) was first dissolved in DMSO (32 μL, 5% v/v) in a 2 mL reaction tube 
(Eppendorf). Then ATA lysate (8 U), potassium phosphate buffer (KPi) 100 mM pH 7.5, 1 mM PLP, 0.1 
mM NAD+, D-glucose (57 mM), D-alanine (130 mM), LDH (90 U) and GDH (30 U) were added. The 
reaction was shaken at 30 °C and 250 rpm for 24 h. To determine the conversion, 10 μL of the mixture 
were diluted with 90 μL of DMSO and analysed by achiral reverse phase with previous centrifuging 
and filtering of the sample. To determine the enantiomeric excess the reaction was quenched by 
addition of aqueous 10 N NaOH (400 μL). The mixture was then extracted with ethyl acetate (2 × 500 
μL) and the organic layers were separated by centrifugation (90 s, 13000 rpm), combined and dried 
over Na2SO4. 
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 Enzymatic transamination of 1-(biphenyl-4-yl)ethanone (5a) using ATAs 
 
Table 31. Enzymatic transamination of 1-(biphenyl-4-yl)ethanone (5a) using ATAs 
 
Entry Enzyme c (%) ee (%) 
1 EX-wt 83 >99 (R) 
2 EX-X2 20 n.d. 
3 EX-X3 25 n.d. 
4 EX-STA 45 >99 (R) 
5 EX-SSA 5 n.d. 
6 EX-SSG 0 n.d. 
7 EX-STA 5 45 n.d. 
8 EX5 15 n.d. 
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 Enzymatic transamination of 1-([1,1'-biphenyl]-4-yl)propan-1-one (5b) using ATAs 
 
Table 34. Enzymatic transamination of 1-([1,1'-biphenyl]-4-yl)propan-1-one (5b) using ATAs 
 
Entry Enzyme c (%) ee (%) 
1 EX-wt 0 n.d 
2 EX-X2 0 n.d 
3 EX-X3 0 n.d. 
4 EX-STA 0 n.d 
5 EX-SSA 0 n.d. 
6 EX-SSG 0 n.d. 
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 Enzymatic transamination of 1-(4-(pyridin-2-yl)phenyl)ethanone (5c) using ATAs 
 
Table 38. Enzymatic transamination of 1-(4-(pyridin-2-yl)phenyl)ethanone (5c) using ATAs 
 
Entry Enzyme c (%) ee (%) 
1 EX-wt 72 >99 (R) 
2 EX-STA 99 >99 (R) 
3 EX-SSA 10 n.d. 
4 EXSSG 10 n.d. 
5 EX-STA5 80 n.d. 
6 EX-X5 40 n.d. 
 
 
 
 
 Enzymatic transamination of 1-(4-(pyridin-3-yl)phenyl)ethanone (5d) using ATAs 
 
Table 39. Enzymatic transamination of 1-(4-(pyridin-3-yl)phenyl)ethanone (5d) using ATAs 
 
Entry Enzyme c (%) ee (%) 
1 EX-wt 82 >99 (R) 
2 EX-STA 99 >99 (R) 
 150 
 
Entry Enzyme c (%) ee (%) 
3 EX-SSA 10 n.d. 
4 EX-SSG 10 n.d. 
5 EX-STA5 95 n.d. 
6 EX-X5 50 n.d. 
 
 
 Enzymatic transamination of 1-(4-(pyridin-4-yl)phenyl)ethanone (5e) using ATAs 
 
Table 40. Enzymatic transamination of 1-(4-(pyridin-4-yl)phenyl)ethanone (5e) using ATAs 
 
Entry Enzyme c (%) ee (%) 
1 EX-wt 75 >99 (R) 
2 EX-STA 99 >99 (R) 
3 EX-SSA 10 n.d. 
4 EX-SSG 10 n.d. 
5 EX-STA5 70 n.d. 
6 EX-X5 82 n.d. 
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 Enzymatic transamination of 1-(3',4'-difluoro-[1,1'-biphenyl]-4-yl)ethanone (5f) using ATAs 
 
Table 35. Enzymatic transamination of 1-(3',4'-difluoro-[1,1'-biphenyl]-4-yl)ethanone (5f) using ATAs 
 
Entry Enzyme c (%) ee (%) 
1 EX-wt 25 n.d. 
2 EX-X2 5 n.d. 
3 EX-X3 10 n.d. 
4 EX-STA 40 >99 (R) 
5 EXSSA 5 n.d. 
6 EX-SSG 0 n.d. 
7 EX-STA5 30 n.d. 
8 EX-X5 30 n.d. 
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 Enzymatic transamination of 1-(4'-fluoro-3'-methyl-[1,1'-biphenyl]-4-yl)ethanone (5g) using 
ATAs 
 
Table 36. Enzymatic transamination of 1-(4'-fluoro-3'-methyl-[1,1'-biphenyl]-4-yl)ethanone (5g) using ATAs 
 
Entry Enzyme c (%) ee (%) 
1 EX-wt 21 n.d. 
2 EX-X2 10 n.d. 
3 EX-X3 12 n.d. 
4 EX-STA 72 >99 (R) 
5 EX-SSA 5 n.d. 
6 EX-SSG 0 n.d. 
7 EX-STA5 55 n.d. 
8 EX-X5 84 n.d. 
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 Enzymatic transamination of 1-(5'-fluoro-2'-methoxy-[1,1'-biphenyl]-4-yl)ethanone (5h) using 
ATAs 
 
Table 37. Enzymatic transamination of 1-(5'-fluoro-2'-methoxy-[1,1'-biphenyl]-4-yl)ethanone (5h) using 
ATAs 
 
Entry Enzyme c (%) ee (%) 
1 EX-wt 25 n.d. 
2 EX-X2 5 n.d. 
3 EX-X3 10 n.d. 
4 EX-STA 30 >99 (R) 
5 EX-SSA 5 n.d. 
6 EX-SSG 5 n.d. 
7 EX-STA5 24 n.d. 
8 EX-X5 30 n.d. 
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 Enzymatic transamination of 1-([1,1'-biphenyl]-3-yl)ethanone (5i using ATAs 
 
Table 32. Enzymatic transamination of 1-([1,1'-biphenyl]-3-yl)ethanone (5i) using ATAs 
 
Entry Enzyme c (%) ee (%) 
1 EX-wt 38 n.d. 
2 EX-X2 23 n.d. 
3 EX-X3 30 n.d. 
4 EX-STA 85 >99 (R) 
5 EX-SSA 17 n.d. 
6 EX-SSG 5 n.d. 
7 EX-STA5 85 n.d. 
8 EX-X5 28 n.d. 
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 Enzymatic transamination of 1-([1,1'-biphenyl]-2-yl)ethanone (5j) using ATAs 
 
Table 33. Enzymatic transamination of 1-([1,1'-biphenyl]-2-yl)ethanone (5j) using ATAs 
 
Entry Enzyme c (%) ee (%) 
1 EX-wt 0 n.d. 
2 EX-X2 8 n.d. 
3 EX-X3 6 n.d. 
4 EX-STA 5 n.d. 
5 EX-SSA 0 n.d. 
6 EX-SSG 0 n.d. 
 
 
 Synthesis of biaryl amines 8a-j using EX-STA with isopropylamine as amine donor  
 
General procedure: 
 In a 2 mL reaction tube, ketone (20 mM) was first dissolved in DMSO (32 μL, 5% v/v) and then 
EX-STA lysate (8 U), KPi buffer 100 mM pH 7.5, 1 M isopropylamine and 1 mM PLP were added. The 
reaction was shaken at 30 °C and 250 rpm for 24 h. To determine the conversion, 10 μL of the mixture 
were diluted with 90 μL DMSO and analysed by achiral reverse phase with previous centrifuging and 
filtering of the sample. To determine the enantiomeric excess the reaction was quenched by addition 
of aqueous 10 N NaOH (400 μL). The mixture was then extracted with ethyl acetate (2 × 500μL) and 
the organic layers were separated by centrifugation (90 s, 13000 rpm), combined and dried over 
Na2SO4.  
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Table 41. ATA-catalysed transamination of biaryl ketones using EX-STA and isopropylamine as amine donor 
 
Entry Ketone c (%) ee (%) 
1 8a 0 n.d. 
2 8b 0 n.d. 
3 8c 0 n.d. 
4 8d 0 n.d. 
5 8e 0 n.d. 
6 8f 0 n.d. 
7 8g 0 n.d. 
8 8h 0 n.d. 
9 8i 0 n.d. 
10 8j 0 n.d. 
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 Bioamination of phenylacetone (1c) 
 
 
General procedure: 
 Reactions were carried out in a 2.0 mL Eppendorf tube. The corresponding ATA (2.0 mg for 
Codexis enzymes or 5.0 mg for Cv-TA, ArR-TA, ArS-TA and ArRmut11-TA) was added to 500 μL of the 
corresponding mixture of DES and buffer 100 mM phosphate buffer pH 7.5, containing propan-2-
amine (1.0 M) and the cofactor PLP (1.0 mM). Then, a solution of 1c (2.0 mg) was added and the 
resulting mixture was shaken at 250 rpm and 30 °C for 24 h. After this time, a 50 L aliquot was 
removed by the determination of the degree of conversion by HPLC (see section 6.2). On the other 
hand, aqueous 10 N NaOH (100 L) was added to the reaction mixture, which was extracted with ethyl 
acetate (2  500 μL). The organic layers were separated by centrifugation (90 s, 13000 rpm), combined, 
and finally dried over Na2SO4. The enantiomeric excess of the resulting amine was determined by 
chiral HPLC after conventional derivatization of the sample using acetic anhydride (2 L / mg of 
substrate). 
 
Table 42. Effect of different DESs-buffer media on the conversion of the ATA-catalysed bioamination of 
phenylacetone (1c) 
  Buffer 1ChCl/2Gly 1ChCl/2H2O 1ChCl/1Sorb 1ChCl/2Urea 
Entry Enzyme  
25% 
DES 
50% 
DES 
75% 
DES 
25% 
DES 
50% 
DES 
25% 
DES 
50% 
DES 
25% 
DES 
50% 
DES 
1 ATA-237 95 98 93 93 90 90 93 88 91 88 
2 ATA-251 95 97 92 92 93 90 >99 91 95 86 
3 ATA-256 57 95 95 95 91 92 85 88 90 85 
4 ATA-P1-G06 95 95 95 92 95 90 96 91 95 90 
5 Cv 91 94 90 85 5 30 12 15 <5 <5 
6 ArS 64 45 42 40 10 25 10 35 <5 <5 
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7 ArR 91 55 60 72 50 80 85 90 70 65 
8 ArRmut11 >99 95 95 95 90 80 73 95 85 90 
 
NP- HPLC (OD-H, hexane/isopropanol 96:4 v/v, 0.8 mL/min, 258 nm) tR = 21.7 min (S), 23.9 min (R) 
 
 
 Preparative-scale synthesis of (R)-1-(4-(pyridin-3-yl)phenyl)ethanamine (8d) 
 
 
 
General procedure: 
 After dissolving 5d (75 mM, 100 mg) in DMSO (319 μL, 5% v/v) in a 50 mL reaction tube, 
lyophilised EX-STA (320 U, 700 mg), 100 mM KPi buffer pH 7.5 (5.8 mL, 1 mM PLP, 0.1 mM NAD+), D-
glucose (114 mM, 293 mg), alanine (260 mM, 332 mg), LDH (3604 U, 682 μL) and GDH (1201 U, 400 
mg) were added. The reaction was shaken at 30 °C and 250 rpm for 24 h. The reaction was quenched 
by addition of aqueous 10 N NaOH (10 mL) to adjust the pH to 14. The mixture was then extracted 
with ethyl acetate (2 × 20 mL) and the organic layers were separated by centrifugation (90 s, 13000 
rpm), combined and dried over Na2SO4. Further evaporation under reduced pressure provided the 
compound (R)-8d as a white solid in 96% yield (ee >99%).  
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 Spectrophotometric activity assay 
 
 Measurement of the enzymatic activity  
 
 The activity of amine transaminases is usually determined with a photometric assay. The 
substrate phenylethylamine is converted to acetophenone, which can be detected 
spectrophotometrically at 300 nm. The absorbance increases with rising product concentration. To 
measure the activities of the identified ATAs, reactions were set up in 1 mL volume with 50 mM KPi 
(pH 7.5) buffer supplemented with 0.1 mM PLP, 5 mM phenylethylamine and 5 mM pyruvic acid. For 
the reaction, 50 µg to 250 µg lysate protein or purified protein were used. The production of 
acetophenone was measured at 300 nm at 30°C for several minutes. The volumetric activity in U/mL 
and the specific activity in U/mg total protein of the enzyme samples is calculated using the law of 
Lambert-Beer with the molar extinction coefficient of acetophenone ε300 = 0.28 cm2/µmol. 
 
Table 43. Measurement of the enzymatic volumetric activity of the identified new ATAs 
Entry Enzyme Activity (U/ml lysate) 
1 Esi 16.9 
2 EX-wt 6.42 
3 EX-STA 23.35 
4 Pac 4.2 
5 Shi 13.21 
6 Tja 3.04 
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 Measurement of the kinetics of EX-STA  
 
Table 44. Measurement of the kinetics of EX-STA at different time intervals for a total of 4 hours 
Entry Time (h) c (%) 
1 0.5 35 
2 1 50 
3 2 75 
4 3 >99 
5 4 >99 
 
 
 Inhibition studies 
 
 Inhibitory effect of the cross-coupling components on the biocatalytic activity  
 
 
 
General procedure: 
 The ketone (20 mM) was first dissolved in DMSO (32 μL, 5% v/v) in a 2 mL reaction tube 
(Eppendorf). Then ATA lysate (8 U), potassium phosphate buffer (KPi) 100 mM pH 7.5, 1 mM PLP, 0.1 
mM NAD+, D-glucose (57 mM), D-alanine (130 mM), LDH (90 U) and GDH (30 U) were added. 
Depending on the type of the study to this mixture the appropriate additive was added. The reaction 
was then shaken at 30 °C and 250 rpm for 24 h. To determine the conversion, 10 μL of the mixture 
were diluted with 90 μL of DMSO and analysed by achiral reverse phase with previous centrifuging 
and filtering of the sample. To determine the enantiomeric excess the reaction was quenched by 
addition of aqueous 10 N NaOH (400 μL). The mixture was then extracted with ethyl acetate (2 × 500 
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μL) and the organic layers were separated by centrifugation (90 s, 13000 rpm), combined and dried 
over Na2SO4. According to the study in question the reaction was repeated several times changing the 
parameters of the additive added. 
 
Table 45. Measurement of the activity of EX-wt at different concentrations of the [Pd]/ligand complex 
Entry 
Additive 
conc. [mM] 
Additive 
[mol%] 
c (%) 
1 0.18 1 81  
2 0.36 2 70  
3 0.54 3 67  
 
Table 46. Measurement of the activity of EX-wt at different concentrations of phenylboronic acid 
Entry 
Additive 
conc. [mM] 
Additive 
[mol%] 
c (%) 
1 10 54 95 
2 20 100 75 
3 30 160 72  
 
Table 47. Measurement of the activity of EX-wt at different concentrations of TPPTS 
Entry 
Additive 
conc. [mM] 
Additive 
[mol%] 
c (%) 
1 2 11 95 % 
2 3 17 74 % 
3 4 22 45 % 
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 Spectrophotometrical measurements of the effect of co-solvents on the biocatalytic 
activity 
 
 
General procedure: 
 To measure the activities of the identified ATAs, reactions were set up in 1 mL volume with 
50 mM KPi (pH 7.5) buffer supplemented with 0.1 mM PLP, 5 mM phenylethylamine, 5 mM pyruvic 
acid and supplemented with a predefined amount of co-solvent in question. For the reaction, 50 µg 
to 250 µg lysate protein or purified protein were used. The production of acetophenone was measured 
at 300 nm at 30°C for several minutes. To measure the absorbance a blank cuvette was placed in the 
spectrophotometer containing all the components except for the enzyme. The volumetric activity in 
U/mL and the specific activity in U/mg total protein of the enzyme samples is calculated using the law 
of Lambert-Beer with the molar extinction coefficient of acetophenone ε300 = 0.28 cm2/µmol. 
 
 
Scheme 58. Effect of co-solvents at different concentrations 
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 Study of the effect of co-solvents on the bioamination of mono- and biaryl 
ketones 
 
General procedure: 
 The ketone (20 mM) was first dissolved in predefined amount of the co-solvent of choice (2.5-
50% v/v) in a 2 mL reaction tube (Eppendorf). Then ATA lysate (8 U), potassium phosphate buffer (KPi) 
100 mM pH 7.5, 1 mM PLP, 0.1 mM NAD+, D-glucose (57 mM), D-alanine (130 mM), LDH (90 U) and 
GDH (30 U) were added. The reaction was shaken at 30 °C and 250 rpm for 24 h. To determine the 
conversion, 10 μL of the mixture were diluted with 90 μL of DMSO and analysed by achiral reverse 
phase with previous centrifuging and filtering of the sample. To determine the enantiomeric excess 
the reaction was quenched by addition of aqueous 10 N NaOH (400 μL). The mixture was then 
extracted with ethyl acetate (2 × 500 μL) and the organic layers were separated by centrifugation (90 
s, 13000 rpm), combined and dried over Na2SO4.  
 
Table 48. Effect of DMSO on the EX-wt-catalysed bioamination of acetophenone 1a 
 
Entry Co-solvent (%) c (%) ee (%) 
1 DMSO (2.5%) 51  >99 (R) 
2 DMSO (5%) 43  >99 (R) 
3 DMSO (10%) 33  >99 (R) 
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Table 49. Effect of co-solvent on the conversion of the ATA-catalysed bioamination of 4’-
bromoacetophenone 1b. 
 
Entry Enzyme Co-solvent (%) c (%) ee (%) 
1 Shi DMSO (2.5%) 95  >99 (R) 
2 Shi DMSO (5%) 93  >99 (R) 
3 Shi DMSO (10%) 87  >99 (R) 
4 Shi i-PrOH (15%) 20  n.d. 
5 EX-wt DMSO (5%) 95 >99 (R) 
6 EX-wt i-PrOH (15%) 22 >99 (R) 
7 EX-wt 1ChCl/2Gly (25%) 55 >99 (R) 
8 EX-STA 1ChCl/2Gly (25%) 93 >99 (R) 
9 Esi DMSO (2.5%) 18 n.d. 
10 Esi i-PrOH (15%) 0 n.d. 
11 Pac DMSO (2.5%) 45 >99 (R) 
12 Pac i-PrOH (15%) 20 n.d. 
13 Tja DMSO (2.5%) 13 n.d. 
14 Tja i-PrOH (15%) 5 n.d. 
 
 
 
 
 165 
 
Table 50. Effect of co-solvent on the ATA-catalysed bioamination of biaryl ketone 5a 
 
Entry Enzyme Co-solvent (%) c (%) ee (%) 
1 EX-wt DMSO (5%) 83 >99 (R) 
2 EX-wt DMSO (5%) 45 >99 (R) 
3 EX-STA 1ChCl/2Gly (25%) 5  n.d. 
4 EX-STA 1ChCl/2Gly (25%) 25  n.d. 
 
 
 
Table 51. Effect of co-solvent on the EX-STA-catalysed bioamination of biaryl ketone 5d. 
 
Entry Co-solvent (%) c (%) ee (%) 
1 THF (5%) 8 >99 (R) 
2 THF (15%) n.d. n.d. 
3 i-PrOH (5%) 64 >99 (R) 
4 i-PrOH (15%) <5 n.d. 
5 DMSO (5%) >99 >99 (R) 
6 DMSO (15%) >99 >99 (R) 
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Entry Co-solvent (%) c (%) ee (%) 
7 1ChCl/2Gly (5%) >99 >99 (R) 
8 1ChCl/2Gly (15%) 95 >99 (R) 
9 1ChCl/2Gly (25%) 60 >99 (R) 
10 1ChCl/2Gly (50%) <5 n.d. 
 
 
 Investigation of process parameters 
 
 Amine donor optimisation 
 
General procedure: 
 The ketone (20 mM) was first dissolved in DMSO (5 % v/v) in a 2 mL reaction tube (Eppendorf). 
Then ATA lysate (8 U), potassium phosphate buffer (KPi) 100 mM pH 7.5 and predefined amounts of 
D-ala, PLP (0.1 mM), NAD+ (1 mM), LDH (90 U) and GDH (30 U) were added. The reaction was shaken 
at 30 °C and 250 rpm for 24 h. To determine the conversion, 10 μL of the mixture were diluted with 
90 μL of DMSO and analysed by achiral reverse phase with previous centrifuging and filtering of the 
sample. To determine the enantiomeric excess the reaction was quenched by addition of aqueous 10 
N NaOH (400 μL). The mixture was then extracted with ethyl acetate (2 × 500 μL) and the organic 
layers were separated by centrifugation (90 s, 13000 rpm), combined and dried over Na2SO4.  
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Table 52. Effect of D-alanine concentration on the ATA-catalysed bioamination of biaryl ketone 5d. 
 
Entry Enzyme Amine donor (mM) c (%) ee (%) 
1 EX-wt 250 >99 >99 (R) 
2 EX-wt 130 >99 >99 (R) 
3 Shi 250 >99 >99 (R) 
4 Shi 130 >99 >99 (R) 
 
 
 Study of the biocatalyst formulation 
 
General procedure: 
 The ketone (5d, 20 mM) was first dissolved in DMSO (5 % v/v) in a 2 mL reaction tube 
(Eppendorf). Then ATA lyophilisate (8 U), potassium phosphate buffer (KPi) 100 mM pH 7.5 and D-Ala 
(130 mM), PLP (0.1 mM), NAD+ (1 mM), LDH (90 U) and GDH (30 U) were added. The reaction was 
shaken at 30 °C and 250 rpm for 24 h. To determine the conversion, 10 μL of the mixture were diluted 
with 90 μL of DMSO and analysed by achiral reverse phase with previous centrifuging and filtering of 
the sample. The mixture was then extracted with ethyl acetate (2 × 500 μL) and the organic layers 
were separated by centrifugation (90 s, 13000 rpm), combined and dried over Na2SO4.  
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Table 53. Enzymatic transamination of 5d catalysed by lyophilised EX-ωTA and its variants upon optimised 
reaction conditions 
 
Entry Enzyme c (%) 
1 EX-wt 7 
2 EX-STA >99 
3 EX-5 55 
4 EX-STA5 98 
 
 
 Substrate loading study 
 
General procedure: 
 The ketone (5d, 20-150 mM) was first dissolved in DMSO (32 μL, 5% v/v) in a 2 mL reaction 
tube (Eppendorf). Then EX-STA lyophilisate (8 U), potassium phosphate buffer (KPi) 100 mM pH 7.5, 1 
mM PLP, 0.1 mM NAD+, D-glucose (57 mM), D-alanine (130 mM), LDH (90 U) and GDH (30 U) were 
added. The reaction was shaken at 30 °C and 250 rpm for 24 h. To determine the conversion, 10 µL of 
the mixture were diluted with 90 µL of DMSO and analysed by achiral reverse phase with previous 
centrifuging and filtering of the sample. To determine the enantiomeric excess the reaction was 
quenched by addition of aqueous 10 N NaOH (400 μL). The mixture was then extracted with ethyl 
acetate (2 × 500 µL) and the organic layers were separated by centrifugation (90 s, 13000 rpm), 
combined and dried over Na2SO4. 
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Table 54. Measurements of conversion at different concentrations of 5d for the enzymatic transamination 
catalysed by EX-STA 
 
Entry Ketone concentration (mM) c (%) 
1 20 99 
2 40 99 
3 75 95 
4 100 60 
5 150 47 
 
 
 
 Enzymatic transamination catalysed by lyophilised EX-ωTA using isopropylamine 
 
General procedure: 
 In a 2 mL reaction tube, ketone (5d, 20 mM) was first dissolved in DMSO (32 μL, 5% v/v) and 
then ATA lyophilisate (8 U), KPi buffer 100 mM pH 7.5, 1 M isopropylamine and 1 mM PLP were added. 
The reaction was shaken at 30 °C and 250 rpm for 24 h. To determine the conversion, 10 µL of the 
mixture were diluted with 90 µL DMSO and analysed by achiral reverse phase with previous 
centrifuging and filtering of the sample. The reaction was quenched by addition of aqueous 10 N NaOH 
(400 μL). The mixture was then extracted with ethyl acetate (2 × 500µL) and the organic layers were 
separated by centrifugation (90 s, 13000 rpm), combined and dried over Na2SO4. The enantiomeric 
excess of amines was measured by chiral HPLC. 
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Table 55. Enzymatic transamination of 5d catalysed by lyophilised EX-ωTA and its variants using 
isopropylamine as amino donor 
 
Entry Enzyme c (%) 
1 EX-wt 5 
2 EX-STA 50 
3 EX-5 30 
4 EX-STA5 35 
 
 
 Enzyme loading studies  
 
General procedure: 
 In a 2 mL reaction tube, ketone (5d, 20 mM) was first dissolved in DMSO (32 μL, 5% v/v) and 
then ATA lyophilisate (1-4 U/mg of substrate), potassium phosphate buffer (KPi) 100 mM pH 7.5, 1 
mM PLP, 0.1 mM NAD+, D-glucose (57 mM), D-alanine (130 mM), LDH (90 U) and GDH (30 U) were 
added. The reaction was shaken at 30 °C and 250 rpm for 24 h. To determine the conversion, 10 µL of 
the mixture were diluted with 90 µL of DMSO and analysed by achiral reverse phase with previous 
centrifuging and filtering of the sample. The reaction was quenched by addition of aqueous 10 N NaOH 
(400 μL). The mixture was then extracted with ethyl acetate (2 × 500 µL) and the organic layers were 
separated by centrifugation (90 s, 13000 rpm), combined and dried over Na2SO4.  
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Table 56. Enzymatic transamination of 5d catalysed by lyophilised EX-STA upon optimised reaction 
conditions at different enzyme loadings 
 
Entry U/mg c (%) 
1 4 99 
2 3 91 
3 2 60 
4 1 17 
 
 
 
 Synthesis of biaryl amines in a one-pot sequential process 
 
 
 
 
General procedure: 
 At first, a suspension of PdCl2 (0.086 mg; 1 mol %) and TPPTS (8.32 mg; 3 mol %) in degassed 
and deionized water was prepared (0.25 mL). After 30 min the resulting catalyst solution was added 
to a mixture consisting of aryl bromide (1 or 3, 0.5 mmol), arylboronic acid (2 or 4, 0.5 mmol), sodium 
carbonate (132 mg, 1.25 mmol), DES (2.0 mL) and degassed and deionized water (0.25 mL). The 
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reaction mixture was heated to 100 °C during 24 h. After cooling to room temperature, EX-STA lysate 
(11 mL, 257 U), KH2PO4 buffer 100 mM pH 7.5 (6.5 mL), PLP (1 mM), NAD+ (0.1 mM), D-glucose (57 
mM), D-alanine (130 mM), LDH (3600 U, 680 μL) and GDH (1200U, 400 mg) were added and the 
reaction was stirred for 24 h at 30 °C. Then, the reaction was quenched by addition of aqueous 10 N 
NaOH (10 mL) to adjust the pH to 14. The mixture was then extracted with ethyl acetate (2 × 25 mL) 
and the organic layers were separated by centrifugation (90s, 13000 rpm), combined and dried over 
Na2SO4 to provide the crude product. Further filtration by flash chromatography (silica gel 60 Å, ethyl 
acetate) yielded the corresponding (R)-biaryl amines 8a-e. The enantiomeric excess of the resulting 
amines was determined by chiral HPLC after conventional derivatization of the sample using acetic 
anhydride (2 µL / mg of substrate). 
 
 Synthesis of (R)-1-([1,1'-biphenyl]-4-yl)ethanamine (8a) 
 
 
 
 
 
Scheme 59. In process HPLC monitoring for the preparation scale synthesis of 8a 
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 Synthesis of (R)-1-([1,1'-biphenyl]-3-yl)ethanamine (8i) 
 
 
Scheme 60. In process HPLC monitoring for the preparation scale synthesis of 8i 
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 Synthesis of (R)-1-(4-(pyridin-2-yl)phenyl)ethanamine (8c) 
 
 
 
Scheme 61. In process HPLC monitoring for the preparation scale synthesis of 8c 
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 Synthesis of (R)-1-(4-(pyridin-3-yl)phenyl)ethanamine (8d) 
 
 
 
 
Scheme 62. In process HPLC monitoring for the preparation scale synthesis of 8d 
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 Synthesis of (R)-1-(4-(pyridin-4-yl)phenyl)ethanamine (8e)  
 
 
 
 
Scheme 63. In process HPLC monitoring for the preparation scale synthesis of 8e 
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